








Lancashire & Cumbria Innovation Alliance Test Bed:  




Christine Milligan, Céu Mateus, Tom Palmer, Sandra Varey, 















Over a period of 30 months, the Lancashire and Cumbria Innovation Alliance Test Bed 
implemented and evaluated a combination of innovative technologies and practices aimed at 
supporting older people (aged 55+) with long-terms conditions (LTCs) to remain well in the 
community, avoiding unnecessary hospital admissions. The combinatorial health 
technologies were designed to better enable older people with LTCs to self-care at home and 
to improve patient activation.  The LTCs included COPD, heart failure, asthma, diabetes and 
dementia - conditions that present a major challenge for the Northwest. Patients with LTCs 
were recruited to one of three cohorts depending on their level of risk of hospital admission 
(Cohort 1 being the highest risk category); individuals with mild to moderate dementia were 
recruited to Cohort 4. The combination of technologies each patient received was dependent 
on their level of risk and their primary LTC. 
 
The Test Bed evaluation focused on two key outcomes: i) the extent to which supported self-
care health technology might improve patient outcomes and the patient experience for frail 
older people living with long-term conditions; and ii) the potential cost effectiveness of the 
intervention and how this might be scaled up to provide better value for both patients and 
taxpayers. The evaluation adopted a two-phase approach: Phase 1 included a bespoke patient 
survey and a matched control analysis (3:1); Phase 2 adopted a qualitative approach including 
observational interviews with patients and carers; and weekly diaries, action learning 
meetings, and focus groups with members of staff and other key stakeholders. The evaluation 
was underpinned by a Logic Model to aid spread and adoption. 
 
Key Messages 
 The data showed that the use of Test bed technology made little difference to hospital 
service usage; 
 
 The costs of the Test Bed intervention exceeded cost savings in secondary care for 
both Cohorts 1 and 2 although this was considerably lower for Cohort 2. If cost is the 
key measure, Test Bed technologies may be more effective for patients with slightly 
lower levels of risk (10-24%) although different models of purchasing health 
technologies should be explored; 
 
 Overall our data show a strong level of engagement and benefit for self-management 
of care and patient activation amongst patients and carers using the Test Bed 
technology; 
 
 Our data suggest an unexpected benefit of the Test Bed technology as a method of 
early detection for previously undiagnosed health problems with good potential for 
cost savings downstream; 
 
 Whilst protected time is needed for staff to deliver combinatorial health technologies 
successfully, the Test Bed enabled staff to have more contact and connections with 
their patients. Many staff also welcomed the added diversity the programme brought 
to their role.  
 
 Decisions about which combinatorial technologies to give to a patient should begin 
with the individual’s healthcare needs, and not what technologies are available. 
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Patients and clinicians need to work together to understand what technologies will 
work for whom. 
 Patients want technologies that can be tailored to individual needs or personalised to 
their own lifestyles. 
 
      Patient Profile 
 The majority of Test Bed participants were retired white, males (61%) which may 
reflect the prevalence of LTCs which were the focus of the Test Bed intervention. Most 
patients lived with a spouse/partner or relative and most already had access to the 
internet.  
 The average age of patients participating in the Test Bed was 71.6 years, indicating 
that older patients are willing to engage with health technology. 
 The percentage of patients in Cohort 1 who stated that they were confident or 
somewhat confident in the use of technology increased over the course of the Test 
Bed programme from 51% to 67%.  This was reinforced by findings from the Phase 2 
data. 
 
Phase 1  
 
Health and Wellbeing 
 Patient activation for those with the lowest level of activation improved during the 
period of the intervention across all cohorts. 
 On average, participants exhibited slightly better health-related quality of life and 
wellbeing at the end of the Test Bed. While there was no statistically significant change 
in overall health and wellbeing, improvements were evident in the dimensions of: 
usual activity; and pain and discomfort. 
 Among Cohort 1 participants, age was negatively correlated with three of the EQ-5D-
5L dimensions: self-care, pain/discomfort, and anxiety/depression. This may reflect 
participants’ ability to adapt to impairments over time and that the combinatorial 
technology may play a role in assisting patients to adapt. With no control comparison 
we are unable to definitively attribute improvements to the use of the technology. 
 
Service Usage 
Based on the matched control data: 
 
 The Test Bed had a very small effect (approximately zero) on the number of A&E visits 
per patient in both Cohorts 1 and 2. 
 There was a reduction in outpatient appointments per patient of 0.26 in Cohort 1 and 
0.27 in Cohort 2. 
 Test Bed patients revealed higher average levels of secondary care service usage than 
those in the control group. 
 The pre-post comparison among the Test Bed and control patients for the number of 
A&E visits per patient; and the probability of being admitted as an inpatient show little 
difference between the two groups. 
 The pre-post comparison of outpatient appointments within Test Bed and control 
group revealed a reduction of 0.15 appointments per patient among the Test Bed 




 For patients participating in the Test Bed, the data show a reduction in the probability 
of inpatient admission of 2% in Cohort 1 and 2.6% in Cohort 2. 
 
Based on the survey data: 
 
 Overall, there was little difference in the mean use of hospital services in the Test Bed 
population. There was a slight increase in the use of day hospital services and a 
decrease in the use of outpatient appointments. 
 In primary care, community health and emergency services there was a slight increase 
in the mean use of services when comparing results at baseline (1.08) and end point 
24 (1.3). 
 Overall, the percentage of patients using at least one primary care service showed 
little change over the period of the Test Bed. There was a 10% reduction in usage 
among Cohort 1 participants but a 12% increase among patients in Cohort 2. 
 Community health services were rarely used by Test Bed participants and showed no 
meaningful change over the 24 weeks of the intervention. Similar patterns were 
observable in the use of other community-based services such as telecare, dentist or 
optician. 
 The decrease observed in the use of services provided by social worker or care 
managers was more than compensated for by the increase observed in the use of 
private home help/cleaner. 
 Due to the relatively short time span of the Test Bed, the evaluation was only able to 
pick up on increases in service utilisation arising from identifying previously unknown 
conditions. It is unable to assess any potential longer-term reductions in in-patient 
care arising from early identification of these conditions versus the delivery of lower 
cost treatment within community settings. 
 
Average Cost and Comparison with Control Group  
 The average cost for hospital services increased from £332 at baseline to £433 at 24 
weeks. The increase was mainly driven by the changes observed in day hospital 
services. 
 Primary care, community health or emergency services show a modest increase over 
the 24 weeks, from £113 to £128. The changes observed in social care services are 
negligible. 
 Community mental health services and other community based services show small 
reductions over the 24 weeks. 
 During the 24 weeks of the intervention, the average monthly cost of medication for 
patients was £228, but patients in cohort 1 spent more than patients in cohort 2 at 
£285 and £152 respectively for the same period. 
 The average cost of the technology made available to participants in cohort 1 was 
£1,486 and £335 for patients in cohort 2. 
 The average cost per patient increased from £1,711 at baseline to £1,822 at week 24.  
 As would be expected, overall costs for patients in cohort 1 were more expensive than 
for patients in cohort 2. However, while there were no meaningful changes in the costs 
of patients in cohort 1 (from £2,426 to £2,437), the average cost of a patient in cohort 
2 increased from £832 to £981. 
 Average costs of patients in cohort 1 were around 2.5 times higher than those found 
for patients in cohort 2 over the 24 weeks. 
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 Compared to the matched control, patients in Cohort 1 showed cost savings in all 
three measures of secondary care. In A&E visits there was a saving of approximately 
£3 per patient, in outpatient appointments the saving was approximately £35 per 
patient and approximately £78 for hospital admissions. Total cost savings for this 
cohort were approximately £116 per patient. 
 Compared to the matched control, patients in Cohort 2 showed cost savings in two of 
the three measures of secondary care. Hospital admission cost savings were 
approximately £101 per patient; and outpatient appointments cost savings were 
approximately £37 per patient. A&E visit costs increased by approximately £5 per 
patient. 
 Overall, the total cost saving for Cohort 2 was approximately £133 per patient. 
 For those patients completing the 6 month intervention in Cohort 1, the cost of the 
Test Bed intervention exceeded by £1,370 (per patient) the cost savings achieved by 
the reduction in secondary care use. 
 For those patients completing the 6 month intervention in Cohort 2, the cost of the 
Test Bed intervention exceeded the cost savings by approximately £175 per patient. 
 The Test Bed reduced secondary care use among Cohort 1 at a higher cost than among 
Cohort 2 patients. This is unsurprising given the higher costs of technology used in 
Cohort 1. 
 The overall finding that the cost of the Test Bed exceeds cost savings due to reductions 
in secondary care use should not be considered in isolation. First, it is important to 
acknowledge both the strengths and limitations of the Phase 1 evaluation approach. 
Second, the time-frame of the Test Bed may have been too short to accurately 
measure changes in secondary care use. 
 
            Phase 2 
 
       Patients 
 Overall, patients’ experiences of using the Test Bed technologies were positive. 
However, many needed the support of a family member or friend when using the 
technology. 
 The majority of patients across all cohorts were confident in using the technologies 
after an initial induction period and this confidence increased over time. 
 Experiences of training and initial support differed significantly across cohorts 
dependent on the technology a patient received. Good training, induction and 
ongoing support is essential for the successful implementation of Test Bed 
technologies. 
 Individualisation of the technology was particularly important for Cohort 4 to ensure 
that individuals were not given information about dementia they did not want or 
expect at that point in time. 
 Patients felt input from a healthcare professional would help them tailor the 
technologies to their own healthcare needs, so gaining more from it. 
 While the data reveal reductions in healthcare system utilisation, examples of 
increased utilisation of healthcare services and medication also exist, due to 
identification of previously undiagnosed conditions, increased patient engagement, or 
the need for alternative or additional medication. Such short-term increases in service 
use are likely to be offset by longer-term cost-savings, but this was not verifiable 
within the time-span of the Test Bed programme. 
 v 
 
 Phase 2 data suggest patients in Cohort 1 gained the largest increase in confidence 
relating to their health. This is largely attributable to an increase in patient/carer 
reassurance as a result of being monitored through the technology. 
 While patients and family carers valued the monitoring of their data by healthcare 
staff, they also took an active role in this monitoring. 
 Patients need clear information about how their data is being used. Concerns were 
expressed about where their data was being held, who had access to it, and the 
purposes for which it was being used. 
 For the small number of Cohort 1 patients who did not report any benefits from taking 
part in the Test Bed, this was because the technology did not address what the patient 
viewed as their primary health condition. 
 Most patients in Cohort 1 increased their knowledge and skills about their health 
condition as a result of taking part in the Test Bed programme. 
 While changes in daily activities can be an indicator of changes in quality of life, this 
may not be an appropriate indicator for those in the highest risk group, many of whom 
are housebound. As a result, the Phase 2 data did not reveal any positive influence on 
daily activities for many Test Bed patients in Cohort 1. 
 Most patients interviewed in Cohort 2 experienced an increase in confidence in 
relation to their health as a result of taking part in the Test Bed. This was linked to an 
increase in knowledge and skills, resulting in people being better able to self-manage 
their health. 
 The majority of Phase 2 patients in Cohort 2 had COPD. Most found participation in 
the Test Bed programme helped them to learn about their condition and how to better 
manage it. 
 Participation in the Test Bed programme had a positive influence on daily activities for 
some participants, with the biggest impact occurring in Cohort 2. 
 In Cohort 3, there was very little evidence of increased confidence relating to health. 
Patients in this cohort differed from the other cohorts in that they were younger, 
many still being in paid employment and did not consider themselves to have a long-
term condition. The lack of increase in confidence was a result of these patients being 
confident in managing their health at the outset. 
 
      Carers 
 There is limited evidence of an increase in health-related confidence or knowledge 
and skills related to dementia as a result of participation in Cohort 4. Where evidence 
did exist, this related to the family carer rather than the patient, and was a direct result 
of knowing the patient was being monitored. 
 The Test Bed technology was often the responsibility of the family carer, with many 
patients saying they could not have participated in the programme without the 
support of a family member of carer. 
 The evaluation highlighted the importance of ensuring family carers are closely 
involved in decision-making regarding the implementation of combinatorial health 
technologies to support patients with dementia, as well as other long-term conditions. 
 There is evidence of significant carer burden across all cohorts. There is also a sense 
of major transitions and changes for family carers and patients related to Cohort 4. 
The family carer is key to negotiating these ongoing changes. Technologies need to 




      Staff 
 The Test Bed enabled members of staff to have more contact and connections with 
their patients, with many welcoming the added diversity the programme brought to 
their role. 
 Time was a key challenge for successful delivery, with the Test Bed resulting in 
additional workload for those operating on the front line. Protected time is required 
for successful delivery of a programme such as this, particularly in the implementation 
stage and especially for patients with dementia. 
 A small number of patients and carers required significant reassurance and support in 
using the technologies. In these cases, service utilisation increased during the Test Bed 
programme. 
 Many people engaged with, and received, better healthcare as a result of Test Bed 
participation. The short-term increases in service utilisation were viewed by staff as a 
positive outcome as patients were receiving better and more appropriate care. 
 Though the Phase 1 data showed little change over the duration of the Test Bed, staff 
maintained that improved healthcare, arising from the Test Bed programme, would 
result in a reduction of emergency care and hospital admissions in the long term.  
 Staff across the Test Bed highlighted the importance of being part of a willing and 
engaged team when embarking on such a programme. Good communication and 
working relationships are key to successful implementation. 
 Where staff felt ownership of the programme and were involved in decision-making, 
there was greater buy-in and support for the Test Bed. Conversely, where staff were 
not involved in decision-making, or ownership was not encouraged, staff felt 
disengaged from the process. 
 Issues arose throughout the Test Bed as a result of clinical teams not being involved 
in decisions and programme design from an early stage. This included members of 
staff being expected to refer their patients into the Test Bed while not knowing what 
the technology entailed, and technology content contradicting advice given to 
patients by healthcare teams. 
 It is important that staff receive appropriate and regular training and support if they 
are to understand the technologies, how they can be tailored to the individual, and 
their value to their patients. 
 Continuity in the staff responsible for identifying and managing patients using 
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Over a period of 30 months, the Lancashire and Cumbria Innovation Alliance (LCIA) Test Bed 
implemented and evaluated a combination of innovative technologies and practices aimed at 
supporting older people (aged 55+) with long-terms conditions to remain well in the 
community, avoiding unnecessary hospital admissions. The combinatorial health 
technologies were also designed to better enable older people with long-term conditions 
(LTCs) to self-care at home and improve patient activation.  The LTCs included COPD, heart 
failure, asthma, diabetes and dementia - conditions that present a major challenge for the 
Northwest. Across the Test Bed, patients with LTCs were recruited to one of three cohorts 
depending on their level of risk of hospital admission; individuals with mild to moderate 
dementia were recruited to the fourth cohort. The combination of technologies each patient 
received was dependent on their level of risk and their primary LTC. 
The LCIA Test Bed was delivered through two neighbouring Vanguard sites – the Fylde Coast 
Local Health Economy and Morecambe Bay Health Community (Better Care Together). 
Located in Lancashire and South Cumbria.  
 
Both our Vanguards were focused on population-based new models of care that were central 
to delivering the vision of the NHS Five Year Forward View: integrated primary and acute care 
systems (PACSs) and multispecialty community providers (MCPs) whose focus was on 
integration. The MCP model was designed to dissolve the historical divide between health 
and social care. It involves redesigning care around the health of the population, irrespective 
of existing institutional arrangements. Blackpool Fylde and Wyre (Your care, Our priority) was 
a MCP Vanguard.  
Better Care Together was a PACS Vanguard. PACS were based on GP registered lists with the 
aim of improving the physical, mental and social health and wellbeing of the local population 
and reducing inequalities. PACS were designed to bring together health and care providers 
with shared goals and incentives, so they could focus on what is best for the local population. 
Critically, the general practice was at its core. The current fragmented and complex 
contracting, funding and governance systems within the NHS, and between NHS and social 
care, were seen to frustrate a focus on population health. The vision was, that by joining up 
services in through PACS, better decision-making and more sustainable use of resources 
would be facilitated, enabling a greater focus on prevention and integrated community-based 
care, and less reliance on hospital care. 
Both Vanguard sites presented significant challenges for delivering healthcare for a number 
of reasons: 
 
Firstly, life expectancy in Lancashire is 18 months shorter than in the rest of the country and 
the prevalence of heart failure, asthma and depression are all higher than average. Lancashire 
has 20% more people with three or more Long Term Conditions (LTCs) than the national 
average (Bradshaw, 2017).  
 
Secondly, Lancashire and South Cumbria encompasses a significant rural population, 
presenting a major challenge to those providing care, with long distances between hospitals 
and patients in rural and remote areas expected to undertake significant travel to attend 
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appointments. For example, the population of the Morecambe Bay Vanguard site is dispersed 
across an area of over 1,000 square miles. Delivering the LCIA Test Bed programme across the 
two Vanguard areas was thus viewed as having the potential to provide a ‘real-world’ test site 
for the use of technology to provide services remotely. 
 
Thirdly, the population of older people is increasing. Compared to the average across England, 
Lancashire has a higher proportion of people in all age bands over 50 years of age. In the Fylde 
Coast, those aged over 65 are projected to increase to between 31-35% by 2028 and 
increasing numbers of these people experience multiple and complex long-term conditions 
(ONS, 2016). 
 
Fourthly, continuing to care for our communities using current modes of practice is financially 
unsustainable.  Forecasts for the 5 year period from 2016-2021 showed that commissioner 
deficits could reach as high as £15m.  The acute provider deficit over this period was expected 
to grow to £56m and local authorities within the footprint anticipated spending cuts of 10%. 
In 2015, Healthier Lancashire's "Alignment of Plans" framework estimated a £180m deficit 
across all Lancashire commissioners, providers and social care. 
 
To address these issues, the Fylde Coast Vanguard implemented an integrated health, 
community and social care ‘Extensive Care Service’ across Lancashire, to support those 
patients over 60 years of age, with 2 or more long-term conditions and a high risk of non-
elective admission. Similarly, the Morecambe Bay Vanguard was in the process of 
implementing a programme which would include an ‘out of hospital model’, involving 
networks of multidisciplinary integrated core teams based in the community to provide care 
focused on frail older people and those with long-term conditions. Both Vanguards included 
projects focused on promoting ‘self-care’ and the home rather than the surgery as the site of 
care, aiming to implement a range of self-care interventions to support patients and their 
carers in managing their health and care.  
Given the region’s dispersed population, innovative and cost-effective solutions are urgently 
required.  The Test Bed was thus seen to offer a valuable and timely opportunity for local 
organisations working within the footprint of the two Vanguard sites to work together to 
address these challenges by supporting people to better manage their own care at home. The 
physical proximity of the Vanguard sites and their aligned focus on the provision of care for 
older people with LTCs through community-based approaches (albeit using different models 
of delivery), offered an ideal site within which the LCIA Test Bed could build on an existing 
system to implement the programme. By building on this infrastructure, the Test Bed was 
seen to offer strong potential for achieving substantial impact in an area of need and enabling 
wider adoption of proven technology. 
Lancashire and Cumbria Innovation Alliance – the partnership 
The LCIA was formed out of an already-established NHS / University partnership - the 
Lancaster Health Hub.  Through the Health Hub, Lancaster University worked with its 10 local 
NHS partner organisations to respond to this call by providing the drive, impetus and 
leadership for designing the Test Bed project and for developing the proposal. This included 
input from the University’s Centre for Ageing Research, which housed academic expertise for 
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a robust and independent evaluation of the Test Bed.  It also involved close working with the 
Innovation Agency (the North West Coast Academic Health Science Network). The NHS 
component of the LCIA focused on the two Lancashire NHS Vanguards, which were the sites 
for recruitment and data collection, as well as the Lancashire Care NHS Foundation Trust, 
which hosted the LCIA.  
The LCIA partnership also included a range of technology innovators, who were selected 
through a matching process that took place prior to the submission of the bid. The aim was 
to introduce bespoke combinatorial technological solutions to support the new models of 
care that were being implemented across the LCIA footprint. An iterative approach was used, 
involving a series of meetings with different large businesses in the Digital sector and senior 
representatives from the NHS Vanguards and Lancaster University. The need was defined 
according to which technology offer would best support the Vanguards’ proposed new 
models of care. At the first “match making” event the NHS partners pitched this need to 
technology providers who were potentially interested, to enable conversations to be opened 
up with those businesses whose solutions could potentially fit the need. A set of scoring 
criteria for assessing the technologies objectively and transparently was drawn up, and each 
potential technology partner was assessed through meetings at which the scoring criteria 
were applied. Philips Health Systems was selected as the LCIA lead innovation partner at this 
point.  
A second “match making” event enabled us to refine our proposal. The identified lead 
technology partner, Philips, was also able to help identify other potential collaborators. Some 
SMEs stepped back at this point for various reasons (i.e. some were unable to see a way 
forward without resource, others did not wish to work with other SME partners etc.). The 
final partnership included the following industry partners, SMEs, social enterprises and 
voluntary organisations, who brought their expertise and technology to help develop and 
introduce this technology-enabled, supported self-care programme: 
 Philips Health Systems 
 Speakset 
 Cambridge Cognition 
 Simple Telehealth 
 Intelesant 
 Good Things Foundation 
 House of Memories 
 
As the bid documents were developed, the combinatorial aspects were developed into a 
compelling narrative underpinned by strong and committed senior leadership from the NHS, 
a robust, high-quality evaluation proposal, and assured by the involvement of Philips Health 
Systems. 
 
Once the bid was awarded, a range of systems and processes for project development, 
implementation and governance were established specifically for this purpose. None of these 
were previously in place. This also required considerable work to configure new roles, appoint 
staff, prepare and submit proposals for ethical approval, and develop plans and systems for 




What follows in this section is an outline of the technologies used and the Cohorts within 
which they were applied. 
Innovator: Philips Technology: Motiva LCIA Test Bed Cohort(s): 1 
and 4 
Overview:  
Using Motiva, patients were able to take their own vital signs using wireless (Bluetooth) 
enabled weighing scales and blood pressure cuffs. Where appropriate, these were 
supplemented by manually entered readings from pulse oximeters and tympanic 
thermometers. These readings were collected through a tablet or television set top box and 
forwarded immediately to the clinical team looking after that patient. The Motiva Clinical 
system used risk profiling algorithms to prioritise patients whose vital signs indicated that 
an intervention was required. 
The clinical team were also able to schedule messages (hints & tips or reminders), 
educational video content (how to take your blood pressure, eating well) and surveys 
(traffic light, validated measures) for the patients to complete. 
  
For Cohort 1, Motiva was used to variously measure one or more of weight, blood pressure, 
pulse and SPO2 depending on the patient’s long-term condition. 
For Cohort 4, Motiva was used mainly for messaging, video and surveys. Vital signs could 
be monitored if the patient was being titrated onto a drug regime. 
 
Notes: 
Patients did not need broadband in their home (though Motiva can use domestic wireless 






Innovator: Philips Technology: Health Watch LCIA Test Bed Cohort(s): 2 
and 4 
Overview:  
This was a health watch (as opposed to a sports watch) with very accurate sensors. It does 
not feature GPS. It is best paired with a smartphone running the Philips Health Suite App. 
For Cohort 2, the watch was used to measure activity of patients with COPD 
For Cohort 4, the watch could be used to record sleep patterns, nutrition and hydration. 
 
Notes: 
Patients needed a smartphone (Apple or Android) to use the health watch. No patient in 





Innovator: Philips Technology: Personal Blood Pressure Cuff LCIA Test Bed 
Cohort(s): 2 
Overview:  
The blood pressure cuff worked in conjunction with the Philips Health Suite App to allow a 
patient to record their own blood pressure. It was not monitored remotely by a clinical 











Innovator: Speakset Technology: Domestic video calling LCIA Test Bed 
Cohort(s): 1 and 4 
Overview:  
Speakset provided a set top box that converted any domestic television into a video calling 
system. It uses the SCART socket on the back of the television to connect the set top box 
and utilises a simple to use remote control. The use of SCART meant that any call would 
automatically cut across the programme being watched; hence the patient did not have to 
do anything other than accept the call using the remote control. The patient was also make 
their own calls from the television. 
 
Whilst many video calling solutions are available, this one was chosen because it uses 
existing televisions (which nowadays are excellent quality, good size and have excellent 
sound). 
Notes: 
Patients needed broadband in their home for this to operate. Speakset was initially trialled 
but there were problems with NHS firewalls, hence the technology was not deployed more 
widely on the Test Bed. These issues have since been resolved. 
 
Images: 





Innovator: Intelesant Technology: COPD monitoring App  
(How are you Today?) 
LCIA Test Bed 
Cohort(s): 2 
Overview:  
This app was co-developed with Lancashire Care NHS Foundation Trust’s respiratory team. 
It asked the same 5 questions each day and recommended a strategy for the day depending 
on replies. Patients were able to invite others to share their plan, and could securely 
message between the patient, their connected people, and the clinical team.  The app 
enabled quick and easy checks whilst incorporating the individual’s action plan in response 
to changes in symptoms. 
 
Notes: 
Patients need a smartphone (Apple or Android) for this to operate. 
 
Images: 





Innovator: uMotif Technology: General symptom capture LCIA Test Bed 
Cohort(s): 3 
Overview:  
uMotif was used to capture patient data through an intuitive graphical user interface. It 
helped patients track and understand their health and symptoms. Up to 10 aspects can be 
captured (e.g. ‘how much coffee have I drunk’, ‘how much energy I have’) as well as 
providing: 
 Health report – compile your own health report, to help improve how the 
individual and his/her clinicians care for them 
 Wearable devices – connect to the individual’s own wearable devices including 
Fitbit, Withings and Jawbone  
 Medication reminders – enables patient to enter his/her own medications and set 
reminders so doses were not missed 
 Task lists – keeps track of the patients regular tasks and sends reminders 
 Daily diary – enables patient to keep a note of how they have been doing and 
enables the creation of a photo diary 
Notes: 
Patients need a smartphone (Apple or Android) to use this technology. 
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Innovator: Cambridge Cognition Technology: Cognitive Testing LCIA Test 
Bed 
Cohort(s): 
1, 2, 3. 
Overview:  
CANTAB Mobile is an assessment tool designed for healthcare professionals to identify the 
earliest signs of clinically significant memory impairment which may be indicative of 
Alzheimer’s disease. The assessment comprised three tests: the Paired Associates Learning 
(PAL) test to assess episodic memory; the Geriatric Depression Scale (GDS) to identify signs 
of depression and an Activities of Daily Living questionnaire (ADL) to assess functionality in 
daily life. Both the PAL and GDS tests were for completion by all patients; the ADL survey 
was only for completion by patients whose memory performance was below the expected 
range.  Using the normative data built in to the software, the patient’s performance would 
automatically be compared to others of the same age, gender and level of education. 
Standardised scoring was designed to ensure consistent interpretation of the results. 
Reports are available to view immediately and are easy to interpret by the healthcare 
practitioner. The aim was to help clinical teams to understand how best to work with their 
patients. 
Notes: 
Patients were to complete this test with a clinician. They would not need any devices to do 
so. The clinical teams trialled CanTab but there were appropriateness concerns and as a 
consequence it was not used within the Test Bed. These concerns have now been resolved 












Technology: SMS based reminders and 
vital sign tracking 
LCIA Test Bed 
Cohort(s): 1, 2, 4 
Overview:  
Florence text messaging service was designed to improve patients’ engagement, 
involvement and adherence to shared clinical management plans. The service is not specific 
to any condition and is suitable for conditions ranging from mental health, COPD, diabetes 
to Parkinson's and medication adherence.  It was designed to increase compliance and 
adherence to shared clinical management plans above the level achievable under normal 
care, with the aim of educating patients to manage their own condition and to participate 
in their own care. The system was designed to help patients in a closed loop environment, 
promoting self-reliance and independence, but it also works equally effectively where 
readings/responses are shared with clinicians in the traditional manor (with notifications 
of alerts where appropriate). 
 








Innovator: House of Memories Technology: Reminiscence Therapy LCIA Test Bed 
Cohort(s): 4 
Overview:  The House of Memories App allowed people living with dementia and their 
carers/families to explore objects from the past and share memories together. Though it 
can be used by anyone, it was designed for, and with, people living with dementia and their 
carers. 
 
The app allows people to browse through objects from across the decades, brought to life 
with multimedia, to reminisce about a range of everyday objects, from school life to sport. 
People are able to create their own memory tree, memory box or memory timeline. It is 
possible to create personal profiles for different people, so that they can save their 
favourite objects and look at them again.  
 
Notes:  Patients need a smartphone (Apple or Android) to use this technology. It was not 
possible to download House of Memories onto the Philips tablet. As a result, patients from 
Cohort 4  were encouraged to access it online. House of Memories came late to the LCIA 







Innovator: Good Things Foundation Technology: Digital 
Inclusion  
LCIA Test Bed Cohort(s): All 
Overview: The Good Things Foundation is the UK’s leading digital inclusion organisation, 
managing a network of 5,000 local places - the Online Centres Network - which provides 
people with the digital skills they need. Since 2013, the Good Things Foundation has been 
running the Widening Digital Participation programme, funded by NHS England, and has 
trained over 130,000 people to improve their digital health skills. They also run the Learn My 
Way learning platform (www.learnmyway.com), which hosts over 30 free courses to help 
people to improve their digital skills, including courses on how to use NHS Choices, and how 
to access GP services online. 
 
Notes:  Good Things  do not provide ‘at home’ one-to-one training for patients, or training on 
the specific technologies being used, hence referrals were limited. 
 
Images: 
    
 
 
Table 1.1 below summarises the combination of technologies provided by the innovator 
partners as used by cohort. In addition, patients in Cohorts 1 and 2 received a range of the 
following technologies dependent on their specific long-term condition: digital scales, pulse 





Table 1.1. Combinatorial Technologies by Cohort 
 
*Installation of these technologies was limited or laid down for this Test Bed. 
 14 
 
3. AIMS AND OBJECTIVES OF THE LCIA TEST BED EVALUATION 
Aims: 
The Test Bed evaluation aimed to focus on two key outcomes:  
Firstly, the extent to which supported self-care telehealth technology might improve patient 
outcomes and the patient experience for frail older people living with long-term conditions in 
Lancashire and Cumbria.  
Secondly, the potential cost effectiveness of the intervention and how this might be scaled 
up to provide better value for both patients and taxpayers. 
Objectives: 
Key objectives of the evaluation were to: 
a) Identify benefits to patients and patient outcomes to include: increased sense of 
empowerment and improved quality of life: increased service satisfaction; enhanced 
knowledge, skills and confidence; enhanced patient activation; 
b) Undertake an economic evaluation (for Cohorts 1 and 2) of costs and cost reductions 
associated with the intervention in comparison to existing services and shifts in resource 
consumption (reducing avoidable healthcare utilisation e.g. medication, GP and other health 
professional visits, home visits, length and number of in-patient admissions and community 
service use); 
c) Identify the strengths and weaknesses of the intervention and how these may be built on 
or addressed; 
d) Assess how the intervention may improve on existing services, make best use of voluntary 
and community services and increase patients' ability to self-care; 
e) Assess the impact of the intervention on the workforce in terms of communication 
between care teams, productivity, capacity and co-ordination of care, work satisfaction. 
f) Identify how the intervention might be constructed as a model that could be scaled up to 




2. EVALUATION DESIGN AND METHODOLOGY 
Ethics and Ethics Approvals 
The evaluation was designed in two inter-linked phases to capture different information 
designed to address the objectives identified above. Phase 1 consisted of a longitudinal survey 
undertaken at three time points and control data (3:1) drawn from the Clinical Commissioning 
Support Unit (CSU) (further details below). The survey was designed to gather information 
which would allow us to assess any change in cost and service usage arising as result of the 
intervention as well as impact of the intervention on patient outcomes. In discussion with the 
Health Research Authority (HRA) and in agreement with the NHS Research and Development 
managers of those NHS trusts involved in the programme, Phase 1 was deemed to be service 
evaluation and as such did not require NHS ethical approval. In keeping with the ethical 
requirements of Lancaster University however, we submitted and received ethics approval 
from Lancaster University’s Faculty of Health and Medicine Research Ethics Committee for 
Phase 1 of the evaluation (Reference: FHMREC16025). 
Phase 2 of the evaluation adopted a qualitative design and focused on understanding the 
impact and experiences of patients using the technologies, and the impact on working 
practices amongst members of staff involved in the delivery of the technologies. Phase 2 was 
deemed by the HRA to be gathering new data and was thus defined as research requiring HRA 
approvals (IRAS Project ID: 208395). Phase 2 of the evaluation was also adopted onto the 
National Institute for Health Research portfolio.1  
Evaluation Design 
The two phases of the evaluation design adopted different methods, sampling and 
recruitment strategies. Each had its own participant information sheets, consent forms and, 
where applicable, schedules (e.g. for the interviews and focus groups) (see Appendices). A 
separate flyer was designed for patients with dementia, providing information about the 
study in an informative and accessible manner, drawing on images and large font (see 
Appendices). In all instances, it was made clear to patients that they could be supported by a 
carer or other family member if they wished.  
All materials developed for the evaluation and submitted to ethical review were shared and 
informed through discussion with: patient by experience groups (including those with 
dementia); a clinical reference group; and an evaluation advisory board. Feedback and 
comment from these three groups was taken into account in finalising the documents 
submitted for ethics approval. 
Further details regarding participation and informed consent to Phase 2 are detailed below in 
the Phase 2 methodology section.  
                                                     
1 NIHR Portfolio reference number is the same as the IRAS number (IRAS Project ID 208395)  
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Participation and informed consent 
Patient participation in Phase 2 of the evaluation was optional and participants were asked 
to indicate if they were willing to take part in Phase 2 in the Phase 1 consent form. Those 
subsequently selected to participate in Phase 2 were consented at the time of their first 
interview. To ensure informed consent and that each participant understood what they were 
consenting to, the researcher discussed each aspect of the form with each participant before 
it was signed. Ethical approval was received from the HRA for an alternative consent form 
with a large font size, and for which clauses on the consent from could be cut into strips, with 
one clause per strip of paper (see Appendices) This enabled the researcher to go through each 
clause with the participant, focusing on one clause at a time. Once the participant understood 
the clause, they were asked to initial it. This option made the information in the consent form 
more manageable for some patients. Prior to ethical approval, this was discussed and 
approved by the Lancaster patient by experience group (linked to the NHS). This approach 
was particularly useful for those patients with poor cognitive ability. Consenting a person to 
Cohort 4 (the dementia cohort), was undertaken with the patient in the presence of a family 
member, friend or carer. 
Anonymity and data  
All qualitative data was audio recorded using an encrypting digital voice recorder. In the 
process of transcription, names of participants were anonymized and any identifying features 
removed or coded. These points were included in the consent forms and discussed with each 
participant before the interview/action research meeting/focus group/deliberative panel. All 
audio files were deleted from the recorder once data analysis was complete. 
Appendix 23 contains information regarding participant payment, data storage, participant 
benefit, potential risk to participants, withdrawal and researcher risk. 
Test Bed Survey 
Self-reported data was collected from the Test Bed participants through a survey undertaken 
at three time points across the 6 months during which they received the intervention: 
baseline, week 12 and week 24. More detail on the survey is provided below.  
Clinical teams from the Vanguard sites, the Evaluation Advisory Group and a ‘patient by 
experience group’ gave feedback on the survey to the Evaluation Team to help fine-tune the 
survey and ensure clarity in the questions asked.  
In general, we received positive comments from participants on the survey. Most participants 
and the clinical teams noted that the language was user-friendly, though some participants 
were unclear about one or two questions. The clinical teams, with the support of the 
Evaluation Team were able to clarify any issues with the survey when needed. 
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Methodology: Phase 1 
Recruitment 
Patients aged 55 years and over who had a long-term condition, including COPD, dementia, 
diabetes and heart failure, were recruited into one of four cohorts dependent on their level 
of risk of hospital admission. Table 2.1 sets out the recruitment criteria.2  
Table 2.1. Recruitment criteria for the four LCIA Test Bed Cohorts 
Cohort Age 




Aged 55 years 
or over 
>25% 
COPD, Heart Failure (HF) 
Cohort 2 10%< risk <25% 
Cohort 3 <10% Diabetes, Asthma, CHD, Hypertension 
Cohort 4 N/A 
Early stage dementia  
(ACE-III assessment tool) 
 
Patients were recruited to the Test Bed by the clinical teams and all patients consenting to 
take part in the programme and receiving the technology were required to participate in 
Phase 1 - the Service Evaluation. The Midlands and Lancashire Clinical Commissioning Support 
Unit (CSU) shared data on long-term conditions and risk of hospital admission with the clinical 
teams to aid identification of potential Test Bed participants. The risk of admission was 
calculated using the Combined Predictive Model.3  
Using information on the percentage of frail and older patients and the number of patients 
estimated to be appropriate for the service in both the Fylde Coast and Better Care Together 
Vanguard Sites, it was originally envisaged that a total of 1,600 patients would be recruited.  
Cohorts 1-3 each had a target of 500 patients with Cohort 4 (early stage dementia) having a 
smaller target of 100 patients. Details of actual recruitment to Phase 1 of the evaluation and 
recruitment trajectories are discussed in the findings section. 
The process of consent and overseeing completion of the Phase 1 surveys was conducted by 
the clinical teams to ensure patient confidentiality; the Evaluation Team did not have access 
to any identifiable patient data in Phase 1.  
Sources of Data 
The dataset used for the evaluation of the Test Bed was created by linking and 
pseudonymising data from the intervention and control group as explained below. 
                                                     
2 Varey et al. 2018. Available at: 
 http://bmjopen.bmj.com/content/8/2/e017268.full?ijkey=bV4BAyJkDLLBABt&keytype=ref Accessed on: 1 
March, 2018. 
3 This Model allows segmentation of the population into relative risk segments and facilitates matching the 
intensity of outreach and intervention with the risk of unwarranted secondary care utilisation. For further 
reference see Wennberg et al. Combined Predictive Model: Final report and technical documentation. London, 




Phase 1 of the evaluation consisted of survey data collected from all Test Bed participants and 
data provided by the CSU for the matched control. 
Participants recruited to the Test Bed were asked to complete 3 surveys each in total: at 
baseline, week 12 and week 24, with a 4-week recall period. The survey included 
sociodemographic data; validated instruments for use with older people to assess health 
related quality of life (HRQoL), health and wellbeing; and use of health care services (hospital, 
primary care and social care services, and medication).4 
For the Test Bed group, the CSU provided one dataset with patient-level administrative 
hospital data for the Fylde Coast and Better Care Together Vanguard Sites. Data included age, 
gender, risk score, and long-term conditions based on primary care data. 
Patients included in the analysis 
The following Test Bed patients were included in Phase 1 of this Evaluation: 
 Patients satisfying the recruitment criteria in terms of age (55 years and over), risk of 
hospital admission and long-term conditions; 
 Participants who completed the 24-week Test Bed programme. We excluded 
individuals who withdrew part-way through the programme; 
 Participants for whom the CSU is allowed to extract data from primary care systems;5 
 Participants for whom the CSU has risk stratification data.6 
For various reasons (including withdrawal, surveys lost or not completed at the appropriate 
time point) we did not have complete survey data for all patients. Following discussion, the 
Evaluation Team took the decision to include only those patients who had completed surveys 
at all three time points. We acknowledge that differences between completers and non-
completers may have implications for the final results, but we cannot assess exactly how this 
might bias the results. More on the implications of this decision will be included in the 
discussion section.  
Comparator group 
The control group was a retrospective sample of patients receiving treatment as usual. It 
comprised people aged 55 and over, with a primary or secondary diagnosis of COPD or heart 
failure, and with predicted risk of admission probability of 10% or greater. These patients 
received standard care in the same Vanguard sites twelve months prior to the start of the 
                                                     
4 To ensure survey data consistency, the survey information was centralised using the software Qualtrics. 
5 Also known as individuals that are not under ‘type 1 objector’. Patients under ‘type 1 objector’ are patients for 
whom the CSU is not allowed to extract data from primary care systems. 
6 This included patients that were not deceased by the date of data extraction (23 April 2018).  Deceased 
patients’ information is removed from the risk stratification processing and the CSU does not keep records of 
their primary care data. Therefore, there is no information to link to.  
Ten Test Bed participants who completed the 24 week intervention have deceased before 23 April. Of them, 5 
participants completed the survey at all 3-time points. The CSU shared risk stratification data as of 30 November 
2017, so we were able to use this information for the 5 participants in this condition.  
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Test Bed programme. Data included identified patients with a hospital discharge date 
between 1 July 2015 and 30 June 2016.  
For the control group, the CSU provided one dataset with patient-level administrative hospital 
data for the Fylde Coast (including Blackpool and Fylde and Wyre Clinical Commissioning 
Group) and Better Care Together (Morecambe Bay)7. Control data included age, gender, risk 
score, and long-term conditions based on primary care data, and hospital service use (A&E 
visits, hospital inpatient admissions, and outpatient visits).8 
Final extraction of all CSU datasets was conducted on 23 April 2018. 
Data Governance 
All patients were recruited by the clinical teams and each was allocated a unique ‘Test Bed 
Code’ by the Test Bed management team. This code was shared with both the CSU and the 
Evaluation Team. The NHS number (and any other patient identifiers) of Test Bed participants 
was held only by the Test Bed management team, clinical teams and the CSU. 
The Test Bed management team shared the ‘Test Bed Code’ and the NHS number with the 
CSU via the Data Services for Commissioners Regional Office (DSCRO) so the latter could 
extract the control sample ensuring that no controls were drawn from the Test Bed 
intervention group. This process ensured only CSU and DSCRO authorised staff within the 
Data Warehouse department were able to manipulate patient identifiable data. 
The Evaluation team were not able to identify the NHS number of patients or any sensitive 
information about participants (e.g. name, address, phone number, NHS number). Hence, 
there was no risk of breaking pseudonymisation either in the Test Bed or control groups. 
Survey Data Collection 
Survey data was collected between 18th October 2016 and 27th April 2018. A total of 460 
participants were considered to be ‘active’9 in Phase 1 of the evaluation. From them, the 
Evaluation Team received 394 baseline surveys, 368 mid-point (12-week) surveys and 373 
end-point (24-week) surveys. These figures varied significantly between the two Vanguards 
sites and across the cohorts.  
In total, 317 Test Bed participants completed both the 24-week intervention and all three 
time-point surveys. This means that at least one survey was missing for 143 of the 
participants, who either did not complete a baseline and / or a mid-point survey. Two 
participants were excluded from the analysis for the following reasons: one participant was 
under the age of 55 years at the time of consent, and the CSU did not have the risk 
                                                     
7 Lancashire North CCG merged with the South Cumbria element of Cumbria CCG on 1st April to become 
Morecambe Bay CCG. 
8 The CSU shared a patient-level and hospital admission-level dataset which was linked using a variable ‘Digest’, 
which is the non-reversible encrypted, pseudo NHS number field. The control data came from the ‘Aristotle’ 
system with two month delayed information. The CSU data has not been subject to rigorous data cleaning and 
validation. 
9 Patients who completed the 24-week programme by the end of April 2018 and were therefore considered 
active in the Phase 1 Evaluation. 
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stratification information for another participant. This gave a total of 315 Test Bed 
participants with complete datasets across the cohorts and both Vanguards sites. 
Participants recruited to Cohorts 1, 2 or 3 were offered the option of completing either a 
paper-based or an online survey. Following consultation with clinicians, Cohort 4 participants 
(early stage dementia) were only offered the paper-based survey. Where participants 
indicated a preference for the paper-based version of the survey, this was administered by 
the clinical teams and then forwarded to the Evaluation Team. Whilst the evaluation team did 
not interact directly with participants regarding survey completion, an evaluation team 
member was available to provide support to participants and clinical staff if required.  
Details of the number of surveys collected from active participants, the type of survey (paper-
based or online) and the number of missing questionnaires are presented in Table 2.2. Further 
detail of surveys received and missing surveys per Cohort is included in Appendix 1. 
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Table 2.2. Survey data collection: October 2016 to April 2018  
Cohort 
Baseline surveys 12-week surveys 24-week surveys 
Total 
















163 34 155 35 158 36 
137 32 169* 












18 Missing 3 Missing 26 Missing 2 Missing 23 Missing 1 Missing 
2 
118 48 103 46 116 41 
87 39 126 











30 Missing 5 Missing 45 Missing 7 Missing 32 Missing 12 Missing 
3 
11 5 10 4 5 2 











4 Missing 6 Missing 5 Missing 7 Missing 10 Missing 9 Missing 
4 
15 15 15 
15 15 15 Paper 15 Paper 15 Paper 
0 Missing 0 Missing 0 Missing 
TOTAL 
394 368 373 
229 88 317 290 Paper, 104 Online 295 Paper, 73 Online 332 Paper, 41 Online 
66 Missing 92 Missing 87 Missing 
*Two participants were excluded from the analysis: one participant was younger than 55 years at the time of consent, and the CSU does not have the 
risk stratification information of another participant. 
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A higher percentage of participants recruited from both Vanguards preferred to complete 
paper-based rather than online surveys. The percentage of mid-point online surveys 
decreased with time. Figure 2.1 shows that the percentage of patients completing online 
surveys in Better Care Together went from 26% at baseline to 19% at 12-weeks and 10% at 
24-weeks. A similar trajectory holds in the Fylde Coast, going from 33% at baseline dropping 
to 26% at 12-weeks and 16% at 24-weeks. These figures may be a reflection of both patients’ 
preferences and operational feasibility during the data collection process.  
Figure 2.1. Paper-based and online surveys per Vanguard Site 
 
To prevent inconsistency, incompleteness or missing data, we undertook a data quality 
assurance process, working closely with the clinical teams to minimise the risk of receiving 
inconsistent or incomplete questionnaires. However, it is important to note that the Test Bed 
population comprised frail older people with long-term conditions. As with all surveys, some 
participants preferred not to respond to certain survey questions, provided inconsistent 
information, or did not complete all three surveys. 
Healthcare Resource: Use and Cost 
We estimated the costs of resource use (hospital services, primary care, social care, 
community mental health and other community-based services), technology and medication 
intake. All costs were assigned as nominal prices as of 2017. No discounting (0%) was taken 
into consideration for the time horizon of this evaluation10 and we did not adjust for inflation. 
Data sources, unit costs, assumptions and data processing details are provided below.11 
Healthcare resource use 
Healthcare resource use was costed using published national reference costs. We obtained 
unit costs from two sources: the PSSRU Unit Costs of Health and Social Care (2017); NHS 
                                                     
10 It is common practice not to apply discount rates for economic evaluation with short (e.g. less than one year) 
time horizons (Husereau et al. 2013). 
11 It is important to note that the cost and use of healthcare resources, cost of technology and medication use 
in this evaluation are estimates based on a number of assumptions. The cost estimates provide an indication of 
























reference costs 2016/17. Unit costs are shown in Table 2.3 and further details on the 
assumptions are provided in Appendix 2. We report average costs in each of the services. 




Unit of measure 
Hospital Services     
Accident and Emergency 259 Visit 
General Hospital Inpatient Admission 3,903 
Stay 
Community Hospital Inpatient Admission 3,903 
Day Hospital a 727 Visit 
Outpatients Visits to Clinical Based at Hospital Site 137 Appointment 
Primary Care, Community Health Services 
General Practitioner (GP) 183 
Working hour 
Paramedic (Ambulance Service) 36 
Community Matron 53 
Community/District Nurse 53 
Practice Nurse 36 
Specialist Nurse 62 
Social Care Services      
Social Worker or Care Manager 59 
Working hour Home Care/Home Help Worker 21 
Private home help/cleaner* 12.5 
Community Mental Health Services   
Psychiatrist / Psycho-geriatrician 108 
Working hour Community psychiatric nurse / Community mental health nurse 62 
Other mental health professional 44 
Other Community-Based Services     
Telecare 36 
Working hour Dentist/ Oral Hygienist 101 
Optician 45 
a Day hospital refers to a medical treatment that has to be administered at the hospital but does not require 
overnight stay. 
Source: Unit Costs of Health and Social Care 2017; NHS reference costs 2016/17. * Online quote for Lancaster 
Technology costs 
The costs of the intervention include technology costs plus the costs of programme delivery 
by clinical staff and are estimates based on different sources and assumptions. In order to 




To cost the license of software (in lieu of the costs of the Motiva software), we considered 
software that is licensed to users and for which a regular payment is due.12 We assume that 
a licence fee includes contingency costs (e.g. battery replacement, power lead, and technical 
support). Regarding equipment, we considered the prices of technologies that had similar 
characteristics to the Test Bed toolkit and which are available in the market (e.g. tablets, 
weighting scales, blood pressure meters, thermometer, mobile apps which require licenses). 
We assumed that people keep their equipment, there were no data storage fees, and that 
the clinical equipment did not have a long-term value.13 Costs shown do not include 
deinstallation and refurbishment (data cleaning) rates. Due to the lack of availability of data 
on the actual technology devices, we did not consider economies or diseconomies of scale in 
the acquisition of equipment. We did not include staff costs of the Test Bed programme 
administration as in wider rollout this would become part of everyday practice that would not 
require specific Test Bed administration.14 
We report the unit cost per patient in each cohort considering the care pathways including 
different combinations of technology: 
 Cohort 1. Three care pathways in both Vanguards: Motiva for patients with COPD; 
Motiva for patients with heart failure; and CANTAB Mobile for all Cohort 1 patients 
(with COPD or heart failure);  
 Cohort 2. Two different care pathways in each Vanguard. For cohort 2 patients in the 
Fylde Coast the care pathway included a combination of Flo, Intelesant and the Health 
Watch. In Better Care Together, the care pathway included a combination of Flo and 
Intelesant.  
We made assumptions to calculate staff costs using the clinical teams’ experience in the Test 
Bed to calculate healthcare staff-time needed to operate the Test Bed programme. We know 
from the focus groups and action learning meetings that staff in different salary bands in each 
Vanguard were involved in conducting the readings, interpreting the information from the 
technology and alerting patients using the toolkit. We report technology and healthcare staff-
time average unit costs per Cohort and care pathway. We also show the total cost per 
Vanguard using the average unit costs. 
Table 2.4 presents the unit costs for costing technology and we provide further details on the 
assumptions in Appendix 3. 
                                                     
12 As for Motiva, the platform provides a service where patients are given access to web based contents relevant 
for the management of their disease. Patients are also given the option to report some health measurements 
on a regular basis. Information reported by patients is stored and alerts are issued to physicians/nurses/carers 
if measurements are out of line. This is the type of service that is licensed to users. Given these general features, 
we have assumed the price of the statistical package SPSS. See for reference: https://www.ibm.com/uk-
en/marketplace/spss-statistics/purchase#product-header-top Accessed on 28 February 2018. 
13 The cost of technology used over a period of time was not amortised over the technology’s useful life. 
14 The cost-effective analysis was done from a UK National Health Service perspective. Therefore, the potential 




Table 2.4. Costs of Test Bed technology and healthcare staff needed per Cohort: Unit costs  
Technology Cost 
Care Pathway a License/Equipment 
Unit Cost 
(£) 
Technology: Motiva toolkit (Cohort 1)   
Cohort 1 (all 
participants HF or 
COPD) 
License Fee 949.56 
Installation 135.00 
Tablet  79.99 
HF 
Wireless weighing scale 80.00 
Blood pressure meter 86.80 
Tympanic Ear Thermometer 16.79 
COPD 
Pulse oximeter (SPO2 monitor) 35.99 
Tympanic Ear Thermometer 16.79 
Technology: Intelesant (Cohort 2)   
Cohort 2 Intelesant License App 9.53 
Technology: Florence/NHS Simple toolkit (Cohort 2) 
Cohort 2  
Flo 
License fee 109.11 
Message fee 12.00 
Tympanic ear Thermometer 16.79 
Pulse Oximeter (SPO2 Monitor) 35.99 
Blood Pressure Monitor 86.80 
Phone (basic cell phone) 10.00 
Technology: Philips Health Watch (Cohort 2)   
Cohort 2  
Health Watch 
Philips Health Watch 157.99 
Technology: CANTAB Mobile (Cohort 1 & 2)   
Cohort 1 and 2 Access to the tool 0.85 
Notes: a While Speakset was originally envisaged as part of the combinatorial technologies on offer, in practice 
this was not used by Test Bed participants. 
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Healthcare Staff Cost 
 
Care Pathway Staff 
Unit Costa 
(£) 
Fylde Coast:  
 
Motiva  
Cohort 1 (all 
participants HF or 
COPD) 
Staff (2 nurse practitioners band 8 and 1 GP 
Consultant)  
 
Reading, interpreting (excluding alerts) 
152.86 
Staff  (2 nurse practitioners band 8 and 1 GP 
Consultant)   
 






Cohort 1 (all 
participants HF or 
COPD) 
Staff (2 nurse practitioners band 8 and 1 GP 
Consultant)  
 
Reading, interpreting (excluding alerts) 
185.61 
Staff  (2 nurse practitioners band 8 and 1 GP 
Consultant)   
 
Only alerts to patients 
46.40 





Staff (GP consultant)  
 
Reading, interpreting (excluding alerts) 
9.92 
Staff  (GP consultant)  
 





Flo and Intelesant 
Cohort 2 
Staff (GP consultant)  
 
Reading, interpreting (excluding alerts) 
163.72 
Staff  (GP consultant)  
 
Only alerts to patients 
27.29 
Note: 
The unit cost is calculated using the cost per working hour, the number of hours and days the staff is involved in 
the Test Bed to estimate the total cost of a week. Then this is scaled to a year and divided by the number of 
cohort members recruited in each Vanguard Site. The unit of measure of the unit cost is staff time per patient. 
 
We report the average unit costs per cohort by showing the average costs of technology and 
healthcare staff by Cohort and Vanguard.  
For the cost-effectiveness analysis we added the unit cost per patient per cohort at the end, 
as we know that these costs only apply to patients in the intervention group.  
Medication 
We followed a micro-costing approach to achieve reliable cost estimates.15 We obtained 
medication unit costs from two commonly-used resources. Firstly, we used the Drug Tariff 
                                                     
15 This represents a challenge. Data on medication requires care and time to collect, and careful documentation 
should be done on how to collate unit costs and process data, including addressing the potentially multiple 
missing-data scenarios that could exist across the relevant variables (see Patel et al, 2017). 
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that lists the price that the NHS reimburses pharmacies for drugs, dressings and devices.16 
Secondly, we used the MIMS online database of prescription drugs. This provides prices of 
new branded drugs that are not included in the Drug Tariff.17 We applied costs of generic 
preparations over branded versions to ensure cost estimations were conservative.  
The costs of medication intake in this evaluation are estimates based on a number of 
assumptions.18 Unit costs tables are not presented here but are available upon request from 
the Evaluation Team. 
The protocol for handling partially missing or incomplete medication and the approach to 
estimating daily costs of prescribed medications is included in Appendix 4. 
Annual average cost: 
The average cost per day per medication was calculated considering the medications reported 
at all three time points per type of medication (LT, MT or ST) and the average number of 
patients taking each type of medication. 
We report the average cost of medications per participant over a 24-week period and the 
annual average cost per type of medication in each cohort, this is generated by multiplying 
the annual cost per day by the proportion of patients taking medications.  
Statistical Analysis 
In the following subsections we set out the methodology used for the quantitative analysis. 
This includes information related to Cohorts 1, 2 and 4. Recruitment to Cohort 3 proved 
challenging as it involved those aged over 55 years with a long-term condition but with a low 
risk of hospital admission (< 10%). As a result, few of these patients were readily identifiable 
to GPs and were difficult to identify through more general recruitment processes. To 
understand this situation, we draw on the example of Better Care Together: 
                                                     
16 The Drug Tariff is issued on a monthly basis. This is good for generic drugs and drugs that are used often. 
Amendments to the Drug Tariff. November 2017. Available at: https://www.nhsbsa.nhs.uk/pharmacies-gp-
practices-and-appliance-contractors/drug-tariff/drug-tariff-updates. Accessed on 10 November, 2017. 
17 Available at: https://www.mims.co.uk/ Accessed on 10 November, 2017 and 3 January, 2018. 
18 Assumptions have been agreed in consultation with a lead GP working within TB. 
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         Strategies and Challenges for Recruitment to Cohort 3 
To recruit to Cohort 3, staff in GP practices searched their patient database 
using the necessary cohort criteria and producing a list of NHS numbers. A clerk 
then logged on to the EMIS system and entered each nine-digit NHS number to 
retrieve individual patient details. At this point the clerk checked each patient 
record for a mobile phone number or email address, indicating that the patient 
may have a Smartphone or Tablet and so suitable to participate. Patients were 
then contacted by the clerk to explain that their GP surgery was part of the Test 
Bed and that the doctor thought that they may benefit from taking part. If the 
patient was willing to take part, they were offered an appointment to attend a 
meeting at the surgery. Despite these efforts, recruitment to Cohort 3 was 
unsuccessful. Many patients did not have a mobile phone number and/or email 
address on file, limiting the number of patients that could be contacted.  
Phase 2 interviews conducted with Cohort 3 patients also suggested that other 
factors may include: not being invited to take part by a healthcare practitioner 
known to the patient; that people in this cohort do not consider themselves to 
be unwell or to have a long-term condition; and that the technology being 
offered did not have an element of interaction or monitoring with healthcare 
staff.  
 
Following discussion with NHSE, the LCIA took the decision to stop recruitment of Cohort 3 at 
an early stage. Whilst a small number of patients had been recruited to this cohort, and 
remained on the Test Bed, figures were too low to allow for any meaningful statistical 
analysis, hence these patients are not included in Phase 1 of the evaluation.   
Health Related Quality of Life and Wellbeing of Test Bed participants 
Changes in health and wellbeing were measured through validated instruments to assess 
health related-quality of life (HRQoL) and wellbeing of Test Bed participants and also through 
the more in-depth qualitative data discussed in other sections in this report.  
For all cohorts, the following validated instruments were used: EQ-5D-5L; Patient Activation 
Measure (PAM13); Warwick-Edinburgh Mental Wellbeing Scale (WEMWBs); and the De Jong 
Gierveld Loneliness Scale.19  
First, we report the number of participants to be included in the statistical analysis of the 
validated instruments used to assess HRQoL. We present the mean values per instrument at 
baseline, 12 and 24 weeks. We also show the sample size, maximum and minimum values per 
instrument and time point. Finally, we report these descriptive statistics per Vanguard site.  
                                                     
19 Only patients judged by a clinician to have an acceptable level of cognitive function to give informed consent 
are invited to take part in the Test Bed. Therefore, the self-reported measures are valid for all the participants 




The EQ-5D is perhaps the most well-known and widely used generic preference-based 
measure of HRQoL for economic evaluation of health care technologies. It comprises five 
dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.20 
Each dimension requires the participant to complete one of five potential responses (scored 
1 to 5) with a sliding scale for health on the day of survey completion (scored 1-100, with 1 = 
poorest health). To compute the index scores, we used the tariffs published for the English 
population (Devlin et al., 2018). 
We report the EQ-5D-5L health profiles at all three time points and 95% confidence intervals 
per cohort. We used a correlation matrix to explore the correlation between the EQ-5D 
dimensions with sociodemographic variables. 
PAM-13 
Individuals’ activation21 was measured using the PAM-13 instrument, which provides two 
core metrics: the PAM score and the PAM level. The activation score is based on a 0-100 point 
scale (100 being the ‘highest’ activation score), with most individuals having activation scores 
between 30 and 90. The activation score is used to categorise individuals into one of four 
progressively higher levels of activation, level 1 being the lowest and level 4 the highest.22  
The developers of PAM13 (Insignia Health®) require all PAMs data be sent to them for 
processing and calculation of the mean PAM score per level of activation. Hence the 
Evaluation Team did not compute these results directly. The percentage of the population 
who improved, declined, or did not change was calculated in comparison to other levels of 
activation due to Test Bed participation. We show the changes from baseline to 24 weeks for 
the overall Test Bed population and for Cohorts 1, 2, and 4. 
WEMWBS 
The Warwick-Edinburgh Mental Well-being Scale (WEMWBS)© is a useful tool for monitoring 
mental wellbeing. This instrument enables investigation of the determinants of mental 
wellbeing. It comprises 14 positively worded statements with five response categories from 
‘none of the time’ to ‘all of the time’ with a two-week recall period. This tool provides a single 
score ranging from 14-70, with 14 being the ‘lowest’ wellbeing score and 70 the highest.23 
                                                     
20 Further details on Eq-5D-5L can be accessed at: https://euroqol.org/ Accessed on: 10 July 2016. 
21 Activated individuals are defined as those who have the knowledge, skills and confidence to self-manage their 
health. These three domains create an underlying human behavioural construct that allows individuals to be 
effective and efficient at self-managing their health or appropriately accessing care (Insignia Health. Patient 
Activation Measure (PAM) Practice Manual). 
22 Level 1 is defined as the ‘Disengaged and overwhelmed’ level; level 2 the ‘Becoming aware, but still struggling’; 
level 3 the ‘Taking action’; and level 4 ‘Maintaining behaviours and pushing forward’ stage. For further reference 
see: ©2017 Insignia Health. Patient Activation Measure® (PAM®) Practice Manual. All rights reserved. ©2017 
Insignia Health. Patient Activation Measure® (PAM®) Administration System. All rights reserved. 
23 See for reference: The Warwick Medical School available at: 
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The Evaluation Team calculated the WEMWBS scale using the information from the official 
user guide.24 We show the mean index values of the score at all three time points and 95% 
confidence intervals per cohort. 
De Jong Gierveld Scale 
Perceived loneliness by Test Bed participants was measured using the De Jong Gierveld 
Loneliness Scale25, a commonly used scale translated and validated in several European 
countries. The Jong Gierveld is a 11-item scale with three response categories, summed to 
provide a single score ranging from 0-11 (11 being the highest score or highest level of 
loneliness).  
We estimated the De Jong Gierveld Loneliness score using the information from the Manual 
of the Loneliness Scale. We report the mean index values of the score at all three time points 
and 95% confidence intervals per cohort. 
Healthcare Resource: Use and Cost 
We provide a summary of the average service use reported by Test Bed participants and the 
average cost at each time point by cohort including the following services: hospital (A&E 
admissions, inpatient admissions, and outpatient attendance); primary care; social care; 
community mental health; and other community-based services (e.g. dentist, optician).26  
Regarding the cost of technology, we report on the average cost per patient on technology 
and healthcare staff per Cohort using information from both Vanguard Sites 
Regarding medication, we report on the number of medications taken by Test Bed 
participants by type of treatment (long, medium or short-term medications). We also report 
the average annual cost per patient. 
Cost Analysis 
In the following subsections we describe the methodology for the cost analysis including 
Cohorts 1 and 2. 
Selecting the matched controls 
We selected a control group, consisting of three controls per Test Bed participant, matched 
for gender, age, long-term condition, and predicted probability (risk) of hospital inpatient 
                                                     
 https://warwick.ac.uk/fac/med/research/platform/wemwbs/  Accessed on: 15 August, 2016. 
24 User guide available at:  
https://warwick.ac.uk/fac/med/research/platform/wemwbs/researchers/userguide/wemwbs_user_guide_jp_
02.02.16.pdf Accessed on: 15 August, 2016. 
25 Jong-Gierveld, J. D. (1999). Manual of the loneliness scale. Available at: 
 https://research.vu.nl/ws/portalfiles/portal/1092113 Accessed on: 15 August, 2016. 
26 All costs refer to the use of healthcare resources reported by patients from October 2016 to April 2018. 
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admission. We performed the matching using a Mahalanobis distance algorithm without 
replacement of the selected controls. The main aim of the matching was to minimise any 
potential confounding effects of the matching variables and hence obtain a control group with 
similar characteristics to the Test Bed participants. 
Outcome measures: secondary care utilisation 
Our measures of secondary care use included A&E visits, outpatient appointments and 
inpatient admissions. In terms of inpatient admissions, we report the number of Test Bed 
participants admitted to hospital at baseline, 12 weeks, and 24 weeks.27 For the purpose of 
this evaluation, we consider that a Test Bed participant has been admitted to hospital if they 
have reported a general hospital or community hospital inpatient admission. This includes 
elective admissions and pre-arranged hospital admissions.28 Additionally we report A&E visits 
and outpatient appointments at each time point. When comparing the Test Bed participant 
figures with the controls at the three time points, we scaled the Test Bed results by a factor 
of four to make the data comparable for a one-year period. This is because we had data over 
one year for the controls. Hence, we compared the scaled baseline period for the Test Bed 
participants to the first 4-month period for the controls; the scaled 12 week survey results to 
the second 4 month period for controls; and the scaled 24 week survey results to the third 4 
month period for controls. 
We report the proportion of patients admitted to hospital for the control group over 12 
months - additionally splitting this into three periods of four months to match the phasing of 
the three surveys. We also report this split by cohort. Finally, we also report accident and 
emergency use and outpatient appointments for the controls. 
To compare the difference between the Test Bed participants and the control group we 
estimated the change in service use over the respective data collection periods. We then 
compared these changes between the two cohorts using a z-test for a difference in 
proportions. 
A simple comparison of service use before and after the Test Bed intervention would not have 
included a control group as a baseline. 
No contamination between the control group and Test Bed participants occurred because the 
Test Bed participants were excluded from the control sample. Additionally, the combination 
of technologies provided by the LCIA Test Bed was not available to the controls. 
                                                     
27 We did not consider it necessary to adjust for seasonality because Test Bed participants were recruited from 
October 2016 to October 2017. As such we recruited participants at different times of the year hence any 
differences arising due to seasonality should average out across the participants. 
28 Elective inpatient admission data exclude emergency admissions or the transfer from a Hospital Bed in another 
Health Care Provider. Definition available at: 
https://www.datadictionary.nhs.uk/data_dictionary/nhs_business_definitions/e/elective_admission_de.asp?s
hownav=1 [Accessed on 1 July 2016]. 
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The control data comes from the year prior to the implementation of the Test Bed 
programme. Therefore, we have data for the controls over a calendar year. Participants were 
active on the Test Bed over an 18 month period because they were recruited in waves 
throughout the Test Bed programme. Whilst recognising that seasonal variations in hospital 
admissions occur, it is our view that the results, for both controls and Test Bed participants, 
were not affected by such variations as data collection occurred over more than one calendar 
year (see Figure 4.1 for Test Bed recruitment trajectories). 
For both controls and Test Bed participants we report within group differences in hospital 
admissions between the three respective time points for each group. We then report a 
difference in difference analysis between control and participant groups over 12 months. We 
also report this analysis for cohorts 1 and 2.  
Statistical analysis was carried out using the statistical software Stata (version 14). 
Methodology: Phase 2  
Phase 2 of the evaluation was designed to complement Phase 1 and gain a more in-depth 
understanding of the impact of the intervention on patients, carers and the patient 
experience, as well as an understanding of the impact of the Test Bed on staff and staff 
working practices. 
The following methods were used in Phase 2 of the evaluation: 
 Observational interviews  
 Staff diaries and action learning meetings 
 Focus groups  
 Deliberative panels 
 Ranking activity 
 Lessons learned activity 
 Logic model and implementation process model  
 
For ease of reference, a summary of the Phase 2 evaluation methods and participants is set 




Table 2.5. Summary of evaluation methods used in Phase 2 and participants 
Phase 2 
Methods 

















Y N/A N/A N/A 
Staff diaries N/A Y N/A N/A 
Action learning 
meetings 
N/A Y Y Y 
Focus groups N/A Y N N 
Deliberative 
panels 
Y Y Y Y 
Ranking activity  Y Y Y Y 
Lessons learned 
activity 
N/A Y Y Y 
Logic model  Y Y Y Y 
 
Patient observational interviews 
Two sequential observational interviews were undertaken with each patient selected to take 
part in Phase 2 in their own home over the six-month period of the intervention: a) in the first 
month of participating in the programme; and b) during the final month (month six). The 
home-based setting was important as it facilitated a better understanding of participants’ 
health status, health knowledge and activation prior to their participation in the programme, 
how they engaged with the service and used the technology within their own homes at the 
outset, and whether this changed over time. This approach was specifically designed to gain 
a more in-depth understanding of: how participants engage with and experience the 
technology and the Fylde Coast Vanguard / Better Care Together services; how this may 
influence patient activation and self-management of care; any barriers to improving self-care; 
whether the programme can increase their sense of empowerment and independence; 
service satisfaction; and overall quality of life. For interview protocols, see the Appendices. 
Patients indicated their willingness to consider participating in Phase 2 of the evaluation 
through ticking a box on the Phase 1 consent form.  More patients indicated a willingness to 
participate in Phase 2 than were required allowing us to select patients through a process of 
theoretical sampling. In particular we were concerned to sample as evenly as possible across 
all 4 cohorts, to consider gender, age (ensuring a spread of ages from younger old to oldest 
old), LTC and the combinatorial technologies being used. Where possible we also considered 
lone dwelling v living with a partner/family member. 
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Staff diaries and action learning meetings  
All key stakeholders and service providers involved in the delivery of the service were invited 
to complete brief weekly diaries and participate in regular ‘action learning’ meetings, 
informed by the diary data, as part of a rapid cycle review process. Weekly diaries were 
completed by 21 members of staff involved in the Test Bed and the five action learning 
meetings were attended by 23 people in total. In the action learning meetings, members of 
the evaluation team met regularly with key stakeholders involved in the implementation and 
delivery of the service to reflect on shared learning, agreed action and the impacts of change. 
This included technology innovators, members of staff from the Test Bed hubs, voluntary 
sector providers and others. 
Action learning meetings took place at three-monthly intervals and involved a cycle of 
discussion, shared learning and reflection, and agreed action to be taken forward regarding 
the operation, delivery and effectiveness of the service. Agreed action from these meetings 
built on this cycle of learning and assessment of the service throughout the Test Bed period. 
To facilitate discussion at these meetings, key stakeholders were asked to complete weekly 
diaries documenting their experiences of the service, including what works well and less well, 
and any observations of patients’ responses to the service (time spent/support 
need/technical difficulties) (see Appendices). Diaries were brief and simple to complete and 
were designed to feed into the action learning meetings and to fine-tune themes for the focus 
groups and deliberative panels. Diaries were submitted electronically with participants being 
encouraged to keep a personal copy as an ‘aide memoire’ to reflect on prior to each action 
learning meeting. 
Focus groups 
Toward the end of the evaluation we held three focus groups with key members of staff 
involved in the delivery of the service, and a further four interviews with staff unable to attend 
the focus groups (N=16 participants in total). Our objective here was to recruit not only those 
directly involved in delivering the service to older participants but also those organising and 
managing it. Recruitment to the focus groups was split evenly across the two sites. The aim 
was to gain an in-depth understanding of how Fylde Coast Vanguard/Better Care Together 
services with the technology impacted on working practices. The focus groups also explored 
the extent to which the programme increased: communication between the care teams; 
productivity; capacity and co-ordination of care; and overall work satisfaction. For the focus 
group protocols, please see Appendices. 
Deliberative discussions 
In the final three months of the evaluation, we held two deliberative discussion groups (one 
per Vanguard site) with 27 key stakeholders, including: older participants; members of the 
Vanguard care teams; key stakeholders from clinical and community settings, and social care; 
innovators; and senior managers and commissioners from the Test Bed sites. 
Deliberative discussion groups are designed to validate and fine-tune outcomes by producing 
an informed and collective view resulting from deliberation. They offer a bottom-up approach 
that can shift evaluation findings into outcomes related to policy, practice and guidance for 
 35 
 
employers. To achieve this, draft findings emerging from the data analyses were presented 
with the aim of drawing on the various expertise of the participants.  
In this evaluation, deliberative discussions helped to identify and validate those key 
components of the programme that would comprise a new model of care that may be scaled 
up for wider roll-out; and helped to finalise the evaluation recommendations. Finally, the 
discussion groups helped us to fine-tune the Logic Model through a process of ‘backward 
mapping’ (see below).  
For a plan of the deliberative panels, see Appendix 25. 
Ranking activity  
 
At the end of each of the two deliberative discussion groups, participants were asked: ‘What 
do you think are the most important things to come out of the LCIA Test Bed?’ In small groups, 
participants identified their top three issues and shared these with the whole group.  
 
Following the two deliberative discussion groups, key issues identified by participants were 
pooled together to form statements that represented feedback received from all the 
deliberative discussions. A brief survey was constructed using the survey software Qualtrics, 
containing two key themes: the first theme covered statements relating to patients and family 
carers; the second theme covered statements relating to members of staff.  
 
The survey was then forwarded by email to all those who attended the deliberative panels (a 
paper version was produced and posted to one participant who had no email access). For 
each of the two themes, participants were asked to rank the statements in order of 
importance. The results of this ranking activity are discussed later in the report. See Appendix 
26 for a full version of the ranking activity survey. 
Lessons learned activity 
In the early stages of the LCIA Test Bed, a ‘lessons learned’ activity was undertaken by 
members of the evaluation team to identify learning that might prove useful for similar 
complex multi-organisational programmes. Four focus groups and five individual interviews 
were undertaken with members of the LCIA Test Bed from the clinical operations groups 
(n=11), the technology innovators (n=4), the evaluation team (n=2) and the project 
management board (n=5). Data were transcribed and thematically analysed, with the results 
from this exercise also informing the development of the logic model, see Appendix 27. 
Logic model 
 
The evaluation is located within a logic model framework designed to develop understanding 
of the impact of the Test Bed programme. It also enables an understanding of the processes, 
management and participation required for wider rollout of a service of this kind using 
combinatorial technologies. 
In developing the logic model, the following key elements were addressed: 
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 Activities – the focus of the logic model is the New Models of Care with Technology 
programme. The programme of work is considered in its context, including the 
partners of the project, and the policies and procedures that are in place. 
 Inputs – the financial, human, organisational, and material resources of the project. 
This includes a range of stakeholders, including: older patients and carers; Fylde Coast 
Vanguard and Better Care Together teams; clinicians; GPs; community nurses; other 
health professionals; and innovator, voluntary and community sector input. 
 Outcomes – the desired and actual results of the project and a logic model that will 
support roll out and scalability. 
 
The initial version of the logic model is presented below in Figure 2.2. 
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The logic model is a process model – one that has been fine-tuned iteratively over the course 
of the Test Bed programme.  The model has been informed by a number of data sources 
including the weekly diaries, the action learning meetings and the lessons learned activity. 
In addition to these data sources, 12 interviews were conducted with 10 key stakeholders 
involved in the management and delivery of the Test Bed including clinical leads, general 
practitioners, nurses, project managers, team co-ordinators, and project evaluators. 
These data aided understanding of the key resources and activities required to successfully 
roll out the Test Bed, and this information was used to populate the draft logic model. Several 
iterations of the model took place as new data was collected, and as the logical relationship 
between the different components (resources, activities, aims and outcomes) became 
clearer. During a biannual evaluation advisory board meeting, members provided feedback 
about the logic model which in turn led to further revisions. 
The final version of the logic model that is presented later in this report was finalised through 
a process of ‘backward mapping’ during the final deliberative discussion group meetings. At 
each of these events, participants were presented with the full draft version of the logic model 
and invited to offer comments and suggestions, both in group discussion and through written 
annotations. In this way, the final logic model was developed by drawing on informed and 
collective views resulting from ongoing iteration and deliberation involving all key 
stakeholders involved in the development and implementation of the LCIA Test Bed. 
 
Qualitative data analysis  
All qualitative data was analysed thematically with the aid of Atlas.ti qualitative software. 
Identification of emerging themes and initial coding was undertaken by the field researcher 
then shared and agreed during evaluation team data analysis workshops. This allowed for the 
verification of the coding framework and enabled the evaluation team to develop an analysis 
of the situation. The coding framework was also shared with the Evaluation advisory board. 
The major codes emerging from the data were presented to the deliberative panels for fine-






The findings are discussed in two main sections reflecting the analyses of Phase 1 and Phase 
2 respectively. Phase1 findings are presented in three main subsections; recruitment, 
descriptive statistics (including resource use of Test Bed participants), and cost-effectiveness 
analysis. Our analysis relates to the Test Bed population overall and to individual cohorts.  
The Phase 2 findings focus on the experiences of patients and carers of engaging with the Test 
Bed programme, its impact on their lives and their sense of subjective health and wellbeing. 
It also addresses the impact of the Test Bed on the working lives of staff involved in the 
programme. This is followed by the discussion of the final Logic Model. 
Findings: Phase 1 
Recruitment 
Recruitment of participants started on October 2016 and finished on October 2017. 
Recruitment targets were based on a completion rate of 70-80% of the original target of 1,600 
patients. However, significant delays occurred with the recruitment process.29 To address the 
challenges for recruitment resulting from these delays, revised recruitment trajectories were 
agreed by the Board and a three-month extension was also granted by NHS England in June 
2017. Recruitment to Cohort 3 proved problematic for this age/risk group and recruitment to 
this Cohort ceased following discussion and agreement with NHS England.30 
Table 3.1. Revised Trajectories as of June 2017 
September 
17 
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Totals 
Fylde Coast 150 140 250 22 562 
BCT 250 250 250 23 773 
Total 400 390 500 45 1335 
Target 500 500 500 100 1600 
% 80% 78% 100% 45% 83% 
 
Despite the extension, final recruitment to the Test Bed was significantly below the original 
and revised targets. A total of 740 participants consented to take part in the Test Bed with 
460 completing the 24-week programme by the end of April 2018 and as such, considered 
active in Phase 1 of the Evaluation. The number of participants recruited and active is 
presented in Table 3.2. 
                                                     
29 Delays in recruitment were due to a number of factors including: longer than anticipated time to advertise 
and appoint the right staff to run the overall programme and to implement the Test Bed within the Vanguard 
sites; resistance from some clinicians who felt excluded from the original bid due to tight timescales leading to 
lack of ‘buy-in’ to the programme; significant delays in final sign off of the Collaboration Agreement; the need 
to write then amend technology protocols in line with clinical requirements. 
30 This group consisted of those aged 55+ with a long-term condition but a lower than 10% risk of admission. As 
these individuals were effectively already living well with their condition they had limited contact with health 




Final recruitment reached 46% (740/1,600) of the original target, though dropout, attrition 
and incomplete data resulted in the Test Bed having only 460 active participants in Phase 1 
of the Evaluation. These figures are shown in column D in Table 3.2. In Cohort 1, active 
participants across both Vanguard sites reached 44% (218/500); in Cohort 2 recruitment 
reached 40% (201/500); Cohorts 3 and 4 reached only 5% and 15%, of the initial target 
respectively. 
Prior to Cohort 3 being laid down, a small number of patients had been recruited. In discussion 
with the clinical teams, it was agreed to continue these patients on the Test Bed. Whilst 
numbers were too small for statistical analysis, these were followed up qualitatively in Phase 
2 of the evaluation. 
Table 3.2. Recruitment to Test Bed by Vanguard and Cohort: October 2016 to April 2018 
Cohort 
A. 
No. recruited participants 
B. 
No. active participants 
(participants in  











B / C (%) 
 BCT a FC b Total BCT a FC b Total Total % 
1 223 149 372 181 37 218 500 44 
2 202 93 295 148 53 201 500 40 
3 17 29 46 15 11 26 500 5 
4 c 27 27 15 15 100 15 
TOTAL 740 460 1,600 29 
Notes: 
a BCT= Better Care Together Vanguard Site 
b FC=Fylde Coast Vanguard Site 
c Participants for Cohort 4 are being recruited through the Memory Assessment Service (MAS) in Fylde & Wyre 
and Better Care Together. 
Recruitment process 
Figure 3.1 below shows the overall trajectory of recruitment of participants for Cohorts 1 and 
2 and the trajectories by Vanguard site from October 2016 to October 2017. Figures vary 
between the two Vanguards. Recruitment rates in Fylde Coast reveal an irregular pattern, 
throughout the recruitment period. The maximum number of participants recruited was 
reached in August 2017. It is likely that these recruitment patterns in Fylde Coast were the 
result of various factors, but mainly by staff absences and changes in staff working on the Test 
Bed. The Fylde Coast appears to have made a concerted effort to increase recruitment in the 




Figure 3.1. Recruitment trajectories of participants in Cohorts 1 and 2 across Vanguard Sites: 
October 2016 to October 2017 
 
Note: Recruited Test Bed participants to Cohort 1 and 2= 667; Fylde Coast (FC)= 242; Better Care Together (BCT)= 
425.The figure shows recruited participants and not active participants recruited. 
In Better Care Together, recruitment rates reveal a steadier pattern of recruitment across the 
programme, enrolling between 35 and 50 participants per month between January and July 
2017. This suggests a more persistent engagement with the intervention but may also be 
linked to the different delivery model used in Better Care Together to implement the Test 
Bed. Further reflections on these differences in recruitment are included in the discussion 
section of the report. 
Recruitment to Cohort 4 
A total of 27 participants consented to take part in Cohort 4 of the Test Bed with 15 
participants remaining active on the programme. The initial recruitment target was 100 
participants, hence the recruitment rate reach 15% of the original target (15/100).  
Figure 3.2 shows the trajectory of overall recruitment to this cohort. No participants were 
recruited on November 2016 and from January to June 2017. 








































































Attrition during the Test Bed was high. A total of 280 patients initially recruited to the 
programme withdrew due to a range of factors (see Table 4.8). The main reasons given for 
withdrawal being: an inability to get on with the technology (N=83, 30%), discharge from the 
Extensive Care Service31 among participants in Fylde Coast (N=47, 17%), or a decline in health 
(N=46, 16%). Thirty-eight patients declined to give a reason for withdrawal (14%). A total of 
23 patients became deceased during the 24 week programme. 
High attrition rates also reflect the general health and frailty of the Test Bed population, 
raising diverse challenges related to the study of the effect of interventions on high-risk 
population.    
In the Fylde Coast 152 patients recruited to Cohort 1 and 2 withdrew from the programme 
compared to 96 patients that did not complete the 24-week Test Bed programme in Better 
Care Together. It is also worth noting that the number of participants withdrawing from the 
Test Bed in the Fylde Coast due to an inability to get on with technology (46) was double that 
of Better Care Together (24). We are unable to say definitively why this difference occurred 
but again it may be linked to the different model of implementation used within the two 
Vanguard sites. Attrition due to declining health across Vanguard sites is similar in absolute 
terms. Drawing on our qualitative data, we explore in more detail reasons why some patients 
did not get on with the technology in Phase 2 of the evaluation.  
Given the lower than anticipated recruitment figures (particularly in the Fylde Coast) and 
attrition rates across both Vanguards, final results in Cohorts 1 and 2 are heavily skewed 
toward Better Care Together. In other sections in this report, we explain further the 
limitations of the recruitment numbers and the implications for the evaluation. 
                                                     
31 Due to delays in deployment of the technologies due to the writing and rewriting of new technology protocols, 
a good number of patients originally consented to the Test Bed within the Fylde Coast Vanguard had completed 
their 6 months on the Extensive Care service before the revised protocols were ready. Clinicians felt unable to 
retain these patients on Extensive Care for a further six months to facilitate the Test Bed, hence these 47 patients 
were withdrawn from the programme.  See also for reference. NHS Blackpool Clinical Commissioning Group (2017) 
‘Extensive Care’. Available at: http://blackpoolccg.nhs.uk/local-services/new-models-of-care/extensive-care/ [Accessed on 




Table 3.3. Attrition: Drop-out and Non-Active Test Bed Participants, April 2018 
Reason 
Fylde Coast Better Care Together  
Total Cohort Cohort  
C1 C2 C3 C1 C2 C3 C4 
Not contactable / unreachable  2 7 2 20   31 
Move of residence  1      1 
Did not get on with technology 19 27 7 10 14 1 5 83 
Decline of health 16 2 2 13 7 1 5 46 
Consent/questionnaire to 
long/upsetting 
   2 3   5 
Other or rather not say 18  2 10 8   38 
Deceased 12 2  5 2  2 23 
Discharged from Extensive Care 47       47 
Removed from study by clinical 
team 
 6      6 
Total 112 40 18 42 54 2 12 280 
 
Descriptive statistics 
A total of 308 Test Bed participants (293 in Cohorts 1 and 2, and 15 patients in Cohort 4) were 
included in the statistical analysis in Phase 1 of the evaluation as illustrated in Table 3.4. 
Table 3.4. Test Bed participants included in the statistical analysis of the validated instruments 
to assess Health Related Quality of Life and wellbeing 
Vanguard Site 
Cohort 
Total Cohort 4* 
1 2 
Fylde Coast  31 39 70 
15 
Better Care Together 136 87 223 
Total 167 126 293 15 
*Participants for Cohort 4 are being recruited through the Memory Assessment Service (MAS) in the Fylde Coast 
and Better Care Together Vanguard Sites. For illustration purposes Cohort 4 is shown in a separate column. 
Socio-demographic characteristics of Test Bed participants 
Table 3.5 below illustrates the socio-demographic characteristics of Test Bed participants. Of 
the 308 Test Bed participants included in Phase 1 of the Evaluation, 120 were female (39%), 
and 188 (61%) were male. In each cohort there was a higher proportion of men (Figure 3.3). 




Figure 3.3. Number and Percentage of Participants by Gender and Cohort 
 
                      Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
 
Figure 3.4. Percentage of Participants by Age Group and Cohort shows the age distribution of 
participants by cohort. The mean age of participants was 71.6 years. On average, participants 
in Cohort 1 were 72.8 years of age. The average age in Cohort 2 was 69.6 years, and in Cohort 
4 the average age was 75 years - and hence they were the oldest group in the Test Bed. 
Figure 3.4. Percentage of Participants by Age Group and Cohort 
 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
There was little ethnic diversity within the Test Bed population (see Table 3.5). This reflects 
the ethnic make-up of the population of the two Vanguard sites. Aggregate data for the 
footprint of these two Vanguard areas, drawn from the 2011 Census, shows that 99% of 
people aged 55 years or above defined their ethnicity as White;32 98% of Test Bed participants 
also described themselves as White. Most of the participants were married or living in civil 
partnerships (58%) although nearly 32% of participants lived alone.33 These figures were very 
                                                     
32 According to 2011 Census aggregate data, in Blackpool and Lancaster area, 99% of people aged 55 years or 
above defined their ethnicity as White. Source: Office for National Statistics; National Records of Scotland; 
Northern Ireland Statistics and Research Agency (2016): 2011 Census aggregate data. UK Data Service (Edition: 
June 2016). DOI: http://dx.doi.org/10.5257/census/aggregate-2011-1  
33 As the aim of the Test bed was to support older people with LTCs to better self-care at home, no Test Bed 
participants were recruited from nursing or residential care settings. 


































similar across both Cohorts 1 and 2. For example, in Cohort 1, 32% of patients lived alone and 
in Cohort 2 34% lived alone. The proportion of patients with early-mid stage dementia in 
Cohort 4 was considerably lower at only 7%. 
In terms of educational status, the majority of Cohort 1 patients had completed secondary 
school (57%) with 40% of them completing college or university level education. In Cohort 2, 
62% and 34% respectively completed these education levels. On average, men in Cohort 1 
were better educated than women, but this pattern was reversed in Cohort 2 where women 
were more educated than men (see Figure A in Appendix 5). 
As expected, given the target age group for this Test Bed, around 84% of all Test Bed 
participants were retired (Figure B in Appendix 5). Around 86% of Cohort 1 participants were 
retired compared to 80% in Cohort 2 and 93% in Cohort 4. 
Around 80% of the Test Bed population overall already had access to the internet at 
recruitment, this figure was similar across patients in both Cohorts 1 and 2.   
Appendix 6 details the background characteristics of the participants at baseline in each 
Vanguard site.  
Table 3.5. Background characteristics of the Test Bed population at baseline 
  
Cohort 1 (n=167) 
N (%) 
Cohort 2 (n=126) 
N (%) 








105 (62.9) 70 (55.6) 13 (86.7) 188 (61.1) 
Female 62 (37.1) 56 (44.4) 2 (13.3) 120 (38.9) 
Age                         
[55,59] 
7 (4.2) 11 (8.7) 1 (6.7) 19 (6.2) 
[60,64] 16 (9.6) 19 (15.1) - 35 (11.4) 
[65,69] 33 (19.8) 41 (32.5) - 74 (24.0) 
[70,74] 42 (25.1) 28 (22.2) 7 (46.7) 77 (25.0) 
[75,79] 33 (19.8) 16 (12.7) 5 (33.3) 54 (17.5) 
[80,84] 28 (16.8) 6 (4.8) 1 (6.7) 35 (11.4) 
[85,89] 7 (4.2) 3 (2.4) 1 (6.7) 11 (3.6) 
[90,94] 1 (0.6) 2 (1.6) - 3 (0.9) 
Average 72.78 69.59 75 71.59 
Ethnicity                       
White 
165 (98.8) 123 (97.6) 15 (100) 303 (98.4) 
Mixed - 1 (0.8) - 1 (0.3) 
Other 1 (0.6) - - 1 (0.3) 
Prefer not to say 1 (0.6) 2 (1.6) - 3 (0.9) 
Marital Status                           
Single 
12 (7.2) 10 (7.9) 1 (6.7) 23 (7.5) 
Married 92 (55.1) 70 (55.6) 13 (86.7) 175 (56.8) 
Civil Partnership 2 (1.2) 1 (0.8) - 3 (0.9) 
Separated - 2 (1.6) - 2 (0.6) 
Divorced 26 (15.6) 16 (12.7) - 42 (13.6) 
Widowed 35 (21) 24 (19) 1 (6.7) 60 (19.5) 
Prefer not to say - 3 (2.38) - 3 (0.9) 





Cohort 1 (n=167) 
N (%) 
Cohort 2 (n=126) 
N (%) 






                                   
Spouse/partner 
Living alone 53 (31.7) 43 (34.1) 1 (6.7) 97 (31.5) 
Parent(s) 1 (0.6) - - 1 (0.3) 
Children 18 (10.8) 3 (2.4) - 21 (6.8) 
Friend(s) - - - - 
Other 9 (5.4) 5 (3.9) - 14 (4.5) 
Spouse and children 13 (7.8) 1 (0.8) - 14 (4.5) 
Education                  
None 
1 (0.6) 3 (2.4) - 4 (1.3) 
Primary school 2 (1.2) - - 2 (0.6) 
Secondary school 95 (56.9) 78 (61.9) 8 (53.3) 181 (58.8) 
College 44 (26.3) 32 (25.4) 5 (33.3) 81 (26.3) 
University 23 (13.8) 11 (8.7) 2 (13.3) 36 (11.7) 
Prefer not to say 2 (0.6) 2 (0.6) - 4 (1.3) 
Employment Employed full 
time 
2 (1.2) 5 (4) - 7 (2.3) 
Employed part time 9 (5.4) 8 (6.3) - 17 (5.5) 
Unable to work due to caring 
responsibilities 
- 1 (0.8) - 1 (0.3) 
Unable to work due to ill health 9 (5.4) 9 (7.1) 1 (6.7) 19 (6.2) 
Unemployed 1 (0.6) - - 1 (0.3) 
Retired 144 (86.2) 101 (80.2) 14 (93.3) 259 (84.1) 
Voluntary 2 (1.2) 1 (0.8) - 3 (0.9) 
Prefer not to say - 1 (0.8) - 1 (0.3) 
Access to the internet No 31 (18.6) 22 (17.5) 1 (6.7) 54 (17.5) 
Yes 133 (79.6) 100 (79.4) 13 (86.7) 246 (79.9) 
Intermittent or poor quality 2 (1.2) 3 (2.4) 1 (6.7) 6 (1.9) 
Prefer not to say 1 (0.6) 1 (0.8) - 2 (0.6) 
Notes: 
a Living arrangements categories are not mutually exclusive. 
b Percentages may not add up to 100% due to rounding. 
Confidence with technology 
Data from the Phase 1 survey reveal that Test Bed participant confidence with the use of 
technology varied across devices, cohorts and across the timespan of the intervention. 
Patients were given access to different combinations of technology depending on the cohort 
and Vanguard that they were assigned to and their specific LTC. 
Among the 308 participants included in this analysis, the tablet and Motiva platform were the 
main technology in the care pathway for Cohort 1 patients; Flo (the text messaging service 
for patients using a mobile phone) was the main technology given to Cohort 2 participants in 
Better Care Together, whilst the health watch the main technology given to Cohort 2 patients 
in the Fylde Coast. Hence Cohort 2 patients received different care pathways and 
combinations of technology across the two Vanguard Sites. Further information about the 




Figure 3.5 illustrates that when comparing baseline to week 24, there was a statistically 
significant increase in the proportion of Cohort 1 participants who felt more confident using 
tablets (Part A). Among Cohort 2 participants, there was a slight increase in confidence with 
the use of mobile phones; however, this change was not statistically significant (Part B).  
Figure 3.5. Participants indicating they felt confident or somewhat confident with the use of 
technology at baseline, 12 weeks and 24 weeks (%). 
A. Confidence using the tablet in Cohort 1 B. Confidence using the mobile phone in Cohort 2 
  
Notes: Percentages were calculated per device. For instance: 42% of participants felt confident using a mobile 
phone, 29% felt somewhat confident, 22% did not feel confident, and 7% did not respond to this question.  
Non-response rate in the level of confidence on technology at baseline ranges from 6% to 11%. At 12-weeks, 
non-response rate goes from 13% to 23% and at 24-weeksranges from 10% to 16%. 
Vertical bars represent 95% Confidence Intervals. 
 
As numbers in Cohorts 4 were low, analysis of confidence with technology is not included in 
this report. Appendix 7 presents the percentage of participants self-defining as confident or 
somewhat confident with other types of technology including smartphone and computer per 
Cohort. 
Health related quality of life and wellbeing of Test Bed participants 
Analyses of the Phase 1 data from the 308 participants who completed the Test Bed 
programme show little change in overall health and wellbeing. However, the data reveal that 
patient activation for those with the lowest level of activation did improve during the period 
of the intervention across all cohorts. 
Table 3.6 presents a summary of the mean values of the validated instruments in all Cohorts, 
with the following sections presenting a more detailed analysis of the figures shown. 
Information on the sample size used to calculate the mean of each validated instrument and 
























Table 3.6. Mean Values of Validated Instrument to Assess Health Related Quality of Life and Wellbeing of Participants at Baseline, 12 weeks and 24 
Weeks Intervention 
Instrument 
Cohort 1 (N=167) Cohort 2 (N=126) Cohort 4 (N=15) Test Bed population (N=308) 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
EQ-5D-5L 0.67 0.69 0.67 0.74 0.73 0.74 0.74 0.75 0.74 0.70 0.70 0.70 
PAM13 60.26 59.60 61.68 61.37 61.88 61.13 48.25 47.29 47.09 60.13 59.93 60.75 
WEMWBS 51.42 50.94 50.96 50.75 50.41 50.66 46.07 47.20 46.25 50.85 50.52 50.58 
De Jong 
Gierveld 
4.04 4.21 4.13 3.99 3.97 4.31 3.64 3.57 3.71 4.00 4.08 4.18 
Notes:  
a Decimal figures are rounded to the nearest hundredth. 
b EQ-5D-5L, PAM13 and WEMWBS scores, the higher the value the better quality of life. In the DeJong Gierveld score, the lower the value the better (less loneliness). 
d The EQ-5D-5L index values have been calculated considering data at all time points on 288 participants. The PAMs scores were estimated using data on 308 patients. The WEMWBS 
was calculated considering data on 280 participants and the De Jong Gierveld Scale on 273 participants. Exclusion of participants is due to non-response and methodological 
considerations per instrument. 







Varying proportions of participants reported having health related quality of life related issues 
for each of the five EQ-5D-5L dimensions across cohorts at all three time points. In the overall 
Test Bed population the mean value of all dimensions (apart from self-care) decreased 
slightly. 34 However, the overall data mask differences between Cohorts 1 and 2, with a slight 
improvement in mobility (from 2.68 at baseline to 2.65 at 24 weeks), usual-activity (from 2.62 
at baseline to 2.54 at 24 weeks), pain/discomfort (from 2.44 at baseline to 2.25 at 24 weeks) 
and anxiety (from 1.66 at baseline to 1.64 at 24 weeks) among Cohort 1 patients. In Cohort 2, 
there was a slight increase in mobility (from 2.22 at baseline to 2.20 at 24 weeks) and anxiety 
(from 1.62 at baseline to 1.59 at 24 weeks). Figure 3.6 illustrates the mean value of each of 
the EQ-5D-5L dimensions over the course of the intervention. 
Using a correlation matrix of pairwise correlations between EQ-5D-5L dimensions and socio-
demographic variables, the data shows that for Cohort 1 patients, being a woman is positively 
correlated with problems in a number of dimensions including: mobility, self-care, 
pain/discomfort, and anxiety/depression (statistically significant at the 5% level). However, 
we found no statistically significant correlation between being a woman and any dimensions 
in Cohort 2 (see Appendix 10 and Appendix 11). 
Regarding the relationship between age and quality of life dimensions, among Cohort 1 
participants, age was negatively correlated with three of the EQ-5D-5L dimensions: self-care, 
pain/discomfort, and anxiety/depression (statistically significant at the 5% level).35 This 
means that older people reported having fewer problems in these particular dimensions, 
which potentially reflects participants’ ability to adapt to impairments over time.  
                                                     
34 The higher the mean in each dimension of the Eq-5D-5L, the more significant or higher the problem related to 
that dimension.  




Figure 3.6. Health related quality of life per dimension by cohort at baseline, 12 weeks, and 24 weeks of intervention: mean values 
   
  
Notes: a EQ-5D-5L level values: No problems (1); Slight problems (2); Moderate problems (3); Severe problems (5); Extreme problems (5). EQ-5D-5L statement levels range from 1 to 
5 (1 means no problem and 5 means unable). Therefore, the higher the mean in each dimension more significant is the problem.   
b The maximum sample size for the Test Bed population is 288; 157 for Cohort 1; and, 116 for Cohort 2. Sample size at each time point is shown in Appendix 8. 
















The EQ-5D-5L index values were calculated to assess HRQoL at baseline, week 12, and week 
24. Figure 3.7 illustrates the mean EQ-5D-5L index values and 95% confidence intervals for 
each of the Cohorts and the overall Test Bed population. 




a Decimal figures are rounded to the nearest hundredth. 
b Vertical bars represent 95% Confidence Intervals. The mean EQ-5D-5L index values have been calculated 
considering data on 288 participants. Non-response from participants has been excluded.  
c The EQ-5D-5L Value Set for England was used to obtain the EQ-5D-5L index values.  
Source: Devlin, N., Shah, K., Feng, Y., Mulhern, B., & van Hout, B. (2017). Valuing health-related quality of life: 
an EQ-5D-5L value set for England. Health Economics. In England, problems with pain/discomfort and 
anxiety/depression were the most important factor in overall quality of life.  
d The higher the EQ-5D-5L index values the better in terms of health-related quality of life level of patients. 
Test Bed, Information from 14 October 2016 to 27 April 2018. 
The mean EQ-5D-5L index value in the population at baseline is 0.70 and varies slightly from 
the estimated mean of the index score for England of 0.662.36 This would suggest that, overall, 
participants within the Test Bed have slightly better health-related quality of life than the 
overall English population. However, this figure needs to be treated with caution as the Test 
Bed population does not have the same make-up as England as a whole. 
                                                     
36 Mulhern et al. (2017) have recently estimated the mean of the index score in England is 0.662. See for 
reference: Mulhern, B.; Feng, Y.; Sha, K.;  van Hout, B; Janssen, B., Herdman, M.; Devlin, N. Comparing the UK 
EQ-5D-3L and the English EQ-5D-5L Value Sets. March 2017. Office of Health Economics. Research Paper 17/02.  
Please note that this mean of the index score has been estimated using the EQ-5D-5L Value Set for England in 
Devlin, et al (2017) Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England. Office of Health 
Economics. Research Paper 16/01. 
Recently, Devlin et al (2017) published an updated EQ-5D-5L Value Set for England, so the mean of the index 
score might be slightly different. 
A. Test Bed Population B. Cohort 1


























































































Part A in Figure 5.6 shows the mean EQ-5D-5L index values of the Test Bed population. At all 
time points this value was around 0.70. The data did not show any change that was 
statistically significant (either in the overall Test Bed population or by cohort).37 Parts B to D 
in Figure 5.6 reveal that there was no statistically significant change across Cohorts 1, 2, and 
4 participants. As expected, Cohort 2 patients were seen to have better health-related quality 
of life (i.e. having a higher EQ-5D-5L index score) than those in Cohort 1. Patients in Cohort 4 
showed similar results to those in Cohort 2. 
In summary, analysis of the EQ-5D-5L data revealed that, on average, there was no statistically 
significant change in the health status of patients participating in the Test Bed programme.38 
PAM-13 
Table 3.7 illustrates the numbers of Test Bed patients sitting within each initial PAM level and 
the mean PAM score for the Test Bed population at baseline and week 24, together with levels 
of change to the mean PAM scores, by number and percentage change. 
The developers of the PAM measure, Insignia Health®, note that emphasis should be placed 
upon monitoring the impact on patients in activation level 1 (defined as the ‘Disengaged and 
overwhelmed’) and 2 (defined as the ‘Becoming aware, but still struggling’). These are the 
two lowest levels of activation, where gains are greatest and most important. 
The average PAM score at baseline of the Test Bed participants was 60.13. In Cohort 1, the 
average PAM score was 60.26 and in Cohort 2 it was 61.37. This means that those in Cohort 
2 had a higher level of activation at baseline than those in Cohort 1. Approximately half of the 
Test Bed population - a total of 48.4%: comprising 16.9% of patients in level 1 (categorised at 
‘disengaged and overwhelmed’) and 31.5% in level 2 (categorised at ‘becoming aware, but 
still struggling’) reported to be in the two lowest levels of activation at baseline.39 However, 
the overall data mask differences between Cohorts 1 and Cohort 2. Around 51% of Cohort 1 
participants were in the two lowest levels of activation, compared to 43% of Cohort 2 
participants who were in the lowest levels of activation. This is unsurprising given the 
difference in risk levels between two groups. 
Following the approach to assessing the correlation of the Test Bed programme with patient 
activation set out by Insignia Health®, we calculated the score change within each activation 
level from baseline to end point.  To calculate the change, we followed patients within each 
of the four levels of activation and compared the mean point change of PAM score from 
baseline to 24 weeks. As illustrated in Table 3.7, the mean PAM score of the overall Test Bed 
                                                     
37 There is no evidence against the null hypothesis that there is ‘no difference’ between the mean EQ-5D-5L 
index values at baseline, at week 12 and at week 24. This means the change is not statistically significant, as can 
be appreciated by the fact that there is an overlap of the 95% confidence intervals across time periods (shown 
in 4.8). 
38 Appendix 8. Sample size, maximum and minimum values per Validated Instrument to Assess Health Related 
Quality of Life and Wellbeing of Participants at Baseline, 12 weeks and 24 Weeks Intervention shows that these 
same conclusions hold when using EQ-5D-3L index values. 
39 Level 1 is defined as the ‘Disengaged and overwhelmed’ level; level 2 the ‘Becoming aware, but still struggling’; 
level 3 the ‘Taking action’; and level 4 ‘Maintaining behaviours and pushing forward’ stage. For further reference 
see: ©2017 Insignia Health. Patient Activation Measure® (PAM®) Practice Manual. All rights reserved. ©2017 




population at baseline from 52 patients at level of activation 1 was 43.64 changing to 48.35 
at end point. Hence, the mean point change from baseline to 24 weeks was 4.71. 
Of those 52 patients in level of activation 1, the mean PAM score improved for 34 of these 
patients (65%); declined for 14 patients (27%) and remained unchanged for the remaining 4 
patients. Parts A-D present the changes per level of activation in each of the cohorts. 
Comparing activation levels 1 and 2 of the overall Test Bed population from baseline to end 
point, the mean PAM score increased 4.71 (from 43.64 to 48.35) and 7.09 (from 51.22 to 
58.31) points, respectively. This suggests an improvement in activation amongst those with 
the lowest levels of activation, especially those patients in Cohorts 1 and 2, who at the start 
of the Test Bed were in activation level 2 (from 51.40 to 58.45 points; and from 50.88 to 57.92 
points respectively). An improvement in activation of those who were in the lowest activation 
levels at baseline in Cohort 4 was also visible; especially among participants initially in 
activation level 2 (from 51 to 63.10 points). 
PAM level of activation 4 should be viewed separately, as these are patients who already had 
a high level of activation at baseline and as a consequence there is likely to be little or no 
change in their PAM score. Indeed, these patients can often fall back a few points, but 
nevertheless, remain in the highest activation level.40 
                                                     




Table 3.7. PAM score change over 24 weeks of Test Bed by Cohort (from baseline to 24 weeks) 
in Test Bed population and Cohort 1, 2 and 4 
A. Test Bed Population 
Test Bed Population (N=308)     
Initial PAM level of the group Level 1 Level 2 Level 3 Level 4 
N 52 97 87 62 
Mean PAM score at baseline 43.64* 51.22† 62.83 83.66 
     
Test Bed Population: Change from Baseline to 24 weeks   









N 52 97 97 62 
Mean PAM score at 24 weeks 48.35* 58.31† 63.37 70.85 
Mean Point Change from 
Baseline 4.71 7.09 0.53 -12.81 
No. of participants score 
declined (%) 14 (26.9) 30 (30.9) 43 (42.2) 49 (79.0) 
No. of participants score 
unchanged (%) 4 (7.7) 16 (16.5) 8 (7.8) 5 (7.8) 
No. of participants score 
improved (%) 34 (65.4) 51 (52.6) 51 (50.0) 8 (12.5) 
* Mean difference between 24 weeks and baseline: 4.71 (95% CI 1.92, 7.5), P=0.001. 
† Mean difference between 24 weeks and baseline: 7.09 (95% CI 4.17, 10.01), P<0.001. 
 
B. Cohort 1 
Baseline Cohort 1 (n=167)     
Initial PAM level of the group Level 1 Level 2 Level 3 Level 4 
N 22 63 50 32 
Mean PAM score at baseline 44.92 51.40 63.28 83.52 
     
Cohort 1: Change from Baseline to 24 weeks   









N 22 63 50 32 
Mean PAM score at 24 weeks 48.05 58.45 66.68 69.62 
Mean Point Change from 
Baseline 3.13 7.05 3.40 -13.90 
No. of participants score 
declined (%) 7 (31.8) 24 (38.1) 16 (32.0) 25 (78.1) 
No. of participants score 
unchanged (%) 3 (13.6) 6 (9.5) 6 (12.0) 3 (9.4) 
No. of participants score 





C. Cohort 2 
Baseline Cohort 2 (n=126)     
Initial PAM level of the group Level 1 Level 2 Level 3 Level 4 
N 21 33 43 29 
Mean PAM score at baseline 44.55 50.88 62.30 84.12 
     
Cohort 2: Change from Baseline to 24 weeks   









N 21 33 43 29 
Mean PAM score at 24 weeks 50.85 57.92 60.69 72.90 
Mean Point Change from 
Baseline 6.30 7.03 -1.61 -11.22 
No. of participants score 
declined (%) 3 (14.3) 6 (18.2) 23 (53.5) 23 (79.3) 
No. of participants score 
unchanged (%) 0 (0.0) 10 (30.3) 2 (4.7) 2 (6.9) 
No. of participants score 
improved (%) 18 (85.7) 17 (51.5) 18 (41.9) 4 (13.8) 
 
D. Cohort 4 
Baseline Cohort 4 (n=15)     
Initial PAM level of the group Level 1 Level 2 Level 3 Level 4 
N 9 1 4 1 
Mean PAM score at baseline 38.42 51.00 62.98 75.00 
     
Cohort 4: Change from Baseline to 24 weeks   









N 9 1 4 1 
Mean PAM score at 24 weeks 43.28 63.10 50.70 51.00 
Mean Point Change from 
Baseline 4.86 12.10 -12.28 -24.00 
No. of participants score 
declined (%) 4 (44.4) 0 (0.0) 4 (100.0) 1 (100.0) 
No. of participants score 
unchanged (%) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 
No. of participants score 
improved (%) 4 (44.4) 1 (100.0) 0 (0.0) 0 (0.0) 
Notes: PAM Scores were calculated by Insignia Health considering data on 308 participants.  
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
©2017 Insignia Health. Patient Activation Measure® (PAM®) Administration System. All rights reserved. 
WEMWBS 
Figure 3.8 presents the WEMWBS mean score for the Test Bed population and cohorts at all 
time points with 95% confidence intervals.41 Part A shows a mean score of the Test bed 
                                                     
41 WEMWBS Population Norms in Health Survey for English data 2011 show that the mean of WEMWBS Score is 




population at baseline of 50.85, 50.52 at mid-point and 50.58 at end point. This suggests that 
the wellbeing score of Test Bed participants was ‘average’ (with the average score being 
between 41 and 59).42 
The mean scores demonstrate a very small decrease (from 50.85 to 50.58) in the mental 
wellbeing of Test Bed participants but the change is not statistically significant (either within 
the overall Test Bed population or within each of the cohorts).43 This means that levels of 
wellbeing do not appear to have changed across the period of the intervention either across 
or within the cohort groups. With no control comparison for the WEMWEBs scores we are 
unable to definitively attribute changes in wellbeing (even if very small) to the use of the 
technology. 
WEMWBS score for all Cohorts at all time points is within the 40-59 points range. The 
following five evidence-based steps are suggested to improve Test Bed patient’s wellbeing: 
get active; connect with others; keep learning; be aware of yourself and the world; and give 
to others. 
                                                     
https://www2.warwick.ac.uk/fac/med/research/platform/wemwbs/researchers/interpretations/wemwbs_po
pulation_norms_in_health_survey_for_england_data_2011.pdf 
42 Wellbeing self-assessment. Available at: https://www.nhs.uk/Tools/Documents/Wellbeing%20self-
assessment.htm [Accessed on 10 June, 2017] 
43 There is no evidence against the null hypothesis that there is ‘no difference’ between the mean WEMWBS 
score values at the three time points. This means the change is not statistically significant, as can be appreciated 
by the fact that there is an overlap of the 95% confidence intervals across time periods (shown in Figure 4.9).  
To estimate the statistically significance in the change of the WEMWBS score, the Wilcoxon signed-rank test is 
performed as suggested by the WEMWBS User Guide available at: 
 https://www2.warwick.ac.uk/fac/med/research/platform/wemwbs/researchers/userguide/ [Accessed on 10 
June, 2017].  
In addition to the user guides provided, we used an Excel Template containing sample data available to 
download. This is a version of one originally produced by Lambeth local authority and adapted by Cheshire and 








a Decimal figures are rounded to the nearest hundredth. 
b Vertical bars represent 95% Confidence Intervals. 
c The mean WEMWBS scores have been calculated considering data on 280 participants. If 4 or more of the 14 
items were not responded, the WEMWBS cannot be calculated. Non-response has been excluded.  
d The higher the WEMWBS score the better in terms of the wellbeing of patients. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
De Jong Gierveld Scale 
Figure 3.9 illustrates mean loneliness score values and 95% confidence intervals by Cohort 
and for the total population. Part A shows the mean loneliness scores of the Test Bed 
population. This score value is 4 at baseline, 4.08 in week 12, and 4.18 in week 24,44 suggesting 
that participants report being ‘moderately lonely’ according to this particular scale. 
The De Jong Gierveld score ranges from 0-11 (11 being the highest score or highest level of 
loneliness). Hence, the data illustrate that loneliness figures for the Test Bed population 
increased slightly during the intervention but that the change is not statistically significant 
(for either the overall Test Bed population or by cohort).45 Parts B and D in Figure 3.9, illustrate 
similar results with regard to the change in mean index values across all cohorts. Hence, levels 
of loneliness do not appear to have changed across the period of the intervention either 
within or across cohorts. 
                                                     
44 When the De Jong Gierveld Score takes a value within the range [3-8] means the population/participants is 
‘moderately lonely’.  
45 There is no evidence against the null hypothesis that there is ‘no difference’ between the mean of De Jong 
Gierveld Loneliness Score values at the three time points. This means the change is not statistically significant, 
as can be appreciated by the fact that there is an overlap of the 95% confidence intervals across time periods 
(shown in Figure 3.9). We used a two-sample test of binomial proportion to assess the differences of the mean. 
A. Test Bed Population B. Cohort 1



































































































































Figure 3.9 De Jong Gierveld Loneliness Score Values at baseline, 12 weeks and 24 weeks 
intervention: mean values 
 
Notes: 
a Decimal figures are rounded to the nearest hundredth. 
b Vertical bars represent 95% Confidence Intervals. 
c The mean scores of the De Jong Gierveld Loneliness Scale have been calculated considering data on 273 
participants. If 2 or more of the 11 items were not responded, the Loneliness Scale cannot be calculated. 
d The higher the De  Jong Gierveld Loneliness score the worse in terms of loneliness. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
Correlations of socio-demographic characteristics and HRQoL and wellbeing 
We used a correlation matrix of pairwise correlations to explore the relationship between the 
validated instruments to assess the health-related quality of life (HRQoL) and wellbeing of 
and the socio-demographic characteristics of Test Bed participants (see Appendix 12). Being 
a man is positively associated with higher EQ-5D-5L scores (better health) at all time points 
(statistically significant at the 5% level). The existing evidence base does suggest that women 
tend to report lower HRQoL scores than men.46 This is interesting given more men than 
women have been recruited to Cohorts 1 and 2. 
Greater age was positively correlated with higher levels of wellbeing and lower levels of 
loneliness (statistically significant at the 5% level). This finding is somewhat surprising given 
the evidence suggests loneliness can increase in later life as older people lose their friendship 
networks (due to increased morbidity and mortality) and can experience lower levels of 
wellbeing as people experience more age-related health issues and co-morbidities. Education 
showed no statistically significant correlation with health, activation, wellbeing or loneliness 
(with the exception of loneliness at baseline). As expected, a higher EQ-5D-5L score is 
associated with higher activation, higher wellbeing, and lower levels of loneliness at all time 
                                                     
46 See for instance Cherepanov, et al (2010) D., Palta, M., Fryback, D. G., & Robert, S. A. (2010). Gender 
differences in health-related quality-of-life are partly explained by sociodemographic and socioeconomic 
variation between adult men and women in the US: evidence from four US nationally representative data 
sets. Quality of Life Research, 19(8), 1115–1124. http://doi.org/10.1007/s11136-010-9673-x 
A. Test Bed Population B. Cohort 1














































































































points. Moreover, EQ-5D-5L, activation, wellbeing and loneliness scores at mid-point and end-
point were positively correlated with scores at baseline (statistically significant at the 5% 
level). This means that the higher the scores at baseline, the higher the scores at mid and end 
point. 
HealthCare Resource: Use and Cost 
Healthcare Resource 
A total of 293 Test Bed participants in Cohorts 1 and 2 were included in the statistical analysis 
of the use of resources and cost-effectiveness analysis in the Test Bed Phase 1 Evaluation. 
Table 3.8 presents a summary of the average use of hospital services, primary care, 
community health or emergency services, social care, community mental health, community-
based and day activity services at each time point for the Test Bed population and each 
cohort. 
On average at baseline, there were 0.82 contacts with hospital services per participant. At 
mid-point, the mean use of hospital services was 0.87 contacts and at end-point it was 0.82 
contacts. 
Overall, there was little difference in the mean use of hospital services amongst the Test Bed 
population. There was a slight increase in the use of day hospital services and a decrease in 
the use of outpatient appointments. 
The mean use of secondary care services among Cohort 1 participants was 0.96 contacts per 
participant at baseline, 1.14 at mid-point and 0.97 at end-point, showing that the highest 
number of contacts occurred mid-way through the intervention. In Cohort 2, the mean use 
was 0.63 at baseline, 0.50 at mid-point, and 0.61 at end-point, illustrating a slight decrease 
from baseline to end-point. As expected, given their higher level of risk of admissions, Cohort 
1 showed a higher mean use of hospital services than Cohort 2 at all-time points. 
The mean use of primary care services of Test Bed participants was 1.08 contacts per patient 
at baseline, 1.28 in mid-point and 1.30 at end-point, suggesting an increase in the mean use 
of primary care services of around 0.22 at the end of the Test Bed programme. The average 
use of primary care services among Cohort 1 went from 1.45 at baseline to 1.52 at end-point. 
Whereas among Cohort 2, the average use of primary care services went from 0.58 at baseline 
to 1.01 at end-point. 
Regarding social services, the decrease observed in the use of services provided by social 
workers or care managers (from mean use of 0.09 at baseline to 0.02 at end-point) was more 
than compensated for by the increase observed in the use of private home help/cleaner (from 
0.48 at baseline to 0.82 at end-point). 
The mean use of primary and social care services for participants in the Fylde Coast appear to 
have a higher mean use than that of Better Care Together, especially among Cohort 1 patients 
at mid and end-point. Appendix 13 includes detailed information on the average use of 





Community health services were very rarely used by the Test Bed participants and showed no 
meaningful change over the period of the intervention. Similar patterns can be observed in 
the use of other community-based services such as telecare, dentist or optician (see Appendix 
15). 
The results presented above are based on the analysis of the self-reported survey data of Test 
Bed participants. In the following sections we compare the mean use of secondary care 
services (A&E visits, inpatient admission, outpatient appointments) between the Test Bed 






Table 3.8. Mean Use of Health and Social Care Services at baseline, 12 weeks and 24 weeks intervention 
Hospital services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Accident & Emergency 0.06 0.06 0.07 0.09 0.10 0.10 0.02 0.01 0.03 
General hospital inpatient admission 0.04 0.05 0.04 0.06 0.08 0.05 0.02 0.02 0.02 
Community hospital inpatient admission 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.01 
Day hospital 0.13‡ 0.15 0.22‡ 0.16 0.21 0.20 0.10 0.06 0.25 
Outpatient visits to clinic based at hospital 
site 
0.48§ 0.52 0.44§ 0.58 0.65 0.56 0.35 0.35 0.29 
Other 0.09 0.09 0.03 0.07 0.11 0.05 0.13 0.06 0.02 
Mean use of hospital services 0.82* 0.87 0.82* 0.96 1.14 0.97 0.63 0.50 0.61 
Patients who have used at least one of 
hospital services 
114 119 111 80 80 72 34 39 39 
% 39%† 41% 38%† 48% 48% 43% 27% 31% 31% 
N 293 293 293 167 167 167 126 126 126 
* P> 0.99 for difference between 24 weeks and baseline. 
† P=0.80 for difference between 24 weeks and baseline. 
‡ P=0.005 for difference between 24 weeks and baseline. 






Primary Care, Community Health or 
Emergency Services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
GP 0.45 0.55 0.48 0.59 0.61 0.44 0.25 0.46 0.54 
Paramedic (Ambulance service) 0.04 0.03 0.06 0.05 0.06 0.06 0.02 0.00 0.06 
Community matron 0.05 0.03 0.02 0.04 0.02 0.02 0.06 0.05 0.02 
Community/District nurse 0.21 0.27 0.29 0.37 0.46 0.47 0.00 0.01 0.06 
Practice nurse 0.21 0.27 0.23 0.27 0.37 0.31 0.13 0.13 0.13 
Specialist nurse  0.13 0.13 0.21 0.13 0.19 0.22 0.12 0.06 0.21 
Mean use of primary care services 1.08‖ 1.28 1.30‖ 1.45 1.71 1.52 0.58* 0.71 1.01* 
Patients who have used at least one of 
primary care services 
129 135 127 94 92 77 35 43 50 
% 44%¶ 46% 43%¶ 56% 55% 46% 28% 34% 40% 
N 293 293 293 167 167 167 126 126 126 
‖ P<0.001 for difference between 24 weeks and baseline. 
¶ P=0.87 for difference between 24 weeks and baseline. 
* P<0.001 for difference between 24 weeks and baseline. 
Social Care Services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Social worker or Care manager 0.09 0.03 0.02 0.14 0.05 0.03 0.02 0.00 0.00 
Home care/home help worker 0.70 0.62 0.66 0.95 0.91 0.98 0.37 0.25 0.25 
Private home help/cleaner 0.48 0.54 0.82 0.57 0.62 0.96 0.37 0.44 0.27 
Mean use of social care services 1.28 1.19 1.50 1.66 1.58 1.97 0.76 0.68 0.88 
Patients who have used at least one of social 
care services 
47 44 49 33 27 32 14 17 17 
% 16% 15% 17% 20% 16% 19% 11% 13% 13% 





Community Mental Health Services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Psychiatrist / psycho-geriatrician 0.02 0.00 0.01 0.00 0.01 0.01 0.04 0.00 0.00 
Community psychiatric nurse / Community 
mental health nurse 
0.02 0.01 0.02 0.04 0.02 0.04 0.00 0.00 0.01 
Other mental health professional 0.03 0.06 0.04 0.01 0.05 0.02 0.06 0.06 0.06 
Mean use of community mental health 
services 
0.06 0.07 0.07 0.04 0.08 0.07 0.10 0.06 0.07 
Patients who have used at least one of the 
community mental health services 
6 7 8 2 5 5 4 2 3 
% 2% 2% 3% 1% 3% 3% 3% 2% 2% 





Other community-based services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Telecare 0.01 0.09 0.01 0.01 0.07 0.01 0.00 0.10 0.00 
Dentist, oral hygienist 0.12 0.14 0.09 0.09 0.13 0.09 0.16 0.15 0.10 
Optician 0.08 0.06 0.05 0.09 0.06 0.05 0.06 0.07 0.04 
Mean use of other community-based 
services 
0.20 0.29 0.15 0.19 0.26 0.16 0.21 0.33 0.13 
Patients who have used at least one of the 
other community-based services 
37 49 27 21 30 17 16 19 10 
% 13% 17% 9% 13% 18% 10% 13% 15% 8% 





Day activity services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Day care – local authority social services 
department 
0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
Day care – voluntary organisation 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.02 
Day care – NHS (community-based) 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 
Lunch club 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.00 
Social club 0.02 0.06 0.03 0.02 0.07 0.04 0.03 0.06 0.02 
Exercise class 0.22 0.19 0.19 0.10 0.02 0.04 0.37 0.42 0.38 
Other services 0.17 0.12 0.09 0.10 0.04 0.11 0.27 0.23 0.07 
Mean use of day activity services 0.43 0.40 0.33 0.23 0.15 0.20 0.70 0.73 0.49 
Patients who have used at least one of the 
day activity services 
48 51 41 14 14 16 34 37 25 
% 16% 17% 14% 8% 8% 10% 27% 29% 20% 





Cost of healthcare resources 
Before comparing Test Bed participants with the controls, Table 3.9 presents the average cost 
of health and social care services at baseline, mid and end-point 12 for the Test Bed 
population and for each cohort. At baseline, the average cost of using hospital services is 
around £331.93. At mid-point, the cost is £390.98 and at end-point it rises to £433.50. This 
increase in the average cost of hospital services was mainly driven by changes observed in 
day hospital services. 
The trajectories of the cost of hospital services followed a different pattern across Cohorts. 
The highest cost among Cohort 1 patients came in the middle period but the highest cost 
among Cohort 2 came at mid-point in the programme. As expected, Cohort 1 revealed a 
higher mean use of hospital services and a higher cost than Cohort 2. 
Primary care, community health and emergency services showed a modest increase over the 
24 weeks of the intervention, from £113 to £128. However, the overall data masks differences 
between Cohort 1 and 2, with a modest increase over the 24 weeks in Cohort 1 but doubling 
the mean use, and therefore the cost, among Cohort 2. 
Changes observed in social care services are negligible in both the overall Test Bed population 
and in Cohort 1. Community mental health services and other community-based services 
showed small reductions over the 24 weeks. 
Using the information on the mean use of services and on the mean average costs of health 
and social care services, Table 3.9 presents a summary of the average costs. 
For all services, at all time points, the majority of the patients were recruited to the Better 





Table 3.9. Average Cost of Health and Social Care Services at baseline, mid-point and end-point of the 24 week intervention 
Hospital services 
Test Bed population Cohort 1 Cohort 2 
Baseline  
Cost (£) 
















Accident & Emergency 15.54 15.54 18.13 23.31 25.9 25.9 5.18 2.59 7.77 
General hospital inpatient admission 156.12 195.15 156.12 234.18 312.24 195.15 78.06 78.06 78.06 
Community hospital inpatient admission 0 0 39.03 0 0 39.03 39.03 0 39.03 
Day hospital 94.51 109.05 159.94 116.32 152.67 145.4 72.7 43.62 181.75 
Outpatient visits to clinic based at hospital 
site 
65.76 71.24 60.28 79.46 89.05 76.72 47.95 47.95 39.73 
Other - - - - - -       
Average cost 331.93 390.98 433.5 453.27 579.86 482.2 242.92 172.22 346.34 
 
Primary Care, Community  
Health or Emergency Services 
Test Bed population Cohort 1 Cohort 2 
Baseline  
Cost (£) 
















GP 82.35 100.65 87.84 107.97 111.63 80.52 45.75 84.18 98.82 
Paramedic (Ambulance service) 1.44 1.08 2.16 1.8 2.16 2.16 0.72 0 2.16 
Community matron 2.65 1.59 1.06 2.12 1.06 1.06 3.18 2.65 1.06 
Community/District nurse 11.13 14.31 15.37 19.61 24.38 24.91 0 0.53 3.18 
Practice nurse 7.56 9.72 8.28 9.72 13.32 11.16 4.68 4.68 4.68 
Specialist nurse 8.06 8.06 13.02 8.06 11.78 13.64 7.44 3.72 13.02 




Social Care Services 
Test Bed population Cohort 1 Cohort 2 
Baseline  
Cost (£) 
















Social worker or Care manager 5.31 1.77 1.18 8.26 2.95 1.77 1.18 0 0 
Home care/home help worker 14.7 13.02 13.86 19.95 19.11 20.58 7.77 5.25 5.25 
Private home help/cleaner 6.00 6.75 10.25 7.125 7.75 12 4.625 5.5 3.375 
Average cost 26.01 21.54 25.29 35.34 29.81 34.35 13.58 10.75 8.63 
 
Community Mental Health Services 
Test Bed population Cohort 1 Cohort 2 
Baseline  
Cost (£) 
















Psychiatrist / psycho-geriatrician 2.16 0 1.08 0 1.08 1.08 4.32 0 0 
Community psychiatric nurse / Community 
mental health nurse 
1.24 0.62 1.24 2.48 1.24 2.48 0 0 0.62 
Other mental health professional 1.32 2.64 1.76 0.44 2.2 0.88 2.64 2.64 2.64 
Average cost 4.72 3.26 4.08 2.92 4.52 4.44 6.96 2.64 3.26 
 
Other community-based services 
Test Bed population Cohort 1 Cohort 2 
Baseline  
Cost (£) 
















Telecare 0.36 3.24 0.36 0.36 2.52 0.36 0 3.6 0 
Dentist, oral hygienist 12.12 14.14 9.09 9.09 13.13 9.09 16.16 15.15 10.1 
Optician 3.6 2.7 2.25 4.05 2.7 2.25 2.7 3.15 1.8 






Table 3.10 summarises the average cost of the technology per patient for Cohorts 1 and 2 
taking into account the different combinations of technologies, different care pathways and 
healthcare staff needed. These are classified into a single scenario. Part A shows the average 
cost of technology per patient in Cohort 1 and Part B presents the average cost of technology 
per patient in Cohort 2. The cost of the technology used for Cohort 1, which includes the cost 
of health care staff required to deliver the programme, is around 4.5 times higher than for 
Cohort 2. 
We have varied the assumptions to calculate the licence fee per patient in the technology 
used by cohort 1 and 2. We costed the license fee per patient using the number of patients 
that received the technology in each care pathway (scenario 1). 
Regarding the average cost per patient, the costs of the care pathways for Cohort 1 patients 
were approximately £1,486 in both scenarios considering different assumptions. This figure 
includes the unit cost of the technology (around £1,260) and the cost of healthcare staff-time 
(around £220). However, the costs of technology per patient in Cohort 2 differ across 
scenarios. In scenario 1, the cost per patient was £335, including £200 for technology devices 
and around £135 for healthcare staff-time.  
The last five columns of Table 3.10 show the cost per Vanguard using the average cost per 
patient and the number of patients per Vanguard within each care pathway. Under the 
scenario we present, costs per patient the cost of the technology and healthcare staff-time of 
providing the service to the 31 patients in Cohort 1 in Fylde Coast is approximately £46,500 
(approx., £1500 per patient). In Better Care Together, the cost of providing the technology to 
136 patients is around £200,000 (approx. £1470 per patient). Hence despite differences in the 
models of delivery used in each Vanguard, there is little difference in the cost per patient. The 
cost of the technology and healthcare staff-time is calculated using the number of patients as 
specified in the table.  
Under scenario 1, the cost of the technology and healthcare staff-time for providing the 
service to the 39 patients in Fylde Coast is approximately £11,300 (approx. £290 per patient). 
In Better Care Together, the cost of providing the technology to 87 patients is around £31,000 




Table 3.10. Technology: Unit Costs of technology and Costs per Cohort and Vanguard 
Scenario 1. Cohort 1        
     Fylde Coast Better Care Together   




N Cost (£) N Cost (£) 
Total Cost 
(£) 
Technology        
Motiva-COPD 1,217.33  17 20,694.61 94 114,429.02 135,123.63 
Motiva-Heart Failure (HF) 1,348.14  14 18,873.96 42 56,621.88 75,495.84 
CANTAB Mobile b 0.85  31 26.35 136 115.60 141.95 
Average 1,262.04   39,594.92   171,166.50 210,761.42 
Healthcare Staff c        
Motiva- COPD or HF 224.42  31 6,956.94 136 30,520.78 37,477.73 
Average Unit Cost 1,486.46  
 46,551.86   201,687.28 248,239.15 
Notes: a A total of 45 patients in Cohort 1 had both COPD and HF. For the purposes of the Test Bed they could only chose 
one care pathway on Motiva (i.e. COPD or HF). We assumed that 50% of those patients used COPD care pathway and 50% 
used HF care pathway. b The cost of licence per patient using CANTAB Mobile is calculated over 293 active participants in 
Cohorts 1 and 2 (250/293=0.85). c Average healthcare staff time unit cost per patient is estimated over 149 participants 
recruited in the Fylde Coast and 223 patients recruited in Better Care Together. 
Scenario 1. Cohort 2        
     Fylde Coast Better Care Together   




N Cost (£) N Cost (£) 
Total Cost 
(£) 
Technology        
Flo b 270.69  4 1,082.76 70 18,948.30 20,031.06 
Intelesant c 9.53  4 38.12 17 162.01 200.13 
Health Watch 157.99  31 4,897.69 0 0.00 4,897.69 
CANTAB Mobile d 0.85  39 33.15 87 73.95 107.10 
Average 200.29   6,051.72   19,184.26 25,235.98 
Healthcare Staff        
Flo, Intelesant, Health Watch e 
or Flo and Intelesant f 
134.96 
 
39 5,263.43 87 11,741.50 17,004.93 
Average Unit Cost 335.25  
 11,315.15   30,925.76 42,240.91 
Notes: a Speakset was not included as this technology was not used by TB participants. b The cost of licence per patient 
using Flo is estimated over 74 active patients using this technology across both Vanguards (8,000/74=109.11). c The cost 
of licence per patient using Intelesant is calculated over 21 active patients using this technology across both Vanguards 
(200/21=9.53). d The cost of licence per patient using CANTAB Mobile is calculated over 293 active participants in Cohorts 
1 and 2 (250/293=0.85). e Care pathway for Cohort 2 participants in Fylde Coast (mixture of the health watch: 80%, 
Intelesant: 10% and Flo: 10%). Percentages assumed based on discussion with clinical teams. Average healthcare staff 
time unit cost per patient is estimated over 93 participants recruited in the Fylde Coast. 
f Care pathway for Cohort 2 participants in Better Care Together (Flo: 80% and Intelesant: 20%). Percentages assumed 
based on discussion with clinical teams. Average healthcare staff time unit cost per patient is estimated over 202 




We acknowledge that our cost-estimations of the technologies used are conservative 
(although in some cases our assumptions may have had the effect of under-estimating costs 
and in some other cases the effect of over-estimating costs). It is also worth noting that as 
this was a Test Bed, all technology costs were based on a new purchase model; alternative 
models (such as leasing arrangements) may be less costly, but due to technology innovator 
confidentiality agreements we were unable to access this information. 
Medication 
Usage of high numbers of medications was reported in the surveys by Test Bed participants. 
Not unexpectedly, given the health conditions and age group of participants in this Test Bed, 
65% of medications reported were long-term medications that patients take continuously. 
Around 30% of reported medications were medium-term medications. 
Table 3.11 summarises the average cost of medication per patient in Cohorts 1 and 2 including 
long, medium and short-term medications. During the 24 weeks of the intervention on 
average patients had a cost of £1,367 in medication. Part A shows the average cost per patient 
in Cohort 1 and Part B presents the average cost per patient in Cohort 2. On average, a patient 
in Cohort 1 cost around £1,710 over the 24-week period of the intervention (£3,421 in 
medication a year or £285 per month), whilst a patient in Cohort 2 cost on average £913 over 
the same period (£1,826 in medication a year or £152 per month). Among both Cohorts, the 




Table 3.11. Medication use: Average Unit Costs per Cohort 
A. Cohort 1 (N=167) 





















F= D * E 
Long Term b 0.40 3.53 329.09 120,116.95 0.021 2,536.87 
Medium Term c 2.89 2.45 668.05 60,124.31 0.015 882.18 
Short Term d 0.41 1.60 18.05 252.67 0.010 2.42 
Total      3,421.48 
Notes: 
a The total cost per day is estimated by summing the cost per day of all medications within a medication type.  
The cost per day per medications is calculated by multiplying the average cost per day per patient by the average 
patients taking each medication. 
b  339 Long Term medications reported by Test Bed participants in Cohort 1. 
c  151 Medium Term medications reported by Test Bed participants in Cohort 1. 
d  31 Short Term medications reported by Test Bed participants in Cohort 1. 
 
 
B. Cohort 2 (N=126) 




















F= D * E 
Long Term b 0.47 2.89 203.78 74,381.50 0.023 1,706.50 
Medium Term c 0.35 2.30 72.11 6,489.65 0.018 118.43 
Short Term d 0.32 1.55 9.47 132.59 0.012 1.63 
Total      1,826.56 
Notes: 
a The total cost per day is estimated by summing the cost per day of all medications within a medication type.  
The cost per day per medications is calculated by multiplying the average cost per day per patient by the average 
patients taking each medication. 
b  238 Long Term medications reported by Test Bed participants in Cohort 2. 
c  98 Medium Term medications reported by Test Bed participants in Cohort 2. 
d  23 Short Term medications reported by Test Bed participants in Cohort 2. 
Total Average Cost per Participant 
Table 3.12 provides a summary of the average cost per patient using health and social care 
services at all three time points of the intervention. The average cost per patient increased 
from £1,711 at baseline to £1,822 at week 24. 
As would be expected, overall costs for patients in cohort 1 were more expensive than for 




patients in Cohort 1 (from £2,426 to £2,437), the average cost of a patient in Cohort 2 
increased from £832 to £981. 
Average costs of patients in Cohort 1 were around 2.5 times higher than those found for 
patients in cohort 2 over the 24 weeks. 
To give a sense of scale using a total of 293 Test Bed participants, we calculated a weighted 
total cost based on the population by multiplying the total average cost per participant by the 
number of participants. 
The weighted total cost ranges from around £501,000 to £534,000 considering a population 
of 293 patients. 
Similarly, we calculated a weighted total cost based on the number of patients in each cohort 
should the combinatorial technologies in each cohort be replicated. Considering a total of 167 
patients in cohort 1, the weighted total cost ranges from approximately £405,122 to 
£407,000. Considering a population of 126 patients in cohort 2, the weighted total cost is 




Table 3.12. Total average cost per participant and per cohort 
Health and Social Care Service 
Test Bed population Cohort 1 Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Hospital services 331.93 390.98 433.50 453.27 579.86 482.20 242.92 172.22 346.34 
Primary Care, Community Health 
or Emergency Services  
113.19 135.41 127.73 149.28 164.33 133.45 61.77 95.76 122.92 
Social Care Services  26.01 21.54 25.29 35.34 29.81 34.35 13.58 10.75 8.63 
Community Mental Health 
Services  
4.72 3.26 4.08 2.92 4.52 4.44 6.96 2.64 3.26 
Other community-based services  16.08 20.08 11.70 13.50 18.35 11.70 18.86 21.90 11.90 
                    
Mean cost of health care services 491.93 571.27 602.30 654.31 796.87 666.14 344.09 303.27 493.05 
             
Technology 991.40 991.40 991.40 1,486.46 1,486.46 1,486.46 335.25 335.25 335.25 
             
Medicines 227.97 227.97 227.97 285.12 285.12 285.12 152.21 152.21 152.21 
Total average cost per patient 1,711.30 1,790.64 1,821.67 2,425.89 2,568.45 2,437.72 831.55 790.73 980.51 





Matching of Test Bed participants to controls 
Table 3.13 shows the descriptive statistics for the participant and control groups for the 
matching variables. The distribution of the covariates used in the matching are almost 
identical in the two groups. The average age is 71 years in both groups, the percentage of 
females is 59.7%, the distribution of long term conditions is very similar (approximately 65% 
COPD, 20% heart failure, 80% both COPD and heart failure), and the average risk of hospital 
admission was 30% in both groups. 
Table 3.13. Baseline characteristics of participants and matched control group 
  Matched Controls 
Test Bed participants 
Cohort 1 & 2 
Number of patients 879 293 
Matching covariates   
Age (average) 71.42 71.41 
Female 59.73% 59.73% 
Long-term conditions     
COPD 64.51% 68.26%  
Heart Failure (HF) 22.98% 20.14%  
COPD or HF 81.23% 81.23%  
Risk of hospital 
admission 30.50 (20.85) 30.10 (21.35) 
Note: Numbers presented are either mean (standard deviation) or percentage. 
Secondary care use 
Table 3.14 shows secondary care use of Cohorts 1 and 2 in the Test Bed as well as secondary 
care use of the matched controls. Our measures of secondary care use included A&E visits, 
outpatient appointments and inpatient admissions. 
For Test Bed patients these measures refer to three periods covering four weeks each: the 
first period was at baseline, the second at mid-point and the third at end point. For control 
patients the measures refer to three periods covering four months each: the first being from 
1st July 2015 to 31st October 2015; the second from 1st November 2015 to 29th February 2016; 
the third from 1st March 2016 to 31st July 2016. 
To allow a comparison of secondary care use between the Test Bed and controls, we scaled 
the measures for Test Bed patients by multiplying them by a factor of four. In this way, we 
compared secondary care use by Test Bed patients over a one-year period to secondary care 
use by control patients also over a one-year period.47 For the Test Bed participants, columns 
                                                     
47 The change is over a one year period because we assumed that the first four months of the year is the 
‘beginning of the year’ and the third four months is the ‘end of the year’. Therefore, the change over one year 




A, D and G show the raw data and columns B, E and H show the scaled data. For the control 
patients, columns B, E and H show the raw data. 
For Test Bed participants the raw data for A&E visits was the total number of visits reported 
by participants whilst for the control patient the raw data for A&E visits was the total number 
of visits recorded in the CSU dataset. Since we matched three controls to each Test Bed 
participant, the total numbers in the Test Bed and control patients are not comparable. 
Therefore, we calculated the number of A&E visits per patient, shown in Column C. Similarly, 
the raw data for outpatient appointments was the total number of outpatient appointments, 
hence we calculated the number of outpatient appointments per patient, shown in Column 
F. 
For inpatient admissions, the raw data was the number of patients admitted to hospital in 
each of the three time periods. Again, to allow comparisons, we calculated the proportion of 
patients admitted, shown in Column I. These numbers can be interpreted as the probability 
of being admitted as an inpatient over a period of four months.48  
Overall, Table 3.14 reveals that the Test Bed participants had much higher secondary care use 
than the control patients. For instance, over the first four-month period, Test Bed participants 
had 0.25 A&E visits per patient, compared to 0.29 at the third of our four-month periods. For 
the controls, the average was much lower being 0.07 A&E visits per patient in the first four 
months, and 0.11 visits per patient in the third of the four-month periods. One reason for this 
may be the different sources of data, i.e. that data on secondary care use by Test Bed 
participants came from self-reported surveys whilst for the control patients the data came 
from administrative records. 
Table 3.14 shows that amongst both the Test Bed participants and the control patients, the 
number of A&E visits was larger in the last 3 month period than in the first. The probability of 
being admitted to hospital, on the other hand, was smaller in the last period compared to the 
first. For outpatient appointments, the trend differed between Test Bed participants and 
control patients: for Test Bed participants the number of appointments was smaller in the last 
period compared to the first period, while for control patients the number was larger in the 
last period. 
Estimating the impact of the Test Bed using simple pre-post differences in secondary care use 
in the Test Bed participants would be misleading because differences in care use could have 
been driven by general trends unrelated to the Test Bed. By comparing the pre-post 
difference in the Test Bed participants to the pre-post differences in the control patients, we 
obtain an approximation of the Test Bed intervention effect. Thus, in Table 3.15 we used the 
data presented in Table 3.14 to estimate the intervention effect using the difference-in-
difference in estimator. The first and second row show the pre-post comparison of A&E visits, 
outpatient appointments and inpatient admissions of the Test Bed participants and the 
control patients over one year respectively. The last row shows the intervention effect 
                                                     
48 Ideally, we would have measured the number of inpatient admissions rather than the number of patients 
being admitted as an inpatient. However, for the Test Bed participants we could not use administrative data on 





calculated as the pre-post difference in the Test Bed participants minus the pre-post 
difference in the control patients.   
There was an increase of A&E visits per patient in both the Test Bed participants and the 
control group. The last row shows the difference in difference estimate for this outcome was 
approximately zero at 0.001 (95% CI -0.075, 0.077) over one year. 
For outpatient appointments, the Test Bed participants showed a decrease of 0.15 
appointments per patient, whereas the controls showed an increase of 0.11 appointments 
per patient over the one-year period. Therefore, the difference-in-difference estimate 
showed a beneficial effect of the Test Bed, with 0.26 fewer outpatient appointments per 
patient (95% CI -0.59, 0.06). However, this effect was not statistically significant at a 5% level 
of significance. 
Regarding the probability of being admitted to hospital, Test Bed participants showed a 
decrease of 2.7% compared to a decrease of 0.5% in controls. Therefore, the difference-in- 
difference analysis showed a benefit of the Test Bed of 2.3% (95% CI -0.09, 0.04) over one 
year. Again, this effect was not statistically significant. 
Figure 3.10 illustrates the results from Table 3.15. Broadly, the same trends are evident across 
the three outcome measures within both Cohorts 1 and 2 and for the overall results. The 
largest impact was on outpatient appointments. Here the data reveal that the average 
number of outpatient appointments in the control group increased over the study period, 
(especially among control patients matched to participants in Cohort 1), whereas the average 
appointments per patient reduced overall and for both in both Cohorts 1 and 2 (especially 
among Cohort 1 participants). The difference-in-difference estimate was very similar in both 




Table 3.14. Secondary care use by Test Bed participants and Controls at three time points 

















F= E / N 
















Test Bed cases: Baseline (N=293)  18 72 0.246 141 564 1.925 14 56 0.191 
Cohort 1 (N=167) 15 60 0.359 97 388 2.323 10 40 0.240 
Cohort 2 (N=126) 3 12 0.095 44 176 1.397 4 16 0.127 
Test Bed cases: 12 weeks (N=293) 17 68 0.232 152 608 2.075 16 64 0.218 
Cohort 1 (N=167) 16 64 0.383 108 432 2.587 14 56 0.335 
Cohort 2 (N=126) 1 4 0.032 44 176 1.397 2 8 0.063 
Test Bed cases: 24 weeks (N=293) 21 84 0.287 130 520 1.775 12 48 0.164 
Cohort 1 (N=167) 17 68 0.407 94 376 2.251 9 36 0.216 
Cohort 2 (N=126) 4 16 0.127 36 144 1.143 3 12 0.095 
Controls first 4 months (N=879) - 58 0.066 - 540 0.614 - 24 0.027 
Cohort 1 (N=501) - 28 0.056 - 342 0.683 - 16 0.032 
Cohort 2(N=378) - 30 0.079 - 198 0.524 - 8 0.021 
Controls second 4 months (N=879) - 92 0.105 - 576 0.655 - 25 0.028 
Cohort 1 (N=501) - 57 0.114 - 359 0.717 - 17 0.034 
Cohort 2(N=378) - 35 0.093 - 217 0.574 - 8 0.021 
Controls third 4 months (N=879) - 93 0.106 - 638 0.726 - 20 0.023 
Cohort 1 (N=501) - 58 0.116 - 434 0.866 - 14 0.028 





Table 3.15 Comparison of secondary care utilisation over one year: difference in difference analysis 
  
Difference in number of A&E visits per patient  
(95% confidence interval) 
Difference in number of outpatient 
appointments per patient 
(95% confidence interval) 
Difference in the probability of inpatient 
admissions  
(95% confidence interval) 
 Test Bed 
population 
Cohort 1 Cohort 2 
Test Bed 
population 
Cohort 1 Cohort 2 
Test Bed 
population 
Cohort 1 Cohort 2 
Test Bed participants                
Change over 1 year 
0.041 0.048 0.032 -0.150 -0.072 -0.254 -0.027 -0.024 -0.032 
(-0.031, 0112) (-0.056, 0.152) (-0.046, 0.109) (-0.473, 0.173) (-0.496, 0.353) (-0.713, 0.205) (-0.089, 0.035) (-0.114,0.066) (-0.109, 0.046) 
Controls                   
Change over 1 year 
0.040 0.060 0.013 0.111 0.184 0.016 -0.005 -0.004 -0.005 




Test Bed compared 
to Controls 
0.001 -0.012 0.019 -0.262 -0.255 -0.270 -0.023 -0.020 -0.026 





Figure 3.10. Changes in secondary care utilisation for the Test Bed, controls and intervention effect 













* denotes statistically significant at the 5% level. 





Monetary value of the change in secondary care use 
To understand how meaningful the Test Bed treatment effects were, we calculated the value 
of the Test Bed intervention by estimating the monetary value of the change in secondary 
care use shows the intervention effect, unit cost and the monetised intervention effect per 
patient for the overall Test Bed population and separately for Cohorts 1 and 2. We monetized 
secondary care use by multiplying the intervention effect by the unit cost per patient. The 
monetized intervention effect in the overall Test Bed population was -125.40. This negative 
value means that the Test Bed intervention resulted in cost savings of around £125 per 
patient. 
In Cohort 1 there were cost savings in the three measures of secondary care. In A&E visits 
there was a saving of around £3 per patient, in outpatient appointments the saving per 
patient was approximately £35 and in hospital admissions of approximately £78. The total 
saving in this cohort was around £116 per patient. 
In Cohort 2 there were cost savings in two of the three measures of secondary care. There 
were cost savings of approximately £101 per patient in hospital admissions and around £37 
per patient in outpatient appointments. However, there was an increased cost in A&E visits 
of £5 per patient. Overall, in cohort 2 the total cost saving was approximately £133 per 
patient. 
Table 3.16. Monetised Test Bed Intervention Effect Per Patient over one year 








Test Bed Population (N=293) 
A&E visits 0.001 259 0.26 
Hospital admissions -0.023 3,903 -89.77 
Outpatient appointments -0.262 137 -35.89 
TOTAL     -125.40 
Cohort 1 (N=167) 
A&E visits -0.012 259 -3.11 
Hospital admissions -0.02 3,903 -78.06 
Outpatient appointments -0.255 137 -34.94 
TOTAL     -116.10 
Cohort 2 (N=126) 
A&E visits 0.019 259 4.92 
Hospital admissions -0.026 3,903 -101.48 
Outpatient appointments -0.27 137 -36.99 
TOTAL     -133.55 
We estimated the potential cost savings of the Test Bed by comparing the average cost 
savings in secondary care per cohort member with the cost of technology per cohort member. 
Table 3.17 shows the cost per patient for the technology provided and the cost savings per 
patient in each cohort under our scenario of assumptions regarding the costs of technology. 




Table 3.17. Unit cost per patient for technology and cost savings per patient over a one year 
period by cohort 
Scenario 1.    
Cohort 
A.  




Cost savings per 
patient (£) 
C= A-B  
Cost of TB per 
patient (£) 
Cohort 1 1,486.46 116.10 1,370.36 
Cohort 2 335.25 133.55 201.70 
Our finding that the cost of the Test Bed exceeds the cost savings due to reductions in 
secondary care use should not be considered in isolation. Firstly, we acknowledge that this 
approach has both strengths and limitations, which will be discussed in more detail in the 
discussion section below. Secondly, it is possible that the time frame of our study was too 
short to be able to accurately measure changes in secondary care use. Thirdly, our analysis 
does not account for health benefits that do not result in direct cost savings for the NHS. 
Linked to this, the analysis also does not account for indirect benefits from a societal 
perspective, such as improved quality of life for carers. Finally, the analysis is based on a new 
purchase model for the technologies, other options (such as leasing) may be more cost 




Findings: Phase 2 
Phase 2 of the evaluation involved a range of participants. Patients and family carers took 
part in observational interviews to evaluate the effectiveness and experiences of participating 
in the Test Bed. Members of staff involved in the delivery of the programme across the two 
Vanguard sites completed weekly diaries and participated in focus groups to explore the 
impact of the Test Bed on daily working practices. In addition, key stakeholders, including 
technology innovators, were involved in regular action learning meetings and focus groups, 
with all learning captured in a logic model. 
The Phase 2 findings section is structured as follows: 
 Patients and Carers 
 Staff 
 Logic model 
 Ranking activity 
Patients and Carers 
Patients taking part in Phase 2 of the Test Bed participated in observational interviews in their 
own homes within month one of using the programme and in the final month (Table 3.18 and 
Table 3.19). 
As the qualitative element of the evaluation, the numbers of patients and carers participating 
in Phase 2 was relatively small. It is therefore important to acknowledge that this phase was 
focused on depth of understanding rather than generalisation of these data. However, it is 
worth highlighting that, of the total 315 patients who completed their participation in the 
Test Bed, 67 took part in the two-phased observational interviews in Phase 2 of the 
evaluation. As a result, the Phase 2 patient data represents 21% of all patient participants in 
the Test Bed. Our patient data is this highly representative of the whole sample.  
Table 3.18. Phase 2 participants and interviews completed 










1 >25 25 22 
2 >10 and <25 20 18 
3 <10 10 10 
4 N/A 18 13 
Carers N/A 4 4 
Total  77 67 
 
As illustrated in Table 3.18, ten patients took part in the initial interview and withdrew from 
the Test Bed before the follow-up interview. These participants’ data are included in the 
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analysis. However, where findings relate only to participants who completed the initial and 
follow-up interviews, this is made clear in the relevant sections. 
Table 3.19. Phase 2 participant demographics  
Cohort Cohort 1 Cohort 2 Cohort 3 Cohort 4 Totals 


























































77.3 years 71.4 years 








































































































































28% in 1-5 
(n=5) 
72% in 1-5 
(n=13) 
















Mean 6.17 Mean 5.27 
Total 
participants 
13 12 9 11 5 5 18 73 
* Based on postcode; 1 is the lowest decile (indicating most deprived areas); 10 is the highest decile (indicating 
least deprived areas)  
Findings related to the patients and carers who participated in Phase 2 of the evaluation are 
discussed around the following themes: 
 Engaging with the Test Bed technologies  
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 Healthcare services and relationships with healthcare professionals  
 Impact on the care environment  
 Patient activation  
 Quality of life 
 Carers 
Engaging with the Test Bed Technologies 
Patient experiences of using the Test Bed technologies   
Prior to participation in the Test Bed programme, many patients were using a variety of digital 
technologies for health and other purposes, including computers, laptops, handheld tablets, 
websites, mobile phones, text messaging, apps and social media. Some, however, did not 
regularly use technologies. Of the total 73 patients who took part in Phase 2 of the evaluation, 
only 18% (n=13) suggested in interview 1 that they lacked confidence when using digital 
technologies. This is presented by Cohort and Vanguard in Table 3.20. 
Table 3.20. Phase 2 participants’ confidence with technologies in general at the outset of the 
Test Bed programme 
Cohort 1 Cohort 2 Cohort 3 Cohort 4 
BCT FCV BCT FCV BCT FCV  
83%* 
(n=15 out 
of 18)  
92% 
(n=12 out of 
13) 
75% 
(n=9 out of 
12)  
78% 
(n=7 out of 
9)  
64% 






In total, 82% (n=60 out of 73) of Phase 2 participants were confident with technologies in general at the 
outset of the Test Bed programme 
* The Cohort 4 figure refers to patients or family carers  
 
Overall, people’s initial experiences of using the Test Bed technologies were positive. Many 
participants however, did need the support of a family member or friend when using the 
technology for the first time. Following the initial induction period, the majority of 
participants in Cohorts 1 and 4 continued to use the Test Bed technologies with a family 
member, often their partner or spouse, for the duration of the intervention, with many 
explaining that it quickly became part of their daily routine.   
Family carer:  Once you get in a routine, it’s a breeze really. 
 
Patient:  Yeah. I have my inhalers after breakfast. 
 
Family carer:  Yeah, we have breakfast… 
 
Patient:  and then we do this [use the Test Bed technologies]. 
(A1-01 Interview 1)  
 
Data suggest that in general, people found the Test Bed technologies easy to use. Those using 
a handheld tablet as part of the Motiva system (Cohorts 1 and 4) found this both easy to use 
and hold, whether or not they had previous experience of using a tablet. Furthermore, the 
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majority of participants across all cohorts found themselves to be confident using the 
technologies after an initial induction period. 
 
Some Test Bed participants required formal support when issues arose with their equipment. 
The most common problem encountered by Cohort 1 and 4 participants related to error 
messages appearing on handheld tablets being used as part of the Motiva system. 
Other problems experienced across the cohorts and technologies included inputting health 
data into text messages in the required format, converting weight from imperial to metric 
format, and getting locked out of apps. Participants were not generally perturbed by such 
hurdles, but problems arose when support channels were not clear to them or where they 
felt they were being a burden. Even when they had been provided with the details for a local 
contact, many patients did not want to be a burden by contacting someone: 
Quite often I got messages that [the tablet] was no longer working, please contact 
the support line, you know. Well, I never did, I just sort of sent it back home and it 
carried on working again, you know [I needed help] just the once where I changed 
my broadband provider and it needed a new pin […] But all the time, I never had a 
number to ring […] It was a bit disappointing, that. I mean to get the new pin in I 
had to actually send [my local contact] an email. And then, you know, she… she 
contacted Red Alert and then… then the guy came and changed it. No, I’ve never 
had a number to contact, you know. 
(B1-01 Interview 1) 
Installation, training and initial support  
Experiences of training and initial support differed across the cohorts depending on the 
equipment a patient received. Participants in Cohorts 1 and 4 received the Motiva technology 
and, as part of the programme, they were visited by a Red Alert colleague49 who installed the 
equipment and provided initial training and support. There was much praise from patients 
and carers for the training and support provided by Red Alert colleagues. At these 
installation/training appointments, patients were provided with hand-written step-by-step 
notes to guide them through the use of the equipment (see Figure 3.11). These notes helped 
patient confidence in using the technologies, with many people referring to them for several 
days or weeks.  
Well, [the Red Alert colleague] he’d done something which I thought was a good 
idea. You have the book… have you seen the booklet? It’s quite a…quite a thick 
thing. And it doesn’t run in logical order. But he gave me a crib list that he’d written 
out himself and it went through it as you do it, and that simplified it a lot, you 
know, you don’t have to wade through the book and find the page […] it’s so easy… 
he’d written a very simple instruction.  
(B1-06 Interview 1) 
In the case of all technologies, the majority of participants did not open or refer to the 
handbooks or instruction leaflets provided with the equipment. In some cases this was 
                                                     




because materials were printed in small text which was inaccessible to the user; participants 
would have benefitted from large text versions. In the case of Cohorts 1 and 4, where 
participants used the Motiva system, the step-by-step notes provided by Red Alert proved to 
be very useful to patients and family carers.  
Figure 3.11. Step-by-step notes provided by Red Alert to patients and family carers 
 
B1-03 Interview 1 
Cohort 2 and 3 participants received a range of other technologies including apps, watches 
and text messaging services. In many of these cases, participants felt unsupported in their 
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induction to the Test Bed programme. Some participants talked about the frustration of 
having to figure out the technology for themselves without training or support. 
Participants suggested that initial one-to-one training by someone who, themselves, had 
received training on the technology would have been beneficial to them. In some cases, 
people attended an initial meeting to be signed up for the Test Bed, but it was sometimes 
clear that the person running the meeting did not know, themselves, how to use the 
technology, nor was it available for a demonstration. While patients received a detailed 
explanation about the Test Bed programme, some say they received little support regarding 
use of the technologies.  
Interviewer: And how… how did you find it when she showed you it? Did you 
pick up straight away how to use it? 
 
Patient:   Well, she didn’t show me […] It was in the box with the 
instructions [and] the instructions weren’t over-good. You’ve got to go through it 
and have a look for yourself really […] In the instructions it doesn’t really tell you 
what to do […] It’s trial and error. 
(A2-01 Interview 1)  
 
I think the thing... when it was originally mentioned at the Health Centre, I think 
basically the lady that introduced it was like a... well, she is a Nursing Auxiliary, 
and she’s a very nice lady, but she herself said she hadn’t had any training and she 
was hoping to have some training, but really she didn’t know what it was about. 
(A3-02 Interview 2) 
Participants suggested that the availability of a live version of the technology at an initial 
meeting would have been very useful. They would also have appreciated support in the early 
stages of the Test Bed programme, including help to download an app or to make selections 
within the technologies which would be most appropriate for their healthcare needs.  
In addition, some patients stressed the need for a more joined-up approach in the Test Bed, 
to ensure that everyone involved in their healthcare is on board and knows about the 
programme.  
Interviewer:  So what happened when you took [the app] with you to the 
doctor? 
 
Patient:   He basically wasn’t interested. It’s only a trial […]  
 
Interviewer:  And how did you feel about that? 
 
Patient:   Well, I thought it was a waste of time having it, you know what I 
mean, afterwards. 
 
Family carer:  But the doctor put you on this, didn’t he? The surgery rung us up. 
 
Patient:   It was the surgery that rung us up […] I showed him it, you know 
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what I mean... I tapped into it [the app] and I showed him ... I 
don’t think he had time or anything because you only... you know 
what I mean? He didn’t have enough time to [look at it]. They 
[GPs] don’t really push you but they definitely do look at the clock 
[…] All the doctors have got to be on-side with it, you know what 
I mean, and if it takes five minutes to read the app, you know, to 
go through it […] They probably haven’t told him properly what 
it’s all about […] Maybe when they do the trials, they’ve got to tell 
all the doctors correctly. 
(A3-01 Interview 2) 
 
Patient acceptability of and trust in the technologies  
Participants in Cohort 3 had high expectations of the technology. Referring back to Figure 3.5. 
Participants indicating they felt confident or somewhat confident with the use of technology 
at baseline, 12 weeks and 24 weeks (%)., 100% of participants in Cohort 3 (n=10) were 
confident with technologies in general at the start of the Test Bed programme, compared 
with 82% for the Phase 2 participants overall. In this cohort, patients were more likely to have 
experimented with other digital health technologies including apps and wearable devices. The 
technology provided to people in this cohort did not meet with their expectations. 
Patient: Is [the app] of any use to me? Erm... could I do without it? Yes. And that’s 
just because of my circumstances really. I’ve got a Fitbit which is a very able piece 
of kit and I use that all the time. This piece of software is different. I get confused 
as to how I should approach using it, if I’m honest […] this tries to do all things for 
all people.  
(B3-02 Interview 2) 
It was a common theme across all cohorts that people were unclear what was happening with 
their data, exactly who had access to their data, and the purposes for which it was being used. 
This is illustrated for each individual cohort and technology in Table 4.28 
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Table 3.21. Phase 2 Participants unsure re who had access to their data  
Cohort Vanguard Number of Phase 2 participants 
unsure what was happening with 
their data 
Percentage by technology 
1 BCT 31% (N=4 out of 13) 31% of participants receiving Motiva 
FCV 17% (N=2 out of 12)  17% of participants receiving Motiva  
2 BCT 56% (N=5 out of 9) 
 
75% of participants receiving Flo (N=3 out of 
4) 
40% of participants receiving Intelesant (N=2 
out of 5)  
FCV 18% (N=2 out of 11)  
 
33% of participants receiving Flo (N=1 out of 
3) 
12.5% of participants receiving watch (N=1 
out of 8)  
3 BCT 60% (N=3 out of 5) 60% of participants receiving Umotif app 
FCV 80% (N=4 out of 5) 80% of participants receiving Umotif app 
4  44% (N=8 out of 18)  44% of participants receiving Motiva 
Totals 36% (N=26 out of 73)  39% participants receiving Motiva 
57% participants receiving Flo 
40% participants receiving Intelesant app  
12.5% participants receiving Philips health 
watch  
70% participants receiving Umotif app  
 
As illustrated in the above table, of the 73 patients who took part in Phase 2 of the evaluation, 
36% raised the issue of uncertainty regarding where and who held their data in interview. The 
key comments received from patients focused on the following aspects: 
 What happens to their data and who had access to it; 
 Uncertainty about exactly who was monitoring their data; 
 Questions about whether anyone is actually looking at their data;  
 What the technology companies were doing with their data; 
 Assuming that someone was looking at their data (when they were not); 
 One patient thought a research centre had access to their data; 
 Some patients believed that Lancaster University had access to all their data for the 
purpose of the evaluation. 
See for example: 
Researcher note: The carer thought Lancaster University, as part of the 
evaluation, were looking at the BP and survey data. We discussed this. It became 
clear she and her husband don’t know who, if anyone, is looking at the data.  
(C4-05 Interview 1)  
Very few patients who received the health watch expressed any concern (12.5%; N=1), 
suggesting that some technologies are more trusted than others. It was also more an issue on 
Cohorts 3 and 4, being raised by 70% and 44% of patients interviewed respectively. This 
compares to 24% and 35% of patients interviewed in Cohorts 1 and 2 respectively. 
While the data suggest some differences across different technologies, they do not suggest 
differences across the two Vanguard sites. This indicates that the uncertainty was unrelated 
to the model of care being implemented within the Vanguards. It is also possible that patients 
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may have received an explanation regarding their data but did not understand or retain the 
information. This was discussed in an action learning meeting where stakeholders felt that 
information-overload in the initial meeting may be an issue. At the initial meeting patients 
were not only signed up to the Test Bed programme, but were also required to complete 
consent forms, complete a baseline evaluation survey, as well as receiving the new 
technology. 
In interview, many participants noted that they would like to be better informed about how 
their data was being used. Some patients and carers commented that, in the induction stage 
of the Test Bed, the focus had been on the programme itself, rather than broader issues of 
data security and management. 
Individualisation of the technologies  
The theme of individualisation of the technologies arose in many of the patient interviews. It 
was clear for example, that some patients would have liked the ability to personalise the 
technologies they were using, for example to state their likes and preferences, and to change 
the times they receive messages. Many participants would have liked input from a healthcare 
professional to help them to tailor the Test Bed technology to their own healthcare needs, 
and therefore get the most out of it.  
I saw [a member of staff] and she more or less explained that it was a trial and 
that all the security side of things, you know, it wasn’t being broadcast all over […] 
and she explained that side, but didn’t go into the specifics, and nobody has been 
into the specifics...as to why I’m doing it and what... what I’m getting out of it. 
(B2-08 Interview 2) 
Others explained that they were already very knowledgeable about their own health 
conditions, having lived with and self-managed them for some time. In these cases, it was felt 
that the technologies could have been better tailored to the individual’s needs.  
Patient: It’s like I said, ten o’clock in a morning… it’s every morning they text me… 
I’m fine [at that time of day]. So, if they could do it at varied times maybe or send 
a text… I don’t know how they could do it… to say, ‘If you’re breathing is bad within 
the next 24 hours, can you text me with your oxygen and…’ Something like that, 
‘…your temperature levels.’ 
 
Interviewer: So that it’s more tailored to you? 
 
Patient: Yeah, not make it at certain times of the day. 
(B2-01 Interview 2)  
Individualisation of the technology was particularly important for Cohort 4 to ensure that 
individuals were not given information about their health condition that they did not want or 
expect at that point in time. The majority of Cohort 4 participants had only recently received 
their dementia diagnosis, and many patients and family carers were still coming to terms with 
the information. So, for example, while some people found the videos in the Motiva system 
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to be useful and informative, others found them upsetting and even distressing, illustrating 
the complexities of providing digital technologies for this patient cohort:  
Family carer:  Something that does have to be mentioned is these little vignettes 
– the videos that they do. They’re like little podcasts – they are absolutely first-
class. I think that they are clear; the people who are speaking have been properly 
directed and it’s just the length of them as well. They’re only on for about three 
minutes, but whatever length it is, and I think: Blimey, we’ve… you know, really 
learnt a lot just in that few minutes. 
(C4-04 Interview 1) 
 
Family carer:  We didn’t look at the videos because we looked at them once, you 
know, there was some videos on it, and we looked at a few of them and then they 
were a bit depressing, weren’t they? […] There’s no point in depressing yourselves, 
you know, about it. 
(C4-01 Interview 2) 
Cohort 3 participants also wanted flexibility in the use of the technology and, unlike patients 
in Cohorts 1 and 2, did not necessarily want to use the equipment every day. For some in this 
cohort, it was too prescriptive to use the technology every day and patients did not 
understand that there was some flexibility in this, and that they did not have to complete all 
sections of the app every day of the week:  
Patient:   I think now really that, you know, you’ve said, if it’s blood pressure 
you’re focusing on, just use it for that. 
 
Interviewer:  Yeah. Are you happier knowing that?  
 
Patient:   Yes […] with the blood pressure, it would be so useful for me to do 
it every day [just for that]. And then, you know, sort of if time 
allows, I can fill in other bits and pieces of it.  
(A3-02 Interview 2) 
Healthcare services and relationships with healthcare professionals 
Relationships and contact with healthcare professionals 
Relationships and contact with healthcare professionals was a key theme within the Phase 2 
data. For participants across all cohorts, access to healthcare along with continuity of care 
were of concern, with many discussing the difficulties they experienced in securing a GP 
appointment, particularly with a GP with whom they were familiar and had previously met 
with.  
Participant B1-07: We… our normal GP that we saw for a long time is [name 
of GP] 
 
Participant B1-08:  But we never see him because he only works two half-days 
a week and we can never get in. They just won’t give you 
an appointment for him. The only way I can get an 
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appointment with [him] is to ask for a telephone 
appointment with [him]. And then he rings me and he’ll 
make me an appointment. 
 
Participant B1-07: Same for me. 
 
Participant B1-08:  And nobody on the desk will give me an appointment with 
him. 
 
Participant B1-07:  They won’t… they won’t… 
(B1-07 and B1-08 Interview 2) 
Data suggest that the Test Bed programme reinforced to patients the importance of key 
healthcare staff in the management of their long-term conditions. Of the 21 people in Cohort 
2, for example, 18 referred to the importance of key healthcare professionals in the 
management of their long-term condition. Key members of staff included community 
matrons, consultants, GPs, pulmonary rehabilitation teams and respiratory nurses. The key 
factor was that people felt they had a good relationship with these professionals and that 
there was some continuity of care.   
Patient:   I mean they’re all very good to me down [at the surgery] because 
they’ve known me... I mean I’ve been there for years, so they’ve 
all known me through whatever’s gone on in life sort of thing – all 
the deaths and, you know, stuff that somebody else wouldn’t 
necessarily know about, but they do. 
 
Interviewer:  Because you’ve had a tough time, haven’t you? I know you’ve lost 
your partner and were you caring for your auntie? 
 
Patient:   Yeah. 
 
Interviewer: Is that important to you that they know that about you? 
 
Patient:   Yeah, because... I mean it’s nearly always the same GP who I get 
every time so he was the one who treated my mum, he treated 
my auntie as well, he looked after my dad and, you know, so he’s 
been involved in everything really. So it’s a case of, if I do phone 
up, he always tries to come. But I ask for him anyway, but he does 
normally try and come out anyway. 
 
Interviewer: So you never wait for an appointment or anything like that? 
 
Patient:  No, not really... no […] I’m very lucky. 
(A2-04 Interview 2) 
 
Relationships and trust between patients and healthcare professionals was a key theme 
within the Phase 2 data. For many participants in Better Care Together, it was their 
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relationship with a healthcare professional that informed their decision to take part in the 
Test Bed programme.  
 
I was interested [in taking part in the Test Bed] because of the way it was described 
to me and really sold to me by [my GP]. He’s my GP and, well, I just trust him and 
I feel he has helped me with my health for about 10 years. And, if he thought that 
I was a suitable candidate who would benefit, then I agreed. 
(B1-03 Interview 1) 
The theme of relationships and trust between patients and healthcare professionals in Cohort 
3, however, differed to that of Cohorts 1 and 2. People in Cohort 3 were younger than in 
Cohorts 1 and 2, many were still in employment and did not consider themselves to have a 
long-term condition. People in Cohort 3 did not lack confidence regarding the self-
management of their health in the way that some patients in Cohorts 1 and 2 appeared to. It 
was, however, apparent that, for some participants in Cohort 3, trust in the healthcare system 
and in healthcare staff was an issue. Some people in Cohort 3 referred to being ‘passed 
around’ different healthcare staff and feeling ‘lost in the system’ awaiting appointments, 
diagnoses, operations or treatments.  
 
Participant:  I have this chronic back problem, I’m on… I take morphine to stem 
the pain, I have 12 hour release. I have to have steroid injections: 
I can have up to two a year […] But then we moved up here and it 
all sort of changed […] I’d had three injections… three or four 
injections done […] I was in agony […] I got a letter off ’em and 
there’s a 28-week waiting list […] what’s gone on since, it’s gone 
worse. I had to have my morphine upped by 50 percent […] when 
my painkillers wear off the pain’s horrendous. 
 
Interviewer:  And then is the depression then linked into that? 
 
Participant:  That…I start getting…you know. I get up first thing in a morning I 
can hardly move and my whole body aches […] So I phoned the 
hospital up to see if there was anything that they could do. So I 
basically got… ‘Well, you are on the list.’ I said, ‘Well, I know that,’ 
I said, ‘but can you help me?’ ‘Just a minute.’ Right, they come 
back. ‘You’re now 270th on the list.’ I went, ‘You are kidding me.’ 
‘Well, you was 480th when you first came to us.’ 
(A3-05 Interview 1)  
There is a suggestion within the Cohort 3 data that dissatisfaction with their healthcare 
informed some people’s decision to take part in the Test Bed programme. Furthermore, the 
data suggest that the Test Bed technology may, for some, go some way to redress the 
perceived imbalance created by negative experiences of healthcare services.  
There are examples in the Phase 2 data of people using the Test Bed technology to improve 
their own healthcare experience. This included the gathering of ‘proof or evidence’ to share 
with a healthcare professional to inform decisions regarding diagnosis and treatment.  
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The arthritis I’ve had for years but the fibromyalgia is quite new, and finding 
somebody else who has it or, you know, trying to find out what it means, erm... 
when I saw the Rheumatology, he wasn’t that helpful on it. I described my 
symptoms to him, he examined me and he said, ‘Fibromyalgia... and this is the 
medication you need,’ and that was it. [My GP] has seen me... and he has... when 
I went in with the medication I said, ‘This is the dose that you gave me, it wasn’t 
sufficient. There was a big dip in the middle where there was too wide a gap 
between the doses, so I’ve increased my medication to this,’ and he goes, ‘Yeah, 
that’s fine.’ […] That, as I understand, is the reasoning behind the [Test Bed] app, 
that you can go in and the GP can have that information and know how you’ve 
been. 
(B3-04 Interview 1) 
Healthcare system utilisation  
A key objective of the Test Bed programme was to reduce healthcare system utilisation, and 
the Phase 2 data contains examples of where such a reduction was realised.  
Patient:   [The app is] stopping me going to the doctor’s.  
 
Interviewer:  Okay. Do you think you’d have had more appointments if you 
hadn’t had the app? 
 
Patient:   I think I would have ended up going back to the doctor’s because, 
like I say, I’d have left it too late again [to take rescue medication 
for a chest infection]. Whereas now, with this [app], it warned me 
that I really needed to start [the medication]. So for me it’s a 
signal: just get your antibiotics started and your Prednisolone. 
And, like I said, I think that’s… that’s why my recovery wasn’t as 
long, because I started in good time […] And it was all down to 
this [app]. Whereas I would have left it and left it and left it and 
I’ve ended up being nearly on my knees, going into the doctor’s. 
 
Interviewer:  So you actually managed to manage your chest infection and get 
better without seeing a GP? 
 
Patient:   Yes. 
(B2-07 Interview 1) 
There are, however, examples of Test Bed participation having the opposite effect, and 
increasing an individual’s utilisation of healthcare services and medication. In these cases, 
participants were often diagnosed with a condition that had been previously undiagnosed. In 
some cases, this a direct result of patients engaging more with their healthcare as a result of 
their participation in the Test Bed. These increases in healthcare service utilisation were 
perceived by patients to be positive, as they felt more engaged in their healthcare, better 
supported in the management of their health, and in receipt of better healthcare than that 
received prior to their engagement with the Test Bed. 
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Impact on the care environment 
Family carers played a key role in all patient cohorts except Cohort 3. Of the 73 patients who 
participated in the Phase 2 evaluation, 32 were accompanied in their interviews by a family 
carer who contributed to discussions. The majority of these family carers were spouses and 
partners (n=30; 94%). In only two cases was the family carer a daughter or son. In addition to 
the family carers being present for observational interviews, interview data revealed a 
broader network of support from family members who did not live with patients but who 
frequently visited and provided support with daily tasks. Other sources of support and help 
included neighbours, friends, family members living away, and support / social groups.  
Of the 73 patients who took part in Phase 2, 26% lived alone (n=19), while 74% (n=54) lived 
with a spouse, partner, or adult child. In interview, participants referred to drawing on a range 
of other support, particularly in Cohort 1, including paying for help with garden maintenance, 
household chores, window cleaning, mobile hairdressers and odd-job services. Many Phase 2 
participants were using or exploring the use of other technologies such as walking aids, 
wheelchairs, mobility scooters, panic alarms, air purifiers, key safes, grab rails and stair lifts. 
Patients and their family carers often discussed other changes they had recently made, or 
were preparing to make, to adapt to changing needs. Some examples include; moving house 
for reasons of layout or location (i.e. to be closer to healthcare services); ceasing to drive or 
selling cars/caravans; and altering gardens for ease of maintenance. A small number of 
participants discussed exploring day care and respite care to provide the family carer with a 
break from caring duties.  
Participants across all cohorts expressed anticipation of changing needs, with many patients 
and carers exploring options available to them should they need support at some point in the 
future. Many Cohort 4 patients and family carers explained that, on receiving a dementia 
diagnosis, they were offered a lot of information, help and support. However, this was often 
at a time when they did not require it, and as months passed and needs changed, people 
often then did not know where to go and who to ask for help.  
Participants’ social networks differed across the patient cohorts. In general, Cohort 3 
participants were active, with fairly large social networks, and often in paid employment. Of 
the ten patients in this cohort, two people lived alone. The majority of Cohort 4 patients were 
living with a spouse or partner, with only two participants living alone. Cohort 4 participants 
were often keeping socially active, sometimes following the advice of a clinician to ensure 
structure to each day, or as a strategy to alleviate cognitive decline. It was sometimes more 
difficult to keep active for patients in Cohorts 1 and 2 who were living with heart failure or 
COPD. For many of the participants with COPD, pulmonary rehabilitation classes were cited 
as an important social connection.  
Along with receiving support themselves, many Phase 2 participants were an important 
source of help and support to other people in their social networks. This included driving 
neighbours to medical appointments and helping with shopping and DIY tasks. In one 
example, a husband and wife ran a social club for older adults, whilst in other examples, 
participants were the chair or treasurer of local groups.  
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Test Bed technologies differed across the patient cohorts, but all were discreet and in general 
did not have an adverse effect on the home environment. Cohort 1 and 4 patients using the 
Motiva system received the most equipment, which included a handheld tablet with a 
combination of pulse-oximeter, blood pressure meter, weighing scales, and thermometer. 
This equipment was generally kept in a convenient place for use each morning when 
participants would take and submit their readings. The only problem regarding the technology 
and layout of the home that arose in the Test Bed related to the handheld tablets. To address 
connection problems, patients were advised to keep their tablets permanently on charge. 
Patients interpreted this to mean the tablet could not be unplugged even when using. This 
then restricted patients’ use of the tablet depending on socket location and availability in the 
home and the length of cable. It also led to concerns about running costs for some 
participants. This is illustrated in the following diagram of a patient’s home (Figure 3.12):  
Figure 3.12. Diagram of layout of participant home highlighting problem with sockets  
 
Patient Activation and Quality of Life 
In this section, patient activation and quality of life are discussed. We discuss each cohort 
separately to draw out the different findings within each of the cohorts.  
Cohort 1 
Overall, patients in Cohort 1 gained the largest increase in confidence, with 86% (n=19) of 
participants in this cohort feeling more confident about their health as a result of taking part 
in the Test Bed programme. The reason for this was largely attributable to an increase in 
reassurance experienced by patient and carer participation in the Test Bed. Of the 22 people 
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in Cohort 1 who took part in both observational interviews, 18 indicated an increase in 
reassurance about their health. The monitoring of patient data by healthcare staff in Cohort 
1 was an important factor in this feeling of reassurance.  
It’s like having a doctor check you over every morning.  
(A1-03 Interview 1)  
 
Well, it’s reassuring, isn’t it? You know that somebody’s watching it and if they 
spot something that you… if they saw something that wasn’t right, they’d ring you 
[…] especially when you’ve had… all my family – every one of ’em – have all had 
high blood pressure.  
(B1-05 Interview 1) 
However, while patients and family carers valued the monitoring of their data by healthcare 
staff, they themselves were also personally active in this monitoring. One participant 
explained how, living alone and suffering from heart failure, she felt panicky one night when 
she was in bed and so used the Test Bed technology to check her sats and reassure herself 
through self-monitoring (A1-03 Interview 2). In many cases, family carers were also using the 
equipment to monitor their loved ones’ health: 
Family carer: I watch him get weighed and […] I am always over his shoulder 
looking when he’s using it. 
(A1-05 Interview 1)  
However, whilst the majority of patients felt a benefit from the technology, this was not 
always the case. Three patients in Cohort 1 - two from Better Care Together and one from 
Fylde Coast - said that they sometimes felt less reassured about their health as result of the 
Test Bed programme. In these cases, knowledge of their own health, for example seeing data 
about their pulse or blood pressure, appeared to exacerbate the health anxieties being 
experienced by these individuals. 
Furthermore, a small number of people in Cohort 1 (n=3) did not report any benefits of taking 
part in the Test Bed. However, it is worth pointing out, that in each of these three cases, the 
patient’s own primary health concern was not the condition being addressed by the Test Bed 
technology. One patient, for example, explained that his main health concern was the chronic 
pain he experienced, which he felt was not well managed, resulting in a lack of trust in 
healthcare staff and services. The Test Bed technology he was given, however, was focused 
on his COPD - which for him was far less of a problem:  
Participant B1-08:  I went to see about going on morphine because [my GP] 
had told me they’d put… if this Gabapentin didn’t work, 
we’ll try morphine, because I go to the pain clinic [in town] 
and that’s a waste of time as well. 
 
Participant B1-07:  You have injections in your spine, don’t you? 
 
Participant B1-08:  I have injections… yeah. And so that was the last resort, 
he’ll put me on morphine… fine. Then when I went to the 
doctor’s, it wasn’t him, it was another doctor and he said 
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to me, ‘I don’t believe in morphine so I’m not giving it you.’ 
And I just said to him, ‘Well, you’re a waste of time talking 
to, aren’t you? Come on, let’s go.’ 
(B1-07 and B1-08 Interview 1) 
A large number of patients in Cohort 1 increased their knowledge and skills about their health 
condition as a result of taking part in the Test Bed programme (68%; n=15). Of the 22 Cohort 
1 patients who took part in the initial and follow up interviews, 64% had COPD (n=14); 32% 
had heart failure (n=7); and 4% had arthritis (n=1). The learning referred to by Cohort 1 
participants as a result of participation in the Test Bed related to the following: 
 Diet and exercise; 
 New tips – such as the importance of drinking plenty of fluids; 
 Learning to better manage their own LTC; 
 Learning for carers – how to support someone with an LTC; 
 Heart failure patients – learning to pace themselves and the activities they do;  
 COPD patients – learning how to cope with COPD, and strategies to manage it  
Participation in the Test Bed programme had a positive impact on daily activities for some 
participants, with a number of patients in Cohort 1 experiencing a positive effect on their daily 
activities as a result of participation in the Test Bed. For these patients, the increase in daily 
activities had a direct impact on their quality of life, as well as the quality of life of their family 
members.  
‘I mean I went into town on… yesterday we went into town. Now it was very cold, 
wind was blowing, and you felt cold and I had to sit down quite a few times, but I 
learnt that off one of the videos that was on the machine. If you feel out of breath, 
sit down. I mean I did get to the stage – I’ll be honest with you – that I didn’t feel 
like going into town, I didn’t feel like going out of the house, but I said to my wife, 
‘Right, we’re going in town, we’re going to get some stuff today.’  
(B1-02 Interview 1)  
While changes in daily activities can be an indicator of changes in quality of life, this may not 
be an appropriate indicator for patients in Cohort 1, many of whom were very unwell and 
unable to leave their home. As a result, the Test Bed programme did not influence daily 
activities for many in this cohort. This is explained in the following interview with a patient 
living with COPD, diabetes and MS, and who is bed-bound:  
Family carer:  It didn’t [affect daily activities] in Mum’s case, it didn’t, because – 
I’m not being horrible – you don’t do activities very much, do you? 
 
Patient:   No. 
 
Family carer:  You used to like get up and do baking etc., like do a bit and then 
come back, have a rest and go back. But your back’s got worse 
and worse… 
 
Patient:   Yeah, it has. 
 100 
 
(A1-01 Interview 2) 
Cohort 2 
A significant number of patients in Cohort 2 (83%; n=15) experienced an increase in 
confidence in relation to their health as a result of taking part in the Test Bed programme. 
The reason for the increase in confidence in this cohort however, differed to that of Cohort 
1. Whilst increased confidence in Cohort 1 was closely linked to reassurance and monitoring; 
in Cohort 2, it was linked to an increase in knowledge and skills, resulting in people feeling 
better able to self-manage their health. Phase 2 data indicated that the patients who learned 
the most were those in Cohort 2, with 94% (n=19) indicating in Interview 2 that they had 
increased their knowledge and skills about their health condition as a result of taking part in 
the Test Bed programme.  
The majority of Phase 2 participants in Cohort 2 had COPD. For a significant number of people 
in this patient group, participation in the Test Bed programme helped them to learn about 
COPD and to understand how to better manage it. It is this increase in knowledge and skills 
which appears to be responsible for increased levels of confidence relating to health in Cohort 
2 patients.  
The increased knowledge and skills relating to COPD included the following:  
 Understanding when and how to correctly use inhalers and other medication;  
 Learning techniques and tips related to respiration wellbeing;  
 Knowing how to identify the early signs of an exacerbation and avoid a crisis situation;  
 Increased awareness of the patient’s own general health and wellbeing;  
 Understanding the importance of looking after oneself;  
 Knowing what questions to ask healthcare professionals at routine check-ups;  
 Becoming more motivated – for example to move more often and walk more steps;  
 Making better use of learning in pulmonary rehabilitation classes (over 40% of Cohort 
2 participants attended, with others being referred as a result of the Test Bed).  
 
Participation in the Test Bed programme had a positive influence on daily activities for some 
participants, with the biggest impact taking place in Cohort 2. For this group of patients, 50% 
(n=9) experienced a positive effect on their daily activities as a result of participation in the 
Test Bed. For the following heart failure participant, the Test Bed programme helped him to 
lose weight which had a positive impact on his quality of life and helped to alleviate his 
depression symptoms:  
 
Patient:  If [my GP] hadn’t shown me that graph [of my Test Bed 
technology data], I’d have still been bloody fighting with myself 
what to do. 
 
Interviewer:  And you say ‘fighting with yourself’… did it feel like a fight… 
 
Patient:   Yes. 
 




Patient:   Yes. It’s always a fight. I think that’s two-thirds of my depression… 
fighting with myself […] I’m not the way I want to be, if you 
understand what I mean […] I’ve always been big and I know I 
can’t do anything about that, but… er, more-so since I had the 
heart operation than owt else. They’ve given me a second chance. 
And they spent all that money on us, it’s no good me being a fool 
and eating and eating and eating and sitting on my backside, like 
they say, not doing anything. They’ve worked hard to save me so 
I’ve got to put a bit in myself […]  
 
Interviewer:  Have you noticed a difference with how you feel [since losing 
weight]? 
 
Patient:   Mm… mm. 
 
Interviewer:  In what way? 
 
Patient:   Well, I’m not getting out of breath as much. I still get out of 
breath…and I will do, because that’s asthma, but er… I’m feeling 
more… get up and go […] It’ll make [activities] easier… yeah. 
(B2-02 Interview 2)  
Many participants in Cohorts 1 and 2 indicated that they would continue to self-monitor their 
health beyond the end of the Test Bed, and some actively purchased their own equipment 
after the intervention finished. In one example (Figure 3.13), a Cohort 1 patient explained that 
she would be ‘carrying on [the Test Bed] in my own little way’ (A1-03 Interview 2) and showed 
the following record she had begun to keep:  
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Figure 3.13. Example of patient monitoring their readings beyond the end of the Test Bed (A1-
03 Interview 2) 
 
Cohort 3 
In Cohort 3, there was very little evidence of increased confidence relating to health, with 
only one participant citing any increase in confidence. It is worth noting however, that Cohort 
3 participants differed significantly from the other three cohorts in that they were younger, 
many were still in paid employment and did not consider themselves to have a long-term 
condition. As a consequence, this lack of evidence of any increase in confidence in comparison 
to the other cohorts was because most in this patient group did not lack in health-related 
confidence prior to becoming involved with the Test Bed programme.   
Patients in Cohort 3 had a range of diagnosed illnesses, with some having more than one co-
morbidity, including: anxiety, arthritis, asthma, back/neck/shoulder injury, chronic pain, 
COPD, depression, fibromyalgia, heart disease, hypertension, lymphedema, and 
stomach/bowel conditions. In Cohort 3, only ten patients took part in Phase 2 of the 
evaluation and it must therefore be acknowledged that these numbers are relatively small. 
Nevertheless, half of those patients interviewed (n=5) indicated that they had increased their 
health-related knowledge and skills as a result of taking part in the Test Bed. The learning 
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referred to by some Cohort 3 patients as a result of participation in the Test Bed related to 
the following: 
 Diet and exercise; 
 Identifying patterns in their own health data – for example, feeling better when 
drinking more fluids; 
 Identifying patterns in their own health data and seeking medical advice / attention;  
 Learning and gathering evidence to support a correct diagnosis by a healthcare 
professional.  
There was little evidence of any impact on daily activities for patients in Cohort 3, with only 
one person stating there was any effect. As previously noted, this cohort had the lowest risk 
of hospital admission and many did not consider themselves to be unwell. Patients in Cohort 
3 were often active, employed with fairly large social networks. These factors help to explain 
why increases in daily activities were not evident for this cohort; many participants explained 
that they were simply busy enough already: 
I haven’t got enough time in the day to do what I do, because I do sew, I do knit. I 
do other things, craft things with the [grand]kids, you know… all sorts. 
(B3-01 Interview 1)  
For others in Cohort 3, however, the Test Bed enabled them to improve their health, which 
had a positive impact on their quality of life. For example, for one Cohort 3 participant, the 
Test Bed programme led to a correct diagnosis of sleep apnoea, which then had a significant 
impact on his and his partner’s quality of life.  
Patient:   With everything what’s happened now, and the control of my 
sleeping, and knowing what’s going on with me, I’m getting up 
now, I’m not tired […] Everything we were doing, the app when I 
was filling it out, you could see what was going on and it was 
bringing a regular pattern in […]  
 
Interviewer:  Which eventually led to your correct diagnosis, didn’t it? 
 
Patient:   Yeah. 
 
Family carer:  He’s now the Treasurer of our Club […]  
 
Interviewer:  Right, so you’ve kind of got a new role? […]  
 
Family carer:  It’s like given him a lease of life where he feels he’s important? 
[…] He’s dead proud to do it, you know. 
(A3-01 Interview 2)  
It was particularly important for Cohort 3 engagement that patients saw the relevance of the 
technology to themselves and their own health. Many commented that they this was not the 
case and that they did not see the relevance of the technology to their own needs or were 
unsure why they had been given it to use. Our findings suggest that patients in Cohort 3 may 
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have benefitted more from the Test Bed had they been involved in decision-making processes 
regarding their healthcare and choice of technologies. 
Cohort 4 
Of the 13 patients who completed the initial and follow up interviews in Cohort 4, only three 
referred to an increase in health-related confidence as a result of participation in the Test Bed 
programme. For one participant, the Test Bed became part of his daily routine which he 
remembered to do without any prompting and was something he was able to do by himself 
without support (C4-11 Interview 2). In the other two cases, the increase in confidence related 
to the family carer, rather than the patient, and was a direct result of knowing the person 
with dementia was being monitored and that someone was looking after them. One carer 
explained that she found it frightening not knowing how her husband’s dementia would 
progress and what the future may hold, and that the Test Bed monitoring went some way 
toward alleviating this anxiety (C4-17 Interview 1). 
All participants in Cohort 4 had received a mild-to-moderate diagnosis of dementia. Of the 13 
participants who completed the initial and follow up interviews, data showed that just under 
a third considered the Test Bed to have increased their knowledge and skills regarding their 
health condition. Importantly, however, in all four of these cases it was again the family carer 
who had increased their knowledge and skills, rather than the patient. One family carer 
explained that her husband was too confused to benefit from the Test Bed technology and 
that it was she who was learning about his condition from participation in the Test Bed (C4-
05 Interview 2). Another family carer explained that the Test Bed helped her to remember 
her husband’s dementia medication, as well as learn about his condition (C4-08 Interview 2), 
whilst another said that, as a result of the Test Bed, ‘I learned it was normal to feel the way I 
do’ (C4-17 Interview 2). 
There was little evidence of any impact on daily activities for patients in Cohort 4, with only 
one person stating there was any effect. However, findings from Cohort 4 do illustrate the 
importance of ensuring family carers are closely involved in decision-making processes 
regarding the implementation of combinatorial health technologies to support patients with 
dementia, as well as other long-term conditions. 
Carers 
There were two ways in which family carers participated in Phase 2 of the LCIA Test Bed. In 
addition to the 73 patients who participated in Phase 2 of the evaluation, 32 family carers 
indirectly took part by being present for interviews and contributing to discussions. Four of 
these carers made up an additional small cohort of family carers who took part in initial and 
follow up interviews, trialling the use of a text message technology focused on the health and 
wellbeing needs of carers. As a result, much data has been gathered in Phase 2 which relates 
directly to family carers and the impact of the Test Bed programme on them.   
The family carer cohort  
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This small cohort was made up of four family carers, all of whom were women whose partners 
had received a mild-to-moderate diagnosis of dementia and who were taking part in Cohort 
4. Three carers completed both interviews 1 and 2, whilst one woman withdrew from the Test 
Bed after interview 1 following her husband’s death.  
Caring responsibilities  
All four women were providing increasing levels of care for their partners, including 
showering, dressing, and managing medication intake. In addition, carers were responsible 
for managing the household finances and affairs, along with medical appointments, cooking, 
cleaning and other household tasks. By interview 2, these responsibilities had increased. Two 
family carers also provided regular care for grandchildren.  
Family carer:  I don’t mind the paperwork but I like to... if I get it, I like to do it: I 
never want to leave it. I like to, you know, do it there and then, 
and if it needs posting, get it posted. But I don’t mind it […] There 
is a lot of paperwork. 
 
Interviewer:  Yeah, and it can easily get... 
 
Family carer:  Panic. 
 
Patient:   You do mine, don’t you, love? 
 
Family carer:  Well... 
 
Patient:   I can’t do it. 
(Carer-04 Interview 2)  
All four carers were living with their own health conditions. Carer-01 suffered from 
depression, anxiety and high blood pressure, and Carer-05 has chronic renal failure for which 
she was awaiting dialysis and possibly a transplant. Carers 02 and 04 were each awaiting an 
operation, but both were delaying it because of their caring responsibilities and concerns 
about who would care for both their partner and themselves during this time.  
I’ve just been for a scan and I’ve two options: one is an injection which would be 
temporary, he said it wouldn’t solve the problem; and other than that it would be 
an operation. But I really don’t know how I would cope with that, to be truthful 
[…] I haven’t got my head round it yet because, you know, apart from me looking 
after [my husband], I think to myself who’s going to look after me? Because I 
wouldn’t be able to drive or I’ll probably be struggling to walk for a little while or 
on crutches, so I haven’t kind of got my head round that. But I feel I need to do 
something rather than be in pain 24/7. It’s just... just gets me down. 
(Carer-04 Interview 2)  
There was an acknowledgement from each of the four carers that they needed to attend to 
their own needs and begin to care more for themselves and their own wellbeing. However, 
this was difficult for them in the context of their increasing caring responsibilities, which 
limited their ability to focus on themselves.  
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[My husband] struggles with time. He’ll look at the… like one of the daughters 
bought him that clock and he’ll look at that and then he’ll forget what time it was 
so, when I come in, it’s ‘Where’ve you been? Where’ve you been?’ you know, and 
‘You don’t have to be this long.’ And so I tend not to go out so much. But the kids 
keep saying, ‘You’ve got to go out because you’ve got to build up yourself to look 
after Dad.’ […] I feel better if someone’s here. 
(Carer-01 Interview 1)  
 
Family carers also talked about their coping strategies:  
You know when you are having… you talked about bad days […] I always think if 
you, you know, if you can wash your hair put something fresh on and just… a bit 
of lipstick and your best coat, you know, and then you just project this. And if you 
can feel that you can project a look or, you know, a way of being, it’s almost like 
role play, isn’t it? […] You believe it and suddenly, before you know it, you know, 
you want to go out, you know, take the first few steps out of the door […] I’m okay 
as long as people don’t ask me how I am because it’s sort of… it’s a bit like opening 
the floodgates. 
 (Carer-02 Interview 1)  
 
More so than for any other participant cohort, there was a sense of transition and change for 
family carers and patients in Cohort 4. This included changes in the roles and responsibilities 
of those within a household, as well as significant changes in relationships brought about as 
the result of changes in health. Carer-05 talked about the uncertainty of the near future for 
her and her husband because of both of their health conditions. Having holidayed in the same 
location in Spain each winter for the past 14 years, they brought everything back with them 
this time explaining, ‘this might be our last winter in Spain’. Other carers talked about similar 
changes taking place in their lives as a result of their partners’ health conditions.  
We sit down after tea, everything’s washed up, done and finished, telly goes on 
and he falls fast asleep [….] And he can sleep from seven till ten […] I think... you 
know, like I’m here on my own […] you’ve nobody to converse with or I say... I’m 
watching and then I say something and I turn round and he’s out of it, so... I think: 
Right, okay, talk to yourself.  
(Carer-04 Interview 2)  
 
I’ve decided to just break-up my teaching library which is […] a wall of massive 
books […] But my God it’s a lot of taking down, you know, checking… getting rid of 
my name from all of the books and so on, and then deciding, you know, what we’re 
going to do […] And it’s all about clearing… I just feel that I need to be… you know, 
I don’t know whether it’s a control thing, but that I need to keep everything as 
clear as I can. And you know those years when you’re putting your house together 
and, ‘That would be nice…’ and ‘I’ve just got a place for that little vase,’ we’re in 
exactly the opposite [situation]. 




Benefits of the Test Bed for the family carer cohort  
Although only a small cohort of family carers, the data provides an insight into the benefits of 
digital technologies for family carers’ health and wellbeing.  
Overall, carers felt that the text messages they received had a positive effect on them. Carer-
01, for example, explained that ‘the messages give me a boost’ and ‘put a smile on my face’. 
Similarly, Carer-05 referred to the text messages as ‘cheering you up messages’ and explained 
that she keeps them on her phone for a while and regularly reads them back to herself.  
The technology also made carers feel better supported. Carer-04 commented that the text 
messages she received made her feel less alone and reminded her ‘there’s thousands like me’. 
Similarly, Carer-05 explained ‘you feel like there’s somebody out there looking out for you’.  
[Flo tells you] don’t think that you’re alone and, you know, there’s always 
somebody to help [...] [I agreed to take part in the Test Bed] because I felt that I 
wasn’t on my own. That, if I wanted, you know, if I wanted to text her back or... at 
least I’d somebody to contact that maybe understood or... because I sometimes, 
some days I find it hard... really hard. 
(Carer-04 Interview 1)  
 
Suggestions for improvements to the Test Bed programme 
The previous quote illustrates a point raised by all four family carers: that they would have 
liked the Test Bed programme to have facilitated two-way communication rather than only 
receiving messages. Carer-05, for example, explained that she wanted to be able to respond 
to Flo because ‘when you receive a text, you automatically think ‘I must reply to that’, but Flo 
is a one-way conversation’. Similarly, Carer-02 felt that a text message isn’t enough and that 
the interaction was missing. Carers explained how they did try to reply to the Flo text 
messages:  
That’s what I found hard because I did a message back about [my husband] being 
in hospital […] and I realised then… well, I showed my daughter and she said, 
‘You’re not supposed to text them back.’ But I think it would be… better if you 
could… answer them […] Because if she [Flo] sends you a text saying, you know, 
like about smiling and that, and if you feel really down, instead of worrying the 
kids about it, if you could just text back saying, ‘Well, I don’t feel great today. 
(Carer-01 Interview 1)  
 
I quite like Flo except you can’t reply to her. That’s the main thing because, at first, 
I sent a text back and then I got another message, ‘Do not understand,’ and I 
thought: How can she not understand what I’m saying? Then I thought: Oh, I’m 
talking to a machine, aren’t I? 
(Carer-05 Interview 2) 
 
Family carers across all patient cohorts  
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As mentioned above, in addition to the small family carer cohort, a total of 32 family members 
indirectly took part in Phase 2 of the evaluation by being present for interviews and 
contributing to discussions. Within this data there is evidence of much carer burden across all 
patient cohorts.   
Patient:   You see [my wife] had to go away because [she] was suffering 
from anxiety and depression. 
 
Family carer:  Depression, and I needed a break. 
 
Patient:   And the nurses said that she needed to go away […]  
 
Family carer:  I went with my friend and her sister and my sister-in-law on a river 
cruise […]  
 
Patient:   [To] give her more confidence about going, I booked myself into 
a care home for a week.  
(A1-05 Interview 2)  
 
As discussed, there was also a sense of significant transition and change for family carers and 
patients related to Cohort 4, including changes in the roles, responsibilities and relationships 
within a household. The family carer is key to negotiating these ongoing changes and there 
were suggestions in the data that technologies should also address the needs of the family 
carer.  
The Test Bed technology was often the responsibility of the family carer, with many patients 
saying they could not have taken part in the programme without the support of a family 
member of carer. Referring back to Figure 3.5 of the total 18 participants in Cohort 4, 83% 
(n=15) indicated in interview 1 that they were confident when using digital technologies at 
the outset of the Test Bed programme. However, it is worth noting that this figure includes 
family carers; when the family carer’s confidence with technologies is removed from these 
figures, only 56% (n=10) of participants claimed that they themselves were confident with 
technologies in general. As a result of cognitive decline in participants in this cohort, it was 
often the case that patients said they were only able to participate in the Test Bed because of 
the support of their family carer.  
Some family carers commented that the technology was more for them than their partner, 
with some commenting that they would have liked for the Test Bed technologies to have also 
addressed their own needs.  
Family carer:  There was quite a lot that I didn’t know that was [in the 
technology] you know, I thought: Oh well, you know... things that 
I didn’t realise were part of the problem...part of the illness.  
 




Family carer:  Yes. Yes, I would say so... yes […] I think you’d get a truer picture 
if you aimed it at the person who was looking after the sufferer, 
i.e. the carer. I think because then you can put things down that 
maybe couldn’t be said or wouldn’t be said. 
(C4-20 Interview 2)  
Staff 
The following key findings relating to members of staff involved in the Test Bed are presented 
here: 
 Benefits to members of staff 
 Impact on everyday working practices  
 Benefits to patients and family carers  
 Impact on service utilisation 
 Healthcare teams and the technologies  
 
Benefits to members of staff  
The Test Bed enabled members of staff to have more contact and connections with their 
patients, with many welcoming the added diversity to their role as a result of the programme.  
I’ve enjoyed the contact with the patients and the feeling that you’re actually 
helping them, aren’t you, to manage their illness? 
(Staff member, BCT)  
Members of staff experienced increased confidence and reassurance in their daily roles as a 
result of the Test Bed. The monitoring of patient data and addressing of alerts increased levels 
of job satisfaction for many as a result of knowing that patients were stable and future issues 
were being prevented.   
I find it quite satisfying that we’re picking people up before they... before they’re 
really unwell. I’ve found that... and blood pressures... a lot of the people with high 
blood pressure, COPD... now COPD patients go for the COPD annual review and 
often the blood pressure gets overlooked. So they’re not having their blood 
pressure monitored and we’ve picked up loads, haven’t we, with hypertension? 
(Advanced Nurse Practitioner, BCT staff focus group)  
It’s not just patient reassurance, it’s ours as well, because we do have very poorly 
patients and it has given us the confidence to know what we’re doing is right, and 
if something isn’t working, like medication, we can change it’.  
(Staff member, FCV) 
Interviewer: Is it nice having that variety, having a bit of a different dimension to 
your day? 
Staff member: Oh, definitely. We do the urgent surgery day in, day out, so that’s 
 110 
 
chest infections, chest pain, you know, musculo-skeletal. [The Test Bed] is more 
chronically unwell people that we don’t deal with. We’ve both done that sort of 
thing in the past […] but we don’t get it now unless they’re acutely unwell. So it’s 
actually nice to talk to people about how they’re managing on a day to day basis. 
(Staff member, BCT)  
As a direct result of their time spent on the tasks associated with the Test Bed, staff cited 
examples of their healthcare colleagues being able to better manage and prioritise their own 
workloads.  
It has cut back on our home visits as well because we can see what we want to 
without going out to each person. We used to go out probably every two weeks 
[…]. Now, if people are quite stable, we’ve cut that back to when they want us. We 
just keep an eye on them on Motiva […] which can save a 25-minute drive each 
way.  
(Staff member, FCV)  
Impact on everyday working practices 
For the majority of staff involved in the Test Bed, their input came on top of their usual 
workload. Staff thus cited time as a key challenge for successful delivery of the Test Bed with 
the Test Bed resulting in additional workload for those operating on the front line. Depending 
on the number of patients using the technologies within a service, and the types of 
technologies being used, daily tasks associated with the Test Bed were often time-consuming 
- including the following:  
 monitoring patient data and looking for trends; 
 addressing alerts when patient data is outside of normal parameters; 
 ongoing revision of individual patient settings, so system parameters reflect what is 
normal for the individual;  
 providing support and reassurance to patients and family carers about their data and 
using the technologies;  
 checking patient data against patient records (on a different system); and 
 following up missing patient data where expected readings are not received. 
 
As the above list reveals, staff were often required to make numerous telephone calls each 
day to ensure the appropriate and safe monitoring of patients taking part in the Test Bed. 
Members of staff stressed that protected time is needed for delivering a programme such as 
this, particularly in the implementation stage, and especially for patients with dementia.  
Patients seemed to be put on a ‘one size fits all’ whereas everybody’s obviously 
different so you need to spend time tweaking [the settings for each individual 
patient].  
(Staff member, FCV) 
[Cohort 4] is such a small cohort of people […] it took such a lot of work to get such 
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a few people using the Test Bed technology.  
(Staff member, Cohort 4)  
As a result of demands on staff time, speed of working is also an important factor in the 
adoption of new technologies. The Test Bed technologies proved to be incompatible with 
patient medical records, resulting in staff working across incompatible patient data systems. 
To add to this complexity, in one area where different GP practices merged during the period 
in which the Test Bed was operating, the practices themselves were also operating on 
different systems for some considerable time: 
And so to log in takes me another 10 minutes, you know, into another practice to 
send them a message. And that shows to me how much more difficult it would be 
if you don’t integrate [the systems] and don’t give access to the clinical record for 
the staff doing it […] We need access, full access to the record […]. As we formed, 
they merged all our records for the five practices so you did have access to all, 
whereas when we started [the Test Bed] that didn’t exist. And we weren’t all the 
same... we were on different computers for a year. 
(Staff member, BCT)  
Benefits to patients and family carers 
While some people required higher levels of support, staff felt that the vast majority of 
patients and carers across the two vanguard sites got on well overall with the Test Bed 
technologies. Members of staff cited many examples of patients and family carers developing 
the knowledge, skills and confidence to better manage their health conditions.  
The technology was a visual reminder and patients could see what they were doing 
right. [One patient] was bad at taking her inhalers and things like that but when 
she took them correctly and then did her sats she could see the benefits and how 
much better she had got, purely from the graphs […] [Patients with COPD] could 
see the signs and feel the signs and knew when to start their rescue medication.  
(Staff member, FCV) 
The concept is good and people have felt empowered by it. It’s encouraged 
interaction between patients and their family carers. I’ve heard family carers say, 
‘I didn’t realise you felt that way’ when a patient has answered a survey question 
such as ‘Do you miss having a close friend?’ 
(Staff member, Cohort 4) 
Impact on service utilisation 
Some patients and family carers required a lot of reassurance and support in relation to their 
use of the technologies and their data. In these cases, service utilisation increased during the 
Test Bed programme. The Test Bed programme has also resulted in members of staff 
diagnosing and treating patients in relation to previously unknown conditions, with such 
instances increasing service and medication utilisation.  
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We’ve actually picked up a lot of [patients with] hypertension that we weren’t 
aware of and messaged GPs, inputted all the data into their records, increased 
their medication or started medication, arranged blood tests, and got the blood 
pressure under control. 
(Staff member, BCT)  
There are many examples within the staff data of people engaging with, and receiving, better 
healthcare as a result of Test Bed participation. These short-term increases in service 
utilisation were referred to by members of staff as a positive outcome of the Test Bed because 
people were receiving better and more appropriate care. As a result of improved healthcare, 
many staff believe the Test Bed programme would result in a reduction of emergency care 
and hospital admissions in the long term.  
I believe the Test Bed has avoided hospital admissions because [patients with 
COPD] can see the patterns for themselves and I can see they have acted quicker 
when they have got a chest infection, whereas previously they would have waited 
and waited and ended up in hospital.  
(Staff member, FCV) 
Staff member 1: Well, for some patients we may have reduced their risk of stroke 
quite massively, just by picking up on something […]  
Staff member 2: It would look as a negative if you were monitoring on cost, yet 
actually the cost of a stroke is a lot more than the cost of blood pressure drugs […] 
when I’m in meetings I’ve said, ‘You wouldn’t believe what we’ve picked up’, 
because I see it. These are people that had life-threatening levels and had no idea 
because that wasn’t being monitored. 
(Staff members, BCT)  
It is worth noting that due to the relatively short time-span of the Test Bed, the health 
economic data was only able to pick up on increases in service utilisation costs arising from 
identifying previously unknown conditions. It is unable to assess any potential longer-term 
reductions in more costly in-patient care arising from early identification of these conditions 
that have facilitated the delivery of lower cost treatment within community environments. 
Nevertheless, it is worth noting that the mean cost of stroke per patient is £46,049 – and 
these costs increase with older age where there is increased likelihood of stroke severity and 
intracerebral haemorrhage (Xu et al. 2018). The potential for cost reduction in in-patient 
admission through early identification of health issues that may lead to stroke or other health 
conditions with a higher prevalence in later life is substantial. 
Healthcare teams and the technologies  
Staff across both vanguards stated the importance of being part of a willing and engaged team 
when embarking on a programme such as the Test Bed. Good communication and working 
relationships are key. Where members of staff had ownership of the programme and were 
involved in decision-making, they believed in and supported the Test Bed. Conversely, when 
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staff members were not involved in decision-making, or where ownership was not 
encouraged, there was a negative effect on their engagement with, or experience of, the Test 
Bed.  
[The Test Bed] was better with us doing it because we knew our patients […]. It 
needs to be controlled by us […]. The Test Bed became more complicated than it 
should have been because we weren’t involved in the decision making.  
(Staff member, FCV)  
 
The team approach [has been important]. If it’s too anonymous, people don’t 
take... they don’t follow it through. In a small team, people are bothered about 
what their colleagues think, as ‘I haven’t finished it off, I haven’t done it right,’ in 
my experience. In a large team, it can be lost... like ‘occlusion of anonymity’ they 
call it, no-one’s responsible for it, then I’m not gonna... it doesn’t matter today. 
(Staff member, BCT) 
A number of issues arose throughout the Test Bed as a result of clinical teams not being 
involved in decisions and programme design from an early stage. This included members of 
staff being expected to refer their patients to the Test Bed while not knowing what the 
technology entailed, along with technology content contradicting the advice given to patients 
by healthcare teams.  
I think [the lack of clinical input at the start of the Test Bed] irritated me, to be 
honest. I felt dropped in and then I’d no actual say at the start, so therefore I had 
to follow something on for 18 months. I’m not sure I would have made huge 
changes, but the fact is I didn’t have any real influence and, now we’ve got a lot 
of knowledge, I’d like to think [we would do it differently in future]. You’d want a 
couple of focus groups on it, or whatever, saying, ‘Will this work or not? What do 
you think?’ people on the ground. 
(Staff member, BCT)  
‘Staff who are visiting patients, we know what our patients’ needs are. There 
wasn’t enough input at the start from clinicians and a chance to say what we need 
from [the Test Bed technologies].  
(Staff member, FCV) 
I think that was the most obvious thing [regarding the content of the technology] 
was a lack of understanding, like I say, of the variables and the sensitivity of 
dementia. It’s not a... it’s not a standard. 
(Staff member, Cohort 4)  
The technology looked fantastic, great in the lab, but it didn’t seem to have any 
clinical input, particularly in relation to knowledge about dementia […]. It seemed 
 114 
 
to be a done deal: ‘this is what we’ll be doing and these are the questions we’re 
doing to ask’ […]. You need to run these things by people who have been through 
it, but we were told there was no time to run it by an expert by experience group. 
I suspect the technology wasn’t even piloted.  
(Staff member, Cohort 4)  
When we were shown the videos early on, we were horrified. It felt like someone 
just took them off YouTube. When you are in a situation, as a clinician and patient, 
you may say something as you can judge person-to-person. You can tell whether 
someone is ready for that information, you can gauge their response. But 
technology can’t make that decision.  
(Staff member, Cohort 4)  
It was considered important by staff to have continuity regarding the people working on the 
Test Bed to enable staff to build up knowledge about patients and ‘get to know the patterns 
and readings’ (Staff member, BCT). Members of staff also stressed the importance of having 
a team made up of experienced staff who are confident in their roles:  
Interviewer: You don’t want to be calling patients unnecessarily?  
Staff member 1: No, no. 
Staff member 2: Which I believe more junior staff would, you know, because I’ve 
seen [it happen] and it’s obvious, isn’t it, if you’ve not got loads of years of 
experience and yet are working at a high level, you are going to resort to making 
sure, and that making sure actually worries [patients] even more because these 
are very anxious people we’re dealing with, aren’t they? 
(Staff members, BCT) 
[A less experienced member of staff took over and] was ringing everybody every 
minute of the day because he didn’t know the patients […]. It’s knowing what’s 
normal for that patient’.  
(Staff member, FCV) 
Staff believed the technologies to be most successful where the technologies had the 
flexibility for healthcare teams, patients and carers to tailor the content to a person’s 
individual needs.  
[There are some patients] who are only just about managing to keep on board 
with [the Test Bed]. They do it three times a week and if you pushed them anymore 
they would stick it because it’s too [demanding}. Some personal knowledge 
definitely helped once you knew them for a while. And I think if you were rigid 
about it, more people would leave the service.  




As detailed in the ‘Methods’ section of this report, the logic model was developed by drawing 
on a range of data sources including interviews, focus groups, diaries and action learning 
meetings with key stakeholders. Following analysis of these data and several iterations, this 
draft Logic Model was presented and finalised through a process of ‘backward mapping’ 
during two deliberative panels. The final version of the logic model is presented below in 
Figure 5.14, along with an accompanying process map (Figure 3.14) and ‘crib sheet’ (see 
Figure 5.15).   
Whilst the process and Logic Model developed from the Test Bed follows a similar process 
across both Vanguards, it is worth noting that within the LCIA Test Bed, two different models 
of care were in operation. These are detailed below:     
Better Care Together  
The North Lancashire Vanguard, Better Care Together, saw healthcare professionals working 
together in partnership to help people manage their own health conditions (Bay Health and 
Care Partners, 2017). This model focused on integrated primary and acute care settings, 
joining up GP, hospital, community and mental health services (NHS England, 2017a).  
 
The Better Care Together approach to the Test Bed was to utilise a small GP-led team, acting 
as a hub for the Test Bed, to recruit to Cohorts 1, 2 and 3. Over an 18-month period, which 
coincided with the LCIA Test Bed programme, six GP practices in the Better Care Together 
Vanguard merged into one large practice. Three of the six practices were considered as failing, 
while the other three had strong reputations for patient care, quality and teaching, but were 
struggling with workload, national targets and to recruit new GPs.  
As a result of the merger, all urgent phone calls were received at one site staffed by a GP, two 
nurse practitioners and five receptionists. If required, a patient would be seen by a GP on the 
day, while like many parts of the country a non-urgent appointment may result in a few 
weeks’ wait.  
Test Bed patients from Better Care Together who received the Motiva technology were 
monitored daily by advanced nurse practitioners and, where the system alerted due to a 
patient’s readings, a nurse phoned the patient directly. Nurses had access to urgent 
appointments each day, along with GP appointments and home visits.  
It was evident in the Phase 2 data from Better Care Together that many patients were 
unhappy with their merged GP service and had experienced difficulties in securing GP 
appointments through this new system.  
Fylde Coast Vanguard  
The Fylde Coast Vanguard50 drew on the Extensive Care model, which brought together a 
range of services in the same location to achieve a co-ordinated team of healthcare 
                                                     
50 The Fylde Coast Vanguard encompasses NHS Blackpool CCG, NHS Fylde & Wyre CCG and Blackpool Teaching 
Hospitals.   
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professionals, with patients each allocated a wellbeing support worker (NHS Blackpool CCG, 
2017). This model focused on multispecialty community providers, moving specialist care out 
of hospitals and into the community (NHS England, 2017b).   
 
The Fylde Coast Vanguard approach to the Test Bed was to utilise a number of services 
including Extensive Care (for Cohorts 1 and 2) and pulmonary rehabilitation teams (Cohort 2). 
GP surgeries were also used to recruit to Cohort 3 but faced the same barriers as Better Care 
Together with the cohort eventually being halted.  
Patients were referred into the Extensive Care service by their GP and referred back to their 
GP following discharge. The length of time spent in the service differed for each patient, 
depending on clinical need. In the Extensive Care service, clinical care co-ordinators each had 
their own caseload of patients, conducting three-month reviews and providing home visits to 
unwell patients.   
Test Bed patients from Fylde Coast Vanguard who received the Motiva technology were 
monitored daily by clinical care co-ordinators and, where the system alerted due to a patient’s 
readings, a member of staff phoned the patient directly, arranging a home visit where 
needed.  
Phase 2 data illustrate that patient experience of the Extensive Care service was incredibly 
positive, with patients often wishing to stay in the service. As part of this model of care, 
patients receive regular phone calls, home visits, and support in relation to more general 
aspects of their health and wellbeing. 
Process 
Process models as set out below were produced for the LCIA Test Bed, with different 
implementation versions created for the two different Vanguards sites involved in the 
programme. Each cohort also had its own process model; each was similar, but the 
staff/equipment/installation processes involved varied slightly. The example below relates to 
the implementation process for Cohort 2. These models emerged from training meetings 
conducted by the evaluation team with clinical partners involved in the delivering the Test 
Bed. Subsequent fine-tuning of these process models was undertaken by the Test Bed 
administrative partners as the implementation process developed.  
The process model sets out all steps undertaken in implementing and evaluating the Test Bed 
programme, however in terms of wider roll-out, where independent evaluation may not be 
required, all steps outlined in red text can be by-passed or replaced with the service’s own 
evaluation measures. The process of implementation should also consider the inputs, 
activities and outputs set out in the Logic Model alongside a Process Model adapted for the 
roll-out location and patient group together with the Crib Sheets provided. The Crib Sheets 
were developed with practitioners, drawing on the lessons learned in the process of 
implementing the LCIA Test Bed. 
An important aspect of the rapid-response design of the LCIA Test Bed evaluation was the 
action learning meetings which took place at regular intervals throughout the Test Bed. The 
action learning meetings involved staff from each of the two Vanguards, colleagues from the 
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technology companies, and the evaluation team. These meetings enabled key issues to be 
identified and addressed and agreed improvements to be made on an ongoing basis. It 
provided an opportunity for partners from across the Test Bed to come together to explore 
early learning, what was working well / not so well for patients, staff and technology providers 
and to agree and changes required before the next action learning meeting. 
The format of the meetings was as follows: 
 A presentation of recent evaluation data (drawing on patient interviews and staff 
diaries as they were undertaken / gathered); 
 Facilitated small group discussions around the issues raised by the data;  
 Large group discussion to reach consensus about the key issues and points requiring 
action; and 
 Agreement on actions to be undertaken before the next action learning meeting. 
The action learning meetings were highly successful as evidenced by the high turnout of staff 
and partners involved in the delivery of the programme. They played an important role in 
contributing to the overall success of the Test Bed programme, as well as to the evaluation. 
Fundamental to the success of these meetings was the willingness and openness of those 
attending to engage in the process and address issues as they arose. The evaluation team 
received positive feedback from all those involved in the action learning meetings, with 
people valuing the opportunity presented by these meetings to share learning as it was taking 
place.  
A number of issues were raised and discussed in the process of the action learning meetings, 
many of which were already being addressed by the Test Bed teams and technology 
companies. Some examples, along with the agreed actions, are outlined below.  
• In Motiva, a number of error messages were being received by patients and they were 
unsure what to do; crib sheets were subsequently developed as a troubleshooting 
guide for both patients and members of staff: ‘this is a message you might receive, 
and this is what to do’. Error messages within the technology were also altered to 
include a support line telephone number if patients wished to speak to someone 
about this;   
• In Flo, patients and members of staff reported that too many text messages were 
being received; the frequency of messages was subsequently revised to three 
messages each week, a change which received positive feedback from patients and 
staff;   
• In Flo, the requirement of a hashtag when replying about the colour of sputum was 
causing people problems; this was subsequently removed, making it easier for 
patients to use the technology;    
• Within the Test Bed programme, both patients and members of staff reported a 
number of cases where people coming to the end of the 6 months in the Test Bed did 
not want to leave; this was raised with the Test Bed Board and efforts were made to 

































no later than 
June 2017 
Operational Manager 
 Phone to arrange visit 
 Visit the patient 
 Gain consent and populate form 
with Test Bed Code 
 Give participant information sheet.  
 Complete first survey (paper) with 
Test Bed Code. If patient has 
consented to contact by the 
University write on survey 
 Complete Telehealth 
Questionnaire 
 Explain type of equipment that will 
be in place and how it will be 
installed. 
 Pass consent form and info leaflet  
to be scanned onto EMIS and enter 
standard text* 
 Send original consent form to LCIA 
Test Bed Project Management  
Office 
 Give paper Survey 1 to LU rep at 
weekly meetings 
 If patient opts to complete online 
survey indicate on consent form 
 Forward diary plan for patient to 
be contacted and 3 and 6 months 
to complete LU Survey 
 
Installation : 
 Register patient on Motiva protocol, 
and Flo pathway (if appropriate) 
using info from Telehealth 
questionnaire. 
 Indicate to RED ALERT Who needs 
to be there (family and/or Ops 
Manager) 
 Automatic alert sent to Red Alert 
for Motiva kit install 
 Red Alert contact patient to arrange 
install of Motiva 
 Contact PMO Office for install of 
Speakset if required  
 Set patient up with Flo 
 Offer support/reassurance to 
patient through installation. 
 PMO Office to ensure control data 
is sent to LU from CSU 
 Monitor clinical hub for alerts from 
point of installation 
 Submit weekly diary sheets to LU. 
email address. Requirement for this 
will be triggered by weekly email 
alert until end of project. 
 Retain a copy of all submitted diary 
sheets for reference 
1 Month 
Post-installation 
Qual interview by 





Qual interview by 






Bed Survey (short 
version) completed 
with patient by [Test 
Bed co-ordinator] or 




Bed Survey (short 
version) completed 
with patient by [Test 
Bed co-ordinator]or 
online by patient 
 
Action Meetings  x 4 monthly 
meetings for Test Bed Clinicians, 
innovators and LU Reps times and 
venues to be agreed 
Deliberative Panel 
Attendees – sample of all those 
involved and their managers  
 Draft findings to be presented 
 Outcomes for Logic Model       
Start 
End 
Over 55 (dob post 1961) 
Chronic Heart Failure, COPD, 
Diabetes 
High Risk of admission 





LCIA Test Bed 
programme 
Inputs Activities Outputs  Short/Mid-term goals Long-term goals Usual practice 
with the LCIA 
Test Bed 
programme 
 Staff - Recruiting new staff with 
appropriate skills and qualities  
- Transferring staff (syncing 
contracts) 
- Training new and existing staff 
- Cascade training 
- Clinical champions / peer 
support  
- Creating hybrid roles 
- Importance of flexibility within 
roles 
- Training courses 
- Rota for monitoring 
- Trigger procedures 
- Key staff to follow programme 
through (continuity of staff)  
- New hybrid roles 
- Capacity – additional 
consultation time during set up 
The right team is in place; team is versatile and ready 
to respond. Staff have the skills to complete the 
tasks involved. All tasks are covered. Clear 
communication and staff know what is going on. 
Flexibility within roles. It is clear to staff who is their 
first line of support for technology issues.  
Intervention is administered smoothly.  
Intervention does not increase workload. 
Staff able to manage changing demands of 
programme. Staff are able to successfully 
monitor and treat a greater number of 
patients with more complex needs.  
 
 Patients and carers / 
family 
- Selecting patients through GP 
records/in 
consultations/memory clinic 
based on long-term condition 
and risk of hospital admission 
- Patient conversations and 
choice  
- Inducting patients 
- Managing patient expectations 
and outcomes  
- Reassessment and review at 
regular intervals  
- Step up / step down patient 
care plan and technology used 
- Managing patient privacy 
within data flows 
- Induction procedure and 
training programme  
- Review procedure  
- Step up / step down chart 
- Data flow agreements with 
patients 
- Privacy agreements for 
different technologies 
- Selection criteria 
- Patient matched carefully to 
technology  
- External digital training 
support  
Matching patient with technology. Patient feels 
supported and not distressed otherwise more likely 
technology is unused. Flexibility built in so that 
patients can move between technologies. Support 
and contact available at an appropriate level. 
Awareness of patients’ capabilities.  
Patients are able to monitor their own 
health conditions at home.  Patient’s 
awareness of condition improves. Patient 
self-confidence, self-care and quality of life 
are improved. 
 
Figure 3.15. Final logic model 
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 Technology - Making decisions around who 
receives tech and when  
- Installation and training  
- Making technology 
comfortable for patients within 
the home 
- Making technology inclusive 
for patients  
- Supporting patients to monitor 
themselves 
- Linking all to a centralised 
system 
- Resolving technical issues (by 
phone/in person) 
- Providing general IT skills 
training (patients/carers) 
- Identifying key stages for 
support/training  
- Providing follow-up training 
(patients/carers) 
- Following patients up when 
data is incomplete 
- Ensuring technology is 
available for patients 
- Patient pathway / patient 
journey map 
- Support systems for patients 
- Technical support lines  
- Feedback loop when 
technology fails 
- Feedback system for 
participants  
- Leaflets/personalised (e.g. 
handwritten) instructions 
- General IT skills training 
course 
- Tools for tracking devices 
available/patients involved & 
communication of this data 
Patient and technology will be appropriately 
matched, and technology will be received at most 
appropriate stage within patient’s condition. 
Implementation of technology will run smoothly. 
Helping patients solve tech problems when they 
arise both supported and independently. 
Technology does not create anxiety and patients 
want to continue using it. Smooth running of 
technology is supported through a range of 
strategies, which provides flexibility within the 
programme.  
Patients can use the technology. Patients 
transmit data to their local health 
professionals and tech problems are solved 
when arise. Technology meets patients’ 
health needs. Technology stimulates 
patient’s awareness of condition and 
supports self-care. Smooth running of 
technology motivates patients to self-care.  
 
 Partnerships - Addressing complexities 
around data sharing 
- Accessing expertise on data 
sharing/data flows 
- Meeting face to face with 
partners 
- Supporting partners through 
organisational tools 
- Recognising/responding to 
needs/strengths of 
smaller/larger partners 
- Supporting tech companies to 
provide training to staff, and to 
- Contract between NHS, tech 
providers and third sector as 
appropriate  
- Data sharing agreements  
- Privacy Impact Assessment of 
tech providers 
- Data flow mapping 
- Identification of data 
controllers/data processes 
- Collaboration with IG 
specialists 
- Electronic portals/online 
meeting points 
The interests of different parties are managed 
effectively. All relevant parties are present from the 
outset. All partners are connected through a central 
portal/platform. Problems anticipated and needs of 
different organisations considered. There is greater 
knowledge around data management and how to 
prepare for this. 
Relevant authorisations are in place. Delays 
to the programme due to data flow issues 
are minimum. Effective communication 
amongst partners. Partners working 
together and responding to problems when 






patients and family members 
where appropriate  
- Newsletters 
 Equipment/Materials - Storing devices and equipment  
- Transporting devices and 
equipment 
- Leasing equipment (including 
cleaning and decontamination)  
- Choosing devices  




- Equipment lease agreement 
packages 
- Equipment care packages  
Patients receive technology on time. Technology is 
managed effectively when in transition between 
patient and hub/care teams. 
Systems in place to care for technology/replace. 
Intervention is distributed smoothly. 
Services are implemented correctly. 
Patients feel motivated to self-care. 
 
 Governance - Involving staff at key early 
stages 
- Key staff/clinicians learning 
how to tweak and adapt 
technologies 
- Early clinical involvement in 
technology content and how 
technologies will be used 
- Modifying technologies where 
appropriate 
- Decision making on the ground 
- Key clinical leads making 
decisions from the outset 
- Clinical leadership involved 
locally from the outset  
- Ensuring flexibility within 
technology packages offered  
- Demonstration of 
technologies and technology 
workshops  
- Technology idea-storming 
sessions 
- Clear policies and protocols on 
clinical activity using 
technologies (including Risk 
procedure, Risk register and 
Risk management plan/Risk 
strategies)  
- Selection of technology 
packages available to choose 
from / flexibility for different 
practices  
Staff will be informed about the programme and will 
have contributed to how tech will be used in practice 
and its clinical content. Potential problems are 
anticipated. Technologies and model of care are 
modified accordingly. Autonomy within teams to 
manage technology and teams involved and 
engaged.  
Intervention is adopted with low levels of 
disruption and potential problems have 
been addressed/strategies in place to 
manage these. Staff on board at different 
levels to enable programme to move 
forward smoothly. Buy-in from key staff 






Monitoring of patient data: This is considered to be more successful when carried out by senior staff. This is because less 
experienced members of staff may be more risk averse, which can create extra work for teams.  
For other teams (EC) monitoring by junior staff has been successful (important to note here the different ways in which 
BCT and EC are set up). 
Incomplete data monitoring: Patients may not always complete the monitoring tasks. Some data remains incomplete. 
Health professionals must follow this up (EC) which can create extra work. Consider with innovators from the outset 
how to manage this (e.g. alerts to the patient?) 
Patients Selecting patients: Check patient’s suitability – does the patient have other conditions that may affect, or be affected by, 
monitoring (e.g, anxiety/depression)? Are patients participating in trials? Also consider if patients have support from 
family/friends to assist with applying/removing the device? Will the patient be able to monitor alone or will they need 
support, and is this in place? 
Technology Installing: Technology may be installed by tech companies at additional costs. Alternatively, core teams can be trained to 
install and cascade. 
Feedback: Patients need to know if the data has been sent/if their task has ended. Some patients expect feedback (a ‘no 
news is good news’ approach may create anxiety for some patients). However, technologies may not be able to offer this 
feedback. Discuss with innovators from the outset how this will be managed. If no feedback/response is offered, this must 
be made clear to patients during the induction stage.  
Self-monitoring: In order to develop self-care, patients must also be shown how to view their data. Some training may also 
be needed on how the data should be interpreted (what is normal for the patient?). 
Support for patients with monitoring: Patients may need support with monitoring and with using the equipment at home, 
such as putting on the devices/removing clothing. Who can fulfil this role? Private agencies may accept/refuse this role. 
How to incorporate this into existing roles? 
Technical Support: Patients often experience multiple minor technical issues. Online support is necessary however tech 
companies may be reluctant to be the first point of contact in case patient queries are clinical. An intermediary is necessary 
in order to direct patients concerns. This may be a member of the admin team within a clinical practice. The team member 
must also track if these technological issues are resolved forming a feedback loop.  The technical line should be continuously 
Figure 3.16. Crib Sheet- Things to Consider 
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staffed – an answering machine will lead to some patients attempting to make further calls to other numbers, often leading 
to frustration and lost messages. 
Patient consent: Patients to sign a document consenting to receiving the technology in their home. This would also explain 
that the tech will be removed if not used by the patient.  
General IT skills training: Some patients need basic IT skills training (troubleshooting/turning off flight mode/managing 
notifications). This was offered to patients when invited onto the programme and then a phone number provided for them 
to book a training session. However, this approach can lead to low levels of take up – patients may be reluctant to make 
that initial step. Consider booking patients on training courses at the moment of recruiting. Alternatively, request patient 
permission to pass their details on to training co-ordinators (patient confidentiality would need consideration/possibly new 
agreements to be arranged for this).  
Tech training for staff: If training is needed for staff, innovators (in particular smaller companies) need advance warning of 
when / how many staff in order to prepare for this.  
Technology timelines: Ensure the technology is ready and available for distribution before agreeing dates with patients. 
Partnerships Collaboration agreements: Bringing relevant partners together (in person) to draw up draft agreements will reduce the 
complexity of making such agreements. Teams need to involve those with contractual/legal backgrounds and to consider 
additional costs if agreements are commissioned to solicitors. 
Information governance restrictions: Information sharing between innovators - particular skills are needed here for 
understanding what can be shared and how. Important to establish this at the beginning as parties involved may not be 
willing to recruit patients or supply technology until agreements are signed.  
Data sharing: Restrictions are in place about the circulation of patient information outside of the NHS – the creation of a 
governance portal (Electronic Portal) can support this process but specialist skills and training are needed on how to use 
such tools. 
Newsletters: Can help to update partners in the development of the programme and to ensure partners are involved. If 
partners fall out of the loop, technology partners may need to reintroduce their technologies/the purpose of their 




Needs of smaller/larger enterprises: Important to consider the work flows of different enterprises and plan for this. Smaller 
enterprises may be able to move/respond quicker to increased demands for services but also may have less flexibility 
around specific times of the year (end of the financial year). For smaller companies, plan ahead to enable timing with other 
projects and programmes. For smaller companies it may be difficult to absorb the costs (financial and time) of meeting 
regularly in person. 
Equipment /Materials Storing: Consider where to store technologies if devices are to be distributed by clinical teams. How will the devices be 
kept secure? Leaflets/instructs may also need to be stored. How will technologies information packs be transported to 
patients? 
Governance Involve relevant teams early in the programme: Decisions about the technologies (and how they will be used) are made 
by people working on the ground. To avoid delays, those involved in the delivery of the programme need to be on board 
from the outset (clinical teams and those who deliver the programme). Relationships must be established between 
innovators and clinical teams to avoid re-introducing the technologies down the line/reversing decisions made. 
Technology Content: It is important to identify the right clinical teams from the outset so they may be involved in 
establishing the most suitable content for the technologies used. Without the involvement of clinical teams early on, the 
content of the technology may not be appropriate causing disruption to both patients and staff at later stages in the service. 
Engaging Staff: Key figures from the delivery team must be involved in the programme from the outset in order to engage 




A ranking exercise was conducted following the two deliberative panels. The approach used 
for this is set out in the Methodology section. 
The survey was sent to all 27 participants who attended the two deliberative panels. 
Responses were received from 18 people, with a 67% response rate.  
Question 1 of the survey contained 11 statements for participants to rank in order of 
importance (see Appendix 26 for the full list). This question focused on statements relating to 
patients and family carers. The four statements considered most important are presented in 
Table 3.22.  
Table 3.22. Ranking activity question 1 results  
Statement 
Percentage of 
respondents who ranked 
this statement between 1 
and 4 in importance 
Decisions about what technologies to give to a patient should 
begin with the individual’s healthcare needs, and not what 
technologies are available 
83.33% 
Patients should be involved in the decision-making about 
what technologies they are to use 
66.66% 
The technologies offered to patients should be tailored to the 
needs of the individual patient 
66.66% 
The healthcare technologies will not be suitable for all 
patients, and therefore patients and clinicians need to work 




Question 2 of the survey focused on staff and contained 7 statements for participants to rank 
in order of importance (see Appendix X for the full list). The four statements considered most 
important are presented in Table 3.23. 
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Table 3.23. Ranking activity question 2 results  
Statement Percentage of 
respondents who ranked 
this statement between 1 
and 4 in importance 
It is important that staff teams receive support and training to 
understand the value of the technologies to their patients 
 
83.33% 
Staff involved in the Test Bed need appropriate and regular 




Healthcare staff must be given the appropriate resources, 
training and time to enable them to tailor the technologies to 




Continuity in the staff responsible for identifying and 
managing patients using healthcare technologies is important 








The LCIA Test Bed focused on taking a combinatorial approach to the use of heath technology 
to assess their potential for improving the health and well-being of older people living with 
long-term conditions. The evaluation of the programme was complex. In the discussion 
section we summarize some of the main findings from the evaluation and address both the 
strengths and limitations of the approach used. We also address the different models of care 
adopted within each Vanguard site and comment on the strengths and challenges these 
presented for implementation of the Test Bed.  
Impact of combinatorial technologies: costs and services 
Somewhat disappointingly, the evaluation found that, overall, the use of combinatorial health 
technologies made little difference to hospital service usage for older people with long-term 
conditions. Further, while patients in some cohorts (e.g. Cohort 1) showed cost savings in all 
three measures of secondary care, the overall costs of the intervention exceeded any cost 
savings. However, it is important to bear in mind a number of factors when considering these 
results: 
Firstly, without access to the actual costs of the innovator technologies, all costings for the 
technologies are based on open market sources. Whilst this is accepted practice within 
economic evaluation, it does mean that the technology costs are conservative. It is possible 
that economies of scale could be made through bulk purchasing or exploring alternative 
models of funding the technologies (such as lease models). 
Secondly, our data reveal that the combinatorial health technologies promoted a strong level 
of engagement and patient activation amongst both patients and carers and that this increase 
in activation was manifest in improved confidence and a better understanding of the patients’ 
health conditions and how to manage these conditions. Indeed, there is some evidence that 
this is manifest in behavioural change of some patients as they take increased responsibility 
for monitoring and managing their own health. 
Thirdly, whilst cost is clearly an important issue, our data reveal other important impacts on 
patients such as the identification of previously undiagnosed conditions, that have potential 
for considerable cost savings ‘downstream’. This is discussed in more detail below, but due to 
the relatively short time-span of the Test Bed we are unable to verify these potential cost 
savings.  
Identification of previously undiagnosed conditions  
A number of the survey responses included messages inserted by patients relating to feelings 
of depression and loneliness. Around eight patients in Better Care Together left a message 
requiring mental health support as a result of being part of the Test Bed resulting in a GP 
reaching all those patients. As a result, the clinical teams were able to identify and treat 
previously undiagnosed health issues that may not otherwise have been detected until 
reaching a more serious stage requiring higher level (and more costly) intervention. This, of 
course was not revealed as a result of the technology use itself, but the technology does allow 
for the inclusion of surveys related to mental health so it would be perfectly feasible for the 
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technology protocols to include assessment of mental health status for those at risk of 
loneliness and depression. 
In addition to the identification of previously undiagnosed health issues through the surveys, 
the recruitment process itself (based on both CSU risk and long-term conditions records and 
clinical judgement by the clinical teams involved) identified previously undiagnosed 
conditions. The clinical teams were able to identify patients with a number of additional 
previously undiagnosed conditions such as hypertension and atrial fibrillation. As a 
consequence, these participants received treatment that they not otherwise have received, 
and whilst this had an immediate cost impact on the Test Bed programme, there are potential 
cost savings to the NHS further ‘downstream’ that we are unable to include in the evaluation. 
For example, figures from Public Health England (2014) revealed that over 5 million people 
int eh UK have undiagnosed hypertension – not only is it one of the biggest risk factors from 
premature death and disability in England, but diseases caused by diseased caused by high 
blood pressure account for 12% of all GP visits in England and are estimated to cost the NHS 
over £2 billion per year51. Similarly, a Kings Fund report on the projected cost of mental health 
care in England estimates that the cost of depression in England will rise to £12.15 bn by 
202652 
The impact of combinatorial technologies on patients 
The evaluation identified a number of benefits of the Test Bed programme to patients and 
staff. A significant number of patients with LTCs experienced an increase in health-related 
confidence. For Cohort 1 patients, this was the result of the reassurance of co-monitoring: 
that is, a combination of being monitored by healthcare staff and of feeling confident enough 
to monitor their own health. In Cohort 2, increased health-related confidence in patients was 
the result of increased knowledge and skills, predominantly in COPD patients, and their 
subsequent ability to better manage their health condition.  
For these patients, an important aspect of the Test Bed was the relevance of the technology 
to their own health condition(s). In Cohort 1, for example, where patients were among the 
most unwell, the technology – with its focus on co-monitoring – offered reassurance to both 
patients and their family carers. For Cohort 2, where many patients’ primary condition was 
COPD, the technologies were seen as highly relevant to this condition and so helped them to 
increase their knowledge, skills and ability to self-manage their long-term condition. The need 
for decisions about the allocation of health technologies to start with the needs of the patient 
and not the technologies available was reinforced in both the final logic model and the ranking 
activity arising from the final deliberative panels.  
Good training, induction and ongoing support are essential for the successful implementation 
of Test Bed technologies. In general, patients found the Test Bed technologies easy to use and 
they quickly became part of the patient’s daily routine. While some Test Bed participants 
                                                     
51 https://www.gov.uk/government/news/new-figures-show-high-blood-pressure-costs-nhs-billions-each-year 
[accessed 12/07/18). 
52 McCrone, P., Dhansiri, S., Patel, A., Knapp, M., and Lawton-Smith, S. (2008) Paying the Price: the costs of 
mental healthcare in England to 2026. Available at: https://www.kingsfund.org.uk/sites/default/files/Paying-
the-Price-the-cost-of-mental-health-care-England-2026-McCrone-Dhanasiri-Patel-Knapp-Lawton-Smith-Kings-
Fund-May-2008_0.pdf [accessed 12/07/18] 
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required formal support when issues arose with their equipment, most did not find this off-
putting, the main problems arose when support channels were not clear to them or if they 
felt seeking help made them a burden to busy NHS staff. 
Experiences of training and initial support differed across the cohorts depending on the 
equipment a patient received. While Cohorts 1 and 4 received formal training from an 
external company, patients in Cohorts 2 and 3 receiving different technologies, including 
apps, with little support or training in how to use them. Initial one-to-one training and support 
in the early stages of using the technology – including help with personalising the technologies 
to meet their own needs - by someone who themselves had received training in using the 
technology would have been beneficial to them. The availability of a live version of the 
technology at an initial meeting would also have been useful. It is important that these 
findings regarding training and support needs are considered for future programmes. 
The importance of the ability to individualise the technologies arose throughout the Test bed 
evaluation. Some patients would have liked the ability to adapt the technologies to meet their 
own specific health care needs, to address their own likes and preferences, and to change the 
times they received messages. For example, Cohort 3 participants, unlike patients in Cohorts 
1 and 2, did not necessarily want to use the equipment every day and patients did not 
understand that there was some flexibility within the technology to do this. Others would 
have liked the ability to tailor the technologies to their own level of knowledge regarding their 
health condition. Participants in Cohort 3 for example, were confident and experienced with 
using technologies in general, and the technology provided to people in this cohort did not 
meet with their expectations. This patient cohort are different in many ways to the other 
participant cohorts and it is important that these differences are considered in future 
programmes.  Individualisation of the technology was particularly important for Cohort 4 
where it was clear that patients had different preferences about when, in their dementia 
journey, they received information. The majority of Cohort 4 participants had only recently 
received a dementia diagnosis, and many patients and family carers were still coming to terms 
with the diagnosis. 
Patients highlighted the importance of being involved in decisions about the healthcare 
technologies they receive, along with having regular opportunities to review progress with 
healthcare staff. Whilst numbers were small in Cohort 3, it was clear that it was particularly 
important to this group that they understood the relevance of the technology to their own 
health, many feeling unsure about its relevance and why they had been given it to use. These 
issues are important as it is already well known from the evidence base that older people are 
more likely to adapt positively to the use of technology where they see a clear relevance and 
utility for their own lives (see for example Age UK, 201153). 
A common theme across all cohorts was the lack of clarity about exactly who had access to 
their data, and the purposes for which it was being used. Patients clearly wished to be better 
informed about how their data were being used, and while patients were informed of this 
during the induction process, this was clearly a point at which they were receiving a whole 
                                                     
53 Age UK (2011) Technology and Older People Evidence Review. Available at: 
https://www.ageuk.org.uk/documents/en-gb/for-professionals/computers-and-
technology/evidence_review_technology.pdf?dtrk=true [accessed 12/07/18] 
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host of other information so staging this delivery of information may be needed to avoid 
information overload.  
Combinatorial technologies and family carers 
Family carers played a crucial role in the Test Bed programme. The technologies were often 
the responsibility of the family carer, with many patients indicating that they could not have 
taken part in the programme without the support of a family member of carer. This was 
particularly the case for Cohort 4, where patients were experiencing cognitive decline. An 
important point to consider when reflecting on the use and applicability of combinatorial 
technologies for improving the health and wellbeing of patients with LTCs, therefore, is that 
for a good number of patients, the technology either required the presence of, or was directly 
used/applied by the family carer rather than the patient themselves. This is not to deny its 
effectiveness, indeed our findings suggest that this led to carers gaining both health literacy 
(a better understanding of the patient’s health conditions or a better ability to monitor 
aspects of the patient health condition/s) and technology literacy. Both of these factors were 
deemed by carers to be important in helping the older person with a LTC to manage their 
condition but also to help them, as carers, to support the patient and help reduce their own 
stress and anxiety. 
The evaluation revealed evidence of significant carer burden across all patient cohorts, with 
some experiencing depression and anxiety. Family carers involved in the Test Bed were 
providing increasing levels of care for their partners, and many were also living with their own 
health conditions. For many carers, the Test Bed technology made them feel better 
supported. In Cohort 4, for example, it was often the family carer who benefited from the 
Test Bed, rather than the patient, with carers noting that the technology helped them feel 
better informed and better prepared for future changes in the condition of the person with 
dementia. They also felt reassured as a result of monitoring. 
This highlights the need for clinicians and technology providers to consider the whether it 
may be appropriate to involve family carers in decision-making and training around the 
implementation of combinatorial health technologies. Given carer breakdown is a major 
factor in the institutionalisation of frail older people (whether that be in hospital or care home 
settings), our findings suggest that supporting family carers through these combinatorial 
technologies, and designing technologies specifically targeted at the needs of the family carer, 
offers potential for enabling older people with LTCs to remain at home for longer. 
The Test Bed: impact on staff  
For staff, the Test Bed programme enabled more contact and connections with patients and 
added diversity to their daily role. Like patients, members of staff experienced increased 
confidence and reassurance as a result of monitoring their patients, with increased levels of 
job satisfaction for many as a result of knowing that patients were stable and future issues 
were being prevented. Staff also cited examples of their colleagues being able to better 
manage and prioritise workloads as a result of the work being undertaken in the Test Bed 
programme. 
However, staff also cited time as a key challenge for successful delivery of the Test Bed, with 
it resulting in additional workload for those operating on the front line. Members of staff 
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stressed that protected time is needed for delivering a programme such as this, particularly 
in the implementation stage. This is particularly the case for patients with dementia. Speed 
of working is also an important factor in the adoption of new technologies, which need to be 
compatible with patient medical records to avoid staff working spending valuable time 
working across a number of incompatible patient data systems. 
Staff need to be given the necessary resources to understand and feel able to tailor 
technologies to their patients’ individual needs. As with patients, staff felt the Test Bed was 
most successful where the technologies had the flexibility for healthcare teams, patients and 
carers to tailor the content to a person’s individual needs. 
It is also important to also note that a number of issues arose throughout the Test Bed as a 
result of clinical teams not being involved in decisions and programme design from the outset. 
In large part this arose as a result of the short lead in time to the submission of the initial Test 
Bed bid and the expectation of a quick start-up following notification of the success of the 
bid. As a result, clinical staff at all levels felt disengaged from a process in which they had not 
been involved but were expected to deliver on. Members of staff were expected to refer their 
patients into the Test Bed while not being involved in decisions about the technologies chosen 
and not knowing what the technology entailed. Some of the technology content contradicted 
the advice given to patients by healthcare teams resulting in technology protocols having to 
be re-written. 
It is thus clearly important to the implementation of a programme like this, that clinical teams 
are involved in decisions and programme design from an early stage. This includes training 
and support for staff regarding the technologies being used, so a mismatch between clinical 
advice and technology content can be picked up at the outset. It would also ensure that 
informed choices can be made between healthcare professionals and patients regarding the 
selection of appropriate technologies.  
Staff across both Vanguard sites emphasised the importance of being part of a willing and 
engaged team when embarking on a programme such as the Test Bed; and where staff have 
sufficient continuity in their Test Bed posts to enable them to develop knowledge about their 
patients and  become familiar with the patterns of their daily readings.  
Strengths and Limitations of the Evaluation Design 
Overall the evaluation design was robust in that it was designed as a mixed method evaluation 
with sample sizes for each cohort that were calculated through known statistics of the older 
population with long-term conditions across the north west. Overall, the strength and quality 
of the evaluation design was recognised through the peer review process and subsequent 
publication in BMJ Open (2018). 
 
Key strengths of the Test Bed Evaluation: 
 The impact of healthcare technology was monitored in as close to real-time as possible 
using self-reported data from Test Bed participants; 
 The evaluation approach, using matched control group, was novel and has advantages 
for measuring intervention effects; 
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 The ‘real-life’ evaluation design was novel in that unlike RCT-type designs, it 
recognised the requirement for flexibility and rapid cycle review to meet the ongoing 
changes of the Test Bed environment; 
 The action learning meetings allowed for rapid cycle review and key learning to be 
identified and implemented by all partners throughout the Test Bed programme; 
 The deliberative panels were novel and facilitated ‘bottom up’ agreement and 
validation of the qualitative findings through representation of all key stakeholders; 
 The ‘lessons learned’ activity undertaken as part of the evaluation, allowed early 
learning from the set-up of the Test Bed programme to be disseminated and fed-in to 
the planning of future test beds at the national level; 
 The strength of the qualitative work in Phase 2 of the evaluation allowed us to develop 
a more nuanced understanding of who the technologies did/did not work for and why.  
 Whilst the recruitment to Cohort 3 was laid down, some patients had already been 
recruited. The qualitative phase of the evaluation enabled us to gain some insights 
into the potential of combinatorial technologies for this cohort. 
Whilst overall, the evaluation design was robust in terms of both its Phase 1 and Phase 2 
methodologies, in practice, like any design, this real-life evaluation raised a number of issues 
that were challenging – particularly for Phase 1 of the evaluation - and which are worth 
considering for those planning to undertake evaluation in similar real-life situations: 
 Recruitment to the Test Bed was a significant issue throughout, with the Test Bed only 
recruiting 46% of its original target. This was due to a number of factors including: 
delays in starting recruitment; lack of early consultation with clinicians resulting in dis-
engagement with the Test Bed programme; delays arising from technical and protocol 
problems with the technology; delays in appointing key staff to deliver the Test Bed; 
failure to allocated dedicated clinical staff time to the delivery of the Test Bed 
(particularly within the Fylde Coast model); high levels of attrition; instances of poor 
handover of clinical staff resulting in the loss or failure to ensure completion of some 
surveys; and the inability to recruit to Cohort 3. 
 The significantly lower than anticipated recruitment levels had an impact on the 
evaluation. Overall, there were 460 active participants with 293 included in the cost 
analysis. When estimating a potentially relatively small intervention effect the 
statistical power of the analysis is reduced with a smaller sample size. 
 For patients taking part in the Test Bed we obtained self-reported data from a survey 
distributed by the Test Bed clinical teams. However, the control data were obtained 
from administrative records held by the Midlands and Lancashire CSU. Data for the 
controls were taken from the year prior to the Test Bed programme to avoid 
contamination between control and intervention groups. Ideally these data would be 
obtained from the same source for both groups and over the same time period. 
 CSU data does not include health related quality of life and wellbeing outcome data. 
Hence, we were unable to gather this data for our controls so were unable to attribute 




 Due to the complexity of the data only  those Test Bed participants who completed all 
three surveys were included in the resource use and cost analysis. The number of 
participants with an incomplete set of surveys was higher in Cohort 2 (40 in cohort 2 
compared to 27 in Cohort 1). We are unable to assess the direction or magnitude of 
any potential bias arising from this decision.   
 The timeframe of the Test Bed overall was two years, (2.25 years with the extension). 
The original plan was to assess patients over a nine month period. However, the delays 
in recruitment meant we had to shorten this timeframe to six months.  It is thus 
possible that the timeframe for our study was too short to enable us to accurately 
measure any statistical change in admissions and in secondary care use.  
 A longer time frame for the evaluation would also be likely to be able to demonstrate 
a reduction in the costs of the intervention due firstly to the costs of technology 
decreasing over time; and secondly to an increase in the effectiveness of the 
programme on secondary care use in the long term. 
 To gain a better understanding of the impact of the technology on primary care, 
community health care and social care, it would have been useful to have this data for 
the control group. 
Data Access and the Collaboration Agreement 
Throughout the Test Bed period, the Evaluation Team explored different alternatives to 
accessing the required data for the analysis. During the first year of the programme we 
explored the use of both Hospital Episode Statistics (HES) and CSU data. The team liaised with 
multiple actors with experience in working with similar data within the NHS but 
communication proved difficult. We were unable to gain access to HES data which would have 
given us a wider national comparison. However, in November 2016, it was confirmed that 
CSU data would be made available to the Evaluation Team. To ensure compliance with the 
Data Protection Act, the evaluation was required to receive approval from the Fylde Coast 
and North Lancashire CCG Caldicott Guardians. Before this data could be released, however, 
the LCIA collaboration agreement was required to include a section on data governance. Data 
governance and the IP   data protection issues attached to this are important issues for all 
partners and particularly so for NHS and industry partners. Developing and finalising the 
Collaboration Agreement was thus a lengthy process. For Information Governance (IG), 
completed questionnaires and privacy impact assessments were required from each party 
within the LCIA Test Bed partnership. These assessments were uploaded on to an electronic 
Information Sharing Gateway portal to which all parties were given access. Parties were then 
asked to sign off the project data sharing agreement.   
In total, the collaboration agreement and administrative paperwork took around six months. 
This had a knock-on effect in terms of recruitment to the Test Bed as innovators did not feel 
able to engage with the Test Bed and until the agreement was signed off. It also meant that 
the CSU was unable to share the first sample of control data with us until June 2017. AS the 
early findings from our ‘lessons learned’ activity suggested, the development of a pro forma 




Models of Test Bed implementation  
The LCIA Test bed was implemented using two different models of care, each taking a 
different approach to the overall delivery and management of the programme in their 
respective Vanguard areas. In Better Care Together the model adopted utilised a small GP-led 
team, which acted as a hub for the Test Bed. Within the Fylde Coast the model was more 
dispersed, utilising a number of services in the area including Extensive Care, pulmonary 
rehabilitation teams and GP practices.  
As noted above, the aim of the Fylde Coast Vanguard area, had been to build on the existing 
Extensive Care service. It was envisaged that this would have the advantage of a ready-made 
service with an existing team that could be extended. In reality there were insufficient 
numbers of patients meeting the criteria for the Test bed coming through the Extensive Care 
service meaning the Test bed had to be extended to the pulmonary rehabilitation service and 
GPs making it more dispersed and less cohesive. Many of these staff had not been actively 
involved in the process and its associated decision-making regarding the delivery of the Test 
Bed. As a result, staff did not feel ownership of the programme. While they could see benefits 
of the Test Bed to both their patients and their working teams, staff in the Fylde Coast 
Vanguard often felt less engaged from the overall process. One consequence of this was that 
the Fylde Coast Vanguard area found it much more difficult to recruit and retain patients on 
the Test Bed, resulting in far lower numbers of active patients. 
The approaches to team working and overall communication between staff were different in 
each of these models of care. For the purposes of implementing the Test Bed, Better Care 
Together developed a new service in which a small GP-led team, acted as a hub for the Test 
Bed. This proved a more effective model of delivery. Staff in the GP-based hub had been 
involved in the process and its associated decision-making from an early stage and thus felt a 
greater sense of ownership and buy-in to the programme. As a small, geographically 
proximate team, communication was easier and staff also had a better understanding of each 
other’s roles, resulting in a better ability to support each other and the process of 
implementing the Test Bed.   
Key to the success of the Better Care Together approach was the appointment of one overall 
operational manager who had oversight of and involvement in all aspects of the Test Bed 
within that Vanguard. The small GP-led hub approach also ensured continuity in the staff 
responsible for identifying and managing patients using healthcare technologies, which was 
key to the successful implementation and management of the programme. Within this team, 
there were excellent working relationships and communication, which were enhanced by the 
role and commitment of the operational manager. 
Despite differences in the models of delivery used in each Vanguard, and the fact that the 
Better Care Together model was a new service rather than one building on existing 
infrastructure, as the Phase 1 findings revealed, there was little difference in the cost per 
patient. The success of this hub model could thus be replicated elsewhere with a relatively 





The Lancashire and Cumbria Innovation Alliance (LCIA) Test Bed was one of seven Test beds 
awarded by NHS England. The LCIA Test Bed was delivered through two neighbouring 
Vanguard sites – the Fylde Coast Local Health Economy and Morecambe Bay Health 
Community (Better Care Together). Located in Lancashire and South Cumbria. Over a period 
of thirty months, it implemented and evaluated a combination of innovative technologies and 
practices aimed at supporting older people with long-terms conditions to remain well in the 
community, avoiding unnecessary hospital admissions. Focusing on older people with long 
term conditions including COPD, heart failure, asthma, diabetes and dementia, the Test Bed 
evaluation aimed to focus on two key outcomes:  
 
 Firstly, the extent to which supported self-care telehealth technology might improve patient outcomes 
and the patient experience for frail older people living with long-term conditions in Lancashire and 
Cumbria; and  
 
 Secondly, the potential cost effectiveness of the intervention and how this might be scaled up to 
provide better value for both patients and taxpayers. 
 
The evaluation of the programme was complex and required the development of a ‘real life’ 
evaluation methodology that allowed for rapid review and cycles of change throughout the 
programme. 
 
Whilst our evaluation found that, overall, the use of combinatorial health technologies made 
little difference to hospital service usage for older people with long-term conditions, it is 
important to take account of the relatively short timescale over which the Test Beds were 
implemented. Our data revealed examples of increased service utilisation due to the 
identification of previously undiagnosed conditions and/or the need for additional or 
increased medication. These short-term increases in service use are likely to be offset by 
longer-term cost-savings, but this was not verifiable within the time-span of the Test Bed 
programme. 
When considering the overall costs of the Test bed it is also important to consider whether 
alternative models of funding could improve the cost effectiveness of the Test Bed 
programme and the extent to which the NHS could use its bulk purchasing power to achieve 
economies of scale in the purchase of the technologies.  
The evaluation did, however, reveal that the use of combinatorial health technologies 
promoted a strong level of engagement and increased patient activation amongst both 
patients and carers. The increase in activation was manifest in improved confidence and a 
better understanding of the patients’ health conditions and how to manage these. Indeed, 
there is some evidence to suggest that is promoting behavioural change amongst some 
patients as they take increased responsibility for monitoring and managing their own health. 
There was also clear potential for increasing the health and wellbeing of family carers of older 




Future directions  
The ‘lessons learned’ from this Test Bed provide some valuable insights into how Test Beds 
can be set up more effectively in the future and how some of the early learning from this Test 
Bed partnership can be used to overcome potential challenges to successful implementation 
in the future. 
The overall timescale only allowed us to follow participants for a period of six months. While 
we were able to observe encouraging signs of behavioural change that have significant 
implications for enhancing older people’s ability to better manage their own care at home; 
and potential longer-term cost savings of identifying and treating previously undiagnosed 
health conditions, a longer period of follow up would enable more definitive answers to these 
questions. 
It was also clear from the evaluation that there is real potential for combinatorial health 
technologies to support family carers and enable them to care for longer whilst monitoring 
and managing their own health conditions. 
Finally, more work is needed to understand the complex needs of dementia patients and 
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Appendix 1. Surveys received and missing surveys per Cohort 
All Cohorts (1, 2 and 4)      Cohort 1     
A. Three surveys completed: 310 71%  A. Three surveys completed: 169 78% 
B. Missing baseline survey: 24 6%  B. Missing baseline survey: 13 6% 
C. Missing second survey: 23 5%  C. Missing second survey: 10 5% 
D. Missing third survey: 15 3%  D. Missing third survey: 6 3% 
E. Missing baseline and second survey: 9 2%  E. Missing baseline and second survey: 2 1% 
F. Missing baseline and third survey: 5 1%  F. Missing baseline and third survey: 2 1% 
G. Missing second and third survey: 30 7%  G. Missing second and third survey: 12 6% 
H. Missing all surveys: 18 4%  H. Missing all surveys: 4 2% 
 TOTAL 434 100%   TOTAL 218 100% 
         
Cohort 2      Cohort 4     
A. Three surveys completed: 126 63%  A. Three surveys completed: 15 100% 
B. Missing baseline survey: 11 5%  B. Missing baseline survey: 0 0% 
C. Missing second survey: 13 6%  C. Missing second survey: 0 0% 
D. Missing third survey: 9 4%  D. Missing third survey: 0 0% 
E. Missing baseline and second survey: 7 3%  E. Missing baseline and second survey: 0 0% 
F. Missing baseline and third survey: 3 1%  F. Missing baseline and third survey: 0 0% 
G. Missing second and third survey: 18 9%  G. Missing second and third survey: 0 0% 
H. Missing all surveys: 14 7%  H. Missing all surveys: 0 0% 




Appendix 2. Healthcare Unit Costs Data Sources and Assumptions  
Service Notes 
Hospital Services   
Accident and Emergency 
This cost was calculated using the following weighted average costs: 
-If A&E attendance does not led to an admission: 
Emergency medicine and no admission: All ambulance services + A&E attendance = £119 + £140 a 
= £259 
a The weighted average cost given in the reference costs spreadsheets is £137.74 for 2015-16 
which when uprated using the HCHS inflator is £140.    
General Hospital Inpatient Admission 
Elective inpatient stays 
Community Hospital Inpatient Admission 
Day Hospital* Day cases HRG data (finished consultant episodes), weighted average of all stays 
Outpatients Visits to Clinical Based at Hospital Site Outpatient attendances, weighted average of all outpatient attendances 
Primary Care, Community Health Services   
General Practitioner (GP) General Practitioner excluding direct care staff costs (without qualification costs) 
Paramedic (Ambulance Service) 
Band 5- Physiotherapist, Occupational therapist, Speech and language 
therapist, Podiatrist, Clinical psychology assistant practitioner (higher 
level), Counsellor (entry level). 
Community Matron Assumption that community matron and district nurse require similar skills 
Band 7 Community/District Nurse 
Practice Nurse Band 5 of nurse scales 
Specialist Nurse Band 8a 
Social Care Services   
Social Worker or Care Manager Cost including qualifications 
Home Care/Home Help Worker Cost per weekday hour 
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Community Mental Health Services   
Psychiatrist / Psycho-geriatrician Hospital-based doctor, Consultant:psychiatric 
Community psychiatric nurse / Community mental health nurse Band 8a 
Other mental health professional NHS community mental health team (CMHT) for older people with mental health problems 
Other Community-Based Services   
Telecare Band 5 of nurse scales 
Dentist/ Oral Hygienist NHS dentist- Performer-Only 
Optician 
Band 6 (Physiotherapist specialist, Occupational therapist specialist, Speech 
and language therapist specialist, Podiatrist specialist, Clinical 
psychology trainee, Counsellor, Pharmacist, Arts therapist (entry level)) 
Assumption: I took the cost per working hour of a physiotherapist/OTs 
*Day hospital refers to a medicat treatment that has to be administered at the hospital but does not require overnight stay. 




Appendix 3. Technology Data Sources and Assumptions  
Care Pathway License/Equipment/Data Data sources and assumptions 
Technology: Motiva toolkit (Cohort 1)   
Cohort 1 (all 
participants HF or 
COPD) 
License Fee 
Assumption: IBM SPSS Statistics software 
£79.13 per user per month (no other fees apply, does not include VAT) 
No additional charge per day per patient using the software. No data storage fee. 
For a year (considering 12 months) the cost per patient would be £79.13*12= £949.56 
 
Source: IBM SPSS Statistics software 
Available at:  
https://www.ibm.com/uk-en/marketplace/spss-statistics/purchase#product-header-top 
Accessed on 28 February, 2018. 
 
Installation £135 per patient  
Tablet  
Assumption: ASUS ZenPad Z380M 8.0" Tablet - 16 GB, Grey 
Only consider a tablet and not a TV box. 
 
Source: Currys PC World 
Available at: https://www.currys.co.uk/gbuk/computing/tablets-and-ereaders/tablets/149_3402_32003_xx_xx/xx-100_xx-
100_xx_xx_5-6-7-8-9-10-11-12-13-14-15-16-criteria.html 
Accessed on 28 February, 2018. 
 
HF Wireless weighing scale 
Assumption: Philips Smart Body Analysis Scale for BMI, Body Fat and Weight Measurements, Bluetooth connectivity, White 
 
Source: Amazon  
Available at: https://www.amazon.co.uk/Philips-Analysis-Measurements-Bluetooth-connectivity/dp/B01FHJ4R3O 




Blood pressure meter 
Assumption: Philips Wireless Upper Arm Blood Pressure Monitor, Bluetooth Connectivity 
 
Source: Amazon 
Available at: https://www.amazon.co.uk/Philips-Wireless-Pressure-Bluetooth-Connectivity/dp/B01FHJ4QSK 
Accessed on 28 February, 2018. 
 
Tympanic Ear Thermometer 
Assumption: MSR Tympanic 1 Second Ear Thermometer (including VAT) 
 
Source: Medisave 
Available at: https://www.medisave.co.uk/msr-tympanic-1-second-ear-thermometer.html 
Accessed on 28 February, 2018. 
 
COPD 
Pulse oximeter (SPO2 
monitor) 
Assumption: ChoiceMMed MD300-D Finger Pulse Oximeter (Including VAT) 
 
Source: Medisave 
Available at: https://www.medisave.co.uk/md300d-finger-pulse-oximeter-p-6895.html  
Accessed on 28 February, 2018. 
 
Tympanic Ear Thermometer 
Assumption: MSR Tympanic 1 Second Ear Thermometer (including VAT) 
 
Source: Medisave 
Available at: https://www.medisave.co.uk/msr-tympanic-1-second-ear-thermometer.html 






Care Pathway License/Equipment/Data Data sources and assumptions 




£200 in total (notes from Board Meeting 21 September 2017) 
License per patient = £9.53 (200/21) 
 
Source: LCIA Test Bed Clinical Operations Group Meetings. 
[Confirm we can give this as a source] 
   
Technology: Florence/NHS Simple toolkit (Cohort 2) 
Cohort 2 Flo 
License fee 
Assumption: Approximately £8,000 in total per year 
License per patient= £109.11 (8,000/74) 
 
Source: LCIA Test Bed Clinical Operations Group Meetings. 
[Confirm we can give this as a source] 
        
Message fee 
Assumption: 3 messages sent per week. 8p (£0.08) per message 
Cost of sending 3 messages per week --> £0.24 per week. For a year (considering approximately 2 weeks of 
bank holidays) the cost would be £0.24*50= £12 
 
Source: Discussion with Clinical Teams. 
[Confirm we can give this as a source] 
        
Tympanic ear 
Thermometer 
Assumption: MSR Tympanic 1 Second Ear Thermometer (including VAT) 
 
Source: Medisave 
Available at: https://www.medisave.co.uk/msr-tympanic-1-second-ear-thermometer.html 
Accessed on 28 February, 2018. 
        
Pulse Oximeter (SPO2 
Monitor) 
Assumption: ChoiceMMed MD300-D Finger Pulse Oximeter (Including VAT) 
 
Source: Medisave 
Available at: https://www.medisave.co.uk/md300d-finger-pulse-oximeter-p-6895.html  
Accessed on 28 February, 2018. 
        
Blood Pressure Monitor 
Assumption: Philips Wireless Upper Arm Blood Pressure Monitor, Bluetooth Connectivity 
 
Source: Amazon 
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Available at: https://www.amazon.co.uk/Philips-Wireless-Pressure-Bluetooth-Connectivity/dp/B01FHJ4QSK 
Accessed on 28 February, 2018. 
Phone (basic cellphone) 
Assumption: MobiWire Pictor 
 
Source: Which magazine 
Available at: https://www.which.co.uk/reviews/simple-mobile-phones/mobiwire-pictor 
Accessed on 28 February, 2018. 
        
Technology: Philips Health Watch (Cohort 2)        
Cohort 2 
Health Watch 
Philips Health Watch 
Assumption: Philips Bluetooth Health & Activity Watch with Heart Rate Monitor – for iOS & Android 
 
Source: Amazon 
Available at: https://www.amazon.co.uk/Philips-Bluetooth-Health-Activity-Monitor/dp/B01FHJ4QOY 
Accessed on 28 February, 2018. 
        
Technology: CANTAB Mobile (Cohort 1 & 2)        
Cohort 1 and 2 Access to the tool 
Assumption: There is no data storage fee. 
License per patient= £0.85 (250/293) 
 
Source: Alzheimers' patients online forum  
Available at: https://forum.alzheimers.org.uk/threads/cantabmobile-new-memory-test.46583/ 
[Confirm we can give this as a source] 
Accessed on 28 February, 2018. 






Care Pathway Staff Data sources and assumptions 
Fylde Coast:  
 
Motiva  
Cohort 1 (all 
participants HF 
or COPD) 
Staff (2 nurse practitioners band 
8 and 1 GP Consultant)  
 
Reading, interpreting (excluding 
alerts) 
Assumption: 1 GP Registrar and 1 band 6 Nurse doing the readings and interpreting information using Motiva. 
GP (Registrar) -  cost per working hour £43 
Nurse band 6 - cost per working hour £45 
 
The nurse and GP alternate to do the monitoring from Monday to Friday (not weekends or bank holidays).  
GP's monitoring is done 3 days per week for around 2 hours per day and nurse's monitoring is done 2 days per week for 
around 2.5 hours per day. 
GP Registrar --> 2 hours per day is £86 per day --> 3 days per week is £258 per week 
Nurse --> 2 hours per day is £90 per day--> 2 days per week is £180 per week 
 
The total cost of a week for doing the readings and interpreting information is £438. For a year (considering 52 weeks in 
a year) the cost would be £438*52= £22,776.00 
Source: Discussion with Clinical Teams and PSSRU Unit Costs 2016-17 
Staff  (2 nurse practitioners band 
8 and 1 GP Consultant)   
 
Only alerts to patients 
Assumption: 0.5 hour a day is used for alerting patients and following those cases. 
Then the total cost of alerting patients per week would be £438/4= £109.50. For a year (considering 52 weeks in a year) 
the cost would be £109.5*52=£5,694.00 





Cohort 1 (all 
participants HF 
or COPD) 
Staff (2 nurse practitioners band 
8 and 1 GP Consultant)  
 
Reading, interpreting (excluding 
alerts) 
Assumption: 3 Nurse Practitioners and 1 GP consulting doing the readings and interpreting information using Motiva.  
Nurse practitioners band 8a - cost per working hour £62 
GP (Consultant: medical) -  cost per working hour £106 
 
The nurses and GP alternate to do the monitoring. Monitoring is done everyday for around 2 hours from Monday to 
Friday (not weekends or bank holidays) 
Nurse practitioner --> 2 hours per day is £124 per day--> 3 days per week is £372 per week 
GP (Consultant: medical) --> 2 hours per day is £212 per day--> 2 days per week is £424 per week 
 
The total cost of a week for doing the readings and interpreting information is £796. For a year (considering 52 weeks in 
a year) the cost would be £796*52= £41,392.00 
Source: Discussion with Clinical Teams and PSSRU Unit Costs 2016-17 
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Staff  (2 nurse practitioners band 
8 and 1 GP Consultant)   
 
Only alerts to patients 
Assumption: 0.5 hour a day is used for alerting patients and following those cases. 
Then the total cost of alerting patients per week would be £796/4= £199. For a year (considering 52 weeks in a year) 
the cost would be £199*52=£10,348.00 
Source: Discussion with Clinical Teams and PSSRU Unit Costs 2016-17 





Staff (GP consultant)  
 
Reading, interpreting (excluding 
alerts) 
There were no readings being taken or checked. 
Assumption: 1 Physiotherapist and 1 clinical support worker helps patients using the watches and checking how they 
were using it as part of the pulmonary rehab classes. 
  
1 Physiotherapist specialist band 6 - cost per working hour £43 
1 Clinical support worker (Physiotherapy) band 4-  cost per working hour £28 
 
Assistance is given 0.5 hour once a week. Physiotherapist specialist supports patients with the watch 15 minutes and 
the clinical support worker gives guidance for around 15 minutes. 
Physiotherapist specialist --> 15 minutes per week is £10.75 per week 
Clinical support worker (Physiotherapy) --> 15 minutes per week is £7 per week  
The total cost of a week is £17.75. For a year (considering 52 weeks in a year) the cost would be £17.75*52= £923.00 
 
Source: Discussion with Clinical Teams and PSSRU Unit Costs 2016-17 
Staff  (GP consultant)  
 
Only alerts to patients 
No alerts being generated.  
 







Staff (GP consultant)  
 
Reading, interpreting (excluding 
alerts) 
GP (Consultant: medical) -  cost per working hour £106 
2 hours 3 times a week GP (Consultant: medical) --> 6 hours per week is £636 per week 
The total cost of a week is £636. For a year (considering 52 weeks in a year) the cost would be £636*52= £33,072 
 
Source: Discussion with Clinical Teams and PSSRU Unit Costs 2016-17 
Staff  (GP consultant)  
 
Only alerts to patients 
Assumption: 1 hour a week is used for alerting patients and following those cases. 
Then the total cost of alerting patients per week would be £106. For a year (considering 52 weeks in a year) the cost 
would be £106*52= £5,512.00 
 
Source: Discussion with Clinical Teams and PSSRU Unit Costs 2016-17 
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Appendix 4. Protocol for handling partially missing or incomplete medication 
data 
If medication name (and route preparation) was incomplete in order to get the appropriate 
unit price, we made the following assumptions: 
a) Generally, prioritise the cheapest presentation of a medication among the different available 
presentations 
b) Do not prioritise liquid presentations because they are more expensive 
c) If there is capsule and tablet presentations for the same medication, prioritise tablets 
d) Do not prioritise modified-release presentation of a medication  
e) If there is emollient and cream presentation, prioritise emollient 
f) If there is gastro-resistant and capsules, prioritise capsules 
g) In inhalers, prioritise preservative free 
h) In inhalers, do not prioritise breath actuated 
If medication name was missing or not found in the Drug Tariff or in MIMS, the medication 
was not included in the analysis. 
If medication dose was missing for solid forms: assumed that 1 dose was taken per day. In 
some cases (as suggested by a lead GP) doses per day were assumed as 3 or 4 per day.54 
If medication dose was missing for non-solid forms: assumed that each prescription lasts 1 
month. 
If dose frequency had more than one value (e.g. 1 or 2 times a day): to ensure cost estimations 
were conservative, we assumed the lowest dose frequency. 
If frequency was 'as necessary' or 'as required': assumed is dose per day. 
We assumed that the number of days the patient has used the medication within the yeas is 
365 days for LT medications, 90 days for MT medications, and 14 days for ST medications. 
Approach to estimating daily costs of prescribed medications 
Unit costs are calculated per solid and non-solid unit dosage form of medication based on 
most efficient pack size: 
 Solid unit dosage form includes: tablet, capsule, suppository, patch, pessary, plaster, sachet; 
 Non-solid dosage form includes: oral suspension/suspension, nebuliser liquid, gel, 
mouthwash, inhaler, cream, ointment, eye drops, nasal spray; 
 Basic price chosen as reported in Drug Tariff (November 2017) and MIMS online data 
(November 2017 and January 2018) 
Cost per day per solid unit applied to medication-level data according to dose and number of 
doses taken per day 
 Unit cost of solid unit dosage is unit price of tablet (=basic price/quantity); 
                                                     
54 Due to the amount of data collected, we identified those medications reported more than 10 times using 
baseline, 12 week and 24 week surveys. From this sample, a lead GP suggested us to assume of 3 doses per day 
for Carbocisteine 375mg capsules and Metformin 500mg tablets.  
Assumption of 4 doses per day for Co-codamol 30mg/500mg tablets and Paracetamol 500mg tablets. 
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 Cost per day is generated by multiplying doses taken per day by unit cost 
Cost per day per non-solid unit applied to medication-level data according to unit price per 
day taken  
 For all non-solid forms assumed 1 tube (or unit presentation) lasts a month and use the biggest 
tube;  
 Unit cost of non-solid unit dosage is an average item cost per day (=basic price/(365/12))  
To obtain the annual average cost we have classified the medications based on a physician’s 
judgement specialised in chronic health conditions into long, medium or short term.
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Appendix 5. Socio-demographic characteristics 
Figure A. Percentage of Participants by Education Level, Gender and Cohort 
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% of Population by Education Level, Female
None Primary school Secondary school College University
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Figure B. Percentage of Participants by Employment Condition and Cohort 
 



















Emp full time Emp part time Unable work (caring resp)




Appendix 6. Background characteristics of the Test Bed population at baseline 
per Vanguard Site 
Fylde Coast 









Gender    
Male 21 (67.7) 21 (53.9) 42 (60.0) 
Female 10 (32.3) 18 (46.1) 28 (40.0) 
Age    
[55,59] - 3 (7.7) 3 (4.3) 
[60,64] 3 (9.7) 2 (5.1) 5 (7.1) 
[65,69] 5 (16.1) 10 (25.6) 15 (21.4) 
[70,74] 8 (25.8) 10 (25.6) 18 (25.7) 
[75,79] 3 (25.1) 9 (23.1) 12 (17.1) 
[80,84] 11 (35.5) 2 (5.1) 13 (18.6) 
[85,89] 1 (3.2) 1 (2.6) 2 (2.9) 
[90,94] - 2 (5.1) 2 (2.9) 
Average 74.42 72.44 73.31 
Ethnicity    
White 31 (100.0) 39 (100.0) 70 (100.0) 
Mixed - - - 
Other - - - 
Prefer not to say - - - 
Marital Status    
Single 2 (6.5) 1 (2.6) 3 (4.3) 
Married 19 (61.3) 22 (56.4) 41 (58.6) 
Civil Partnership - - - 
Separated - 1 (2.6) 1 (1.4) 
Divorced 5 (16.1) 4 (10.3) 9 (12.9) 
Widowed 5 (16.1) 11 (28.2) 16 (22.9) 
Prefer not to say - - - 
Living arrangements    
Spouse/partner 20 (64.5) 22 (56.4) 42 (60.0) 
Living alone 10 (32.3) 16 (41.0) 26 (37.1) 
Parent(s) - - - 
Children - 1 (2.6) 1 (1.4) 
Friend(s) - - - 
Other 2 (6.5) - 2 (2.9) 
Spouse and children - - - 
Education    
None - - - 
Primary school - - - 
Secondary school 18 (58.1) 29 (74.4) 47 (67.1) 
College 8 (25.8) 7 (17.9) 15 (21.4) 
University 5 (16.1) 3 (7.7) 8 (11.4) 
Prefer not to say - - - 
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Employment    
Employed full time - - - 
Employed part time 1 (3.2) - 1 (1.4) 
Unable to work due to caring responsibilities - - - 
Unable to work due to ill health 1 (3.2) 2 (5.1) 3 (4.3) 
Unemployed - - - 
Retired 28 (90.3) 37 (94.9) 65 (92.9) 
Voluntary 1 (3.2) - 1 (1.4) 
Prefer not to say - - - 
Access to the internet 
   
No 5 (16.1) 6 (15.4) 11 (15.7) 
Yes 26 (83.9) 33 (84.6) 59 (84.3) 
Intermittent or poor quality - - - 
Prefer not to say - - - 
Notes: 
a Participants for Cohort 4 are being recruited through the Memory Assessment Service (MAS) in Fylde & Wyre 
and Better Care Together. For this reason, Cohort 4 figures are not shown. 
b Living arrangements categories are not mutually exclusive.  
c Percentages may not add up to 100% due to rounding. 
 
Better Care Together 









Gender    
Male 84 (61.8) 49 (56.3) 133 (59.6) 
Female 52 (38.2) 38 (43.7) 90 (40.4) 
Age    
[55,59] 7 (5.1) 8 (9.2) 15 (6.7) 
[60,64] 13 (9.6) 17 (19.5) 30 (13.4) 
[65,69] 28 (20.6) 31 (35.6) 59 (26.5) 
[70,74] 34 (25.0) 18 (20.7) 52 (23.3) 
[75,79] 30 (22.1) 7 (8.0) 37 (16.6) 
[80,84] 17 (12.5) 4 (4.6) 21 (9.4) 
[85,89] 6 (4.4) 2 (2.3) 8 (3.6) 
[90,94] 1 (0.7) - 1 (0.4) 
Average 72.41 68.32 70.82 
Ethnicity    
White 134 (98.5) 84 (96.5) 218 (97.8) 
Mixed - 1 (1.1) 1 (0.4) 
Other 1 (0.7) - 1 (0.4) 
Prefer not to say 1 (0.7) 2 (2.3) 3 (1.3) 
Marital Status    
Single 10 (7.3) 9 (10.3) 19 (8.5) 
Married 73 (53.7) 48 (55.1) 121 (54.3) 
Civil Partnership 2 (1.5) 1 (1.1) 3 (1.3) 
Separated - 1 (1.1) 1(0.4) 
Divorced 21 (15.4) 12 (13.8) 33 (14.8) 
Widowed 30 (22.0) 13 (14.9) 43 (19.3) 
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Prefer not to say - 3 (3.4) 3 (1.3) 
Living arrangements    
Spouse/partner 82 (60.3) 54 (62.0) 136 (61.0) 
Living alone 43 (31.6) 27 (31.0) 70 (31.4) 
Parent(s) 1 (0.7) - 1 (0.4) 
Children 18 (13..2) 2 (2.3) 20 (8.9) 
Friend(s) - - - 
Other 7 (5.1) 5 (5.8) 12 (5.4) 
Spouse and children 13 (9.6) 1 (1.1) 14 (6.3) 
Education    
None 1 (0.7) 3 (3.4) 4 (1.8) 
Primary school 2 (1.5) - 2 (0.9) 
Secondary school 77 (56.6) 49 (56.3) 126 (56.5) 
College 36 (26.5) 25 (28.7) 61 (27.3) 
University 18 (13.2) 8 (9.2) 26 (11.7) 
Prefer not to say 2 (1.5) 2 (2.3) 4 (1.8) 
Employment    
Employed full time 2 (1.5) 5 (5.7) 7 (3.1) 
Employed part time 8 (5.9) 8 (9.2) 16 (7.2) 
Unable to work due to caring responsibilities - 1 (1.1) 1 (0.4) 
Unable to work due to ill health 8 (5.9) 7 (8.0) 15 (6.7) 
Unemployed 1 (0.7) - 1 (0.4) 
Retired 116 (85.3) 64 (73.6) 180 (80.7) 
Voluntary 1 (0.7) 1 (1.1) 2 (0.9) 
Prefer not to say - 1 (1.1) 1 (.4) 
Access to the internet 
   
No 26 (19.1) 16 (18.4) 42 (18.8) 
Yes 107 (78.7) 67 (77.0) 174 (78.0) 
Intermittent or poor quality 2 (1.5) 3 (3.4) 5 (2.2) 
Prefer not to say 1 (0.7) 1 (1.1) 2 (0.9) 
Notes: 
a Participants for Cohort 4 are being recruited through the Memory Assessment Service (MAS) in Fylde & Wyre 
and Better Care Together. For this reason, Cohort 4 figures are not shown. 
b Living arrangements categories are not mutually exclusive.  
c Percentages may not add up to 100% due to rounding. 
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Appendix 7. Percentage of Participants self-defining as confident or somewhat 
confident with the use of technology at baseline, 12 weeks and 24 weeks 
intervention  
 
Note: Percentages were calculated per device. For instance: 42% of participants feels confident using a mobile 
phone, 29% feels somewhat confident, 22% does not feel confident, and 7% did not respond about their level 
of confidence. Therefore, the sum of the proportions of level of confidence per device is 100%. These figures are 
not shown in the table.   
Non-response rate in the level of confidence on technology at baseline ranges from 6% to 11%. At 12-weeks, 
non-response rate goes from 13% to 23% and at 24-weeksranges from 10% to 16%. 
Vertical bars represent 95% Confidence Intervals. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
A. Cohort 1 B. Cohort 2
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Appendix 8. Sample size, maximum and minimum values per Validated Instrument to Assess Health Related Quality of Life 
and Wellbeing of Participants at Baseline, 12 weeks and 24 Weeks Intervention 
Instrument 
(min/max value) 
Cohort 1 (N=167) 
n 
(min / max values) 
Cohort 2 (N=126) 
n  
(min / max values) 
Cohort 4 (N=15) 
n 
(min / max values) 
Test Bed population (N=308) 
n 
(min / max values) 













































































































































a Decimal figures are rounded to the nearest hundredth. 
b EQ-5D-5L, PAM13 and WEMWBS scores, the higher the value the better quality of life. In the DeJong Gierveld score, the lower the value the better (less loneliness). 
c The EQ-5D-5L and EQ-5D-3L index values have been calculated considering data at all time points on 288 participants. The PAMs scores were estimated using data on 308 patients. 
The WEMWBS was calculated considering data on 280 participants and the De Jong Gierveld Scale on 273 participants. Exclusion of participants is due to non-response and 
methodological considerations per instrument. 




Appendix 9. Mean values of validated instruments to assess health related quality of life and wellbeing of participants per 
Vanguard Site  
Mean values per instrument and time point: Fylde Coast 
Instrument 
Cohort 1 (n=31) Cohort 2 (n=39) Test Bed population (n=70) 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
EQ-5D-5L 0.63 0.73 0.67 0.71 0.75 0.71 0.68 0.74 0.69 
PAM13 58.13 59.67 63.83 59.82 60.63 58.84 59.07 60.21 61.05 
WEMWBS 48.07 50.64 50.06 50.14 50.86 50.68 42.23 50.77 50.41 
DeJongG 4.33 3.53 3.63 4.00 3.97 4.50 4.15 3.76 4.09 
Sample size, maximum and minimum values per instrument and time point- Fylde Coast 
Instrument 
(min/max value) 
Cohort 1 (n=31) 
N (min / max values) 
Cohort 2 (n=39) 
N (min / max values) 
Test Bed population (n=70) 
N (min / max values) 

















































































Notes: a Participants for Cohort 4 are being recruited through the Memory Assessment Service (MAS) in Fylde & Wyre and Better Care Together. For this reason, Cohort 4 figures 
are not shown. b Decimal figures are rounded to the nearest hundredth. 
c EQ-5D-5L, PAM13 and WEMWBS scores, the higher the value the better quality of life. In the DeJong Gierveld score, the lower the value the better (less loneliness). d The EQ-5D-
5L and EQ-5D-3L index values have been calculated considering data at all time points on 64 participants. . The PAMs scores was estimated using data on 70 patients. The WEMWBS 
was calculated considering data on 68 participants and the De Jong Gierveld Scale on 64  participants. Exclusion of participants is due to non-response and methodological 
considerations per instrument. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018.  
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Mean values per instrument and time point: Better Care Together 
Instrument 
Cohort 1 (n=136) Cohort 2 (n=87) Test Bed population (n=223) 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
EQ-5D-5L 0.68 0.67 0.67 0.76 0.72 0.74 0.71 0.69 0.70 
PAM13 60.26 59.60 61.68 62.07 62.44 62.16 61.26 60.70 61.57 
WEMWBS 52.27 51.02 51.18 51.04 50.19 50.65 51.78 50.68 50.97 
DeJongG 3.97 4.37 4.26 3.99 3.97 4.23 3.97 4.37 4.26 
 
Sample size, maximum and minimum values per instrument and time point- Better Care Together 
Instrument 
(min/max value) 
Cohort 1 (n=136) 
N (min / max values) 
Cohort 2 (n=87) 
N (min / max values) 
Test Bed population (n=223) 
N (min / max values) 


























































































Notes: a Participants for Cohort 4 are being recruited through the Memory Assessment Service (MAS) in Fylde & Wyre and Better Care Together. For this reason, Cohort 4 figures 
are not shown. 
b Decimal figures are rounded to the nearest hundredth. 
c EQ-5D-5L, PAM13 and WEMWBS scores, the higher the value the better quality of life. In the DeJong Gierveld score, the lower the value the better (less loneliness). 
d The EQ-5D-5L and EQ-5D-3L index values have been calculated considering data at all time points on 209 participants. . The PAMs scores was estimated using data on 223 patients. 
The WEMWBS was calculated considering data on 197 participants and the De Jong Gierveld Scale on 195 participants. Exclusion of participants is due to non-response and 
methodological considerations per instrument. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
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Appendix 10. Correlations of sociodemographic characteristics and EQ-5D-5L dimensions, Cohort 1 
 
Notes: 
a N=308 Test Bed participants (Cohort 1=167, Cohort 2=126,  Cohort 4=15). 
b Gender (1=Male, 0=Female); Marital Status (1=Single, 2=Married, 3=Civil part, 4=Separated, 5=Divorced, 6=Widowed); Lone Dwelling (1=Living Alone, 0=Otherwise); Education 
(1=None, 2=Primary, 3=Secondary, 4=College, 5=University); Employment (1=Full time emp, 2=Part time, 4=Unable work ill health, 6=Retired, 7=Voluntary) Access to internet (0=No, 
1=Yes, 2=Intermittent). 
c *Correlation coefficients significant at the 5% level or better. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
  
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks
Gender 1
Age 0.1707* 1
Risk 0.1162 0.2122* 1
Marital Status -0.1967* 0.111 0.0496 1
Lone dwelling -0.0086 0.1118 0.0603 0.6244* 1
Education 0.0346 0.1245 0.0573 0.0685 0.0661 1
Employment -0.0154 0.3592* 0.0298 0.0663 0.1034 0.0045 1
Access to internet 0.103 0.0583 0.092 -0.1299 -0.1302 -0.0064 -0.0324 1
Mobility at Baseline -0.126 -0.0359 0.3043* 0.2296* 0.1081 0.011 0.0459 -0.0221 1
Mobility at 12 weeks -0.2364* -0.0156 0.2485* 0.1979* 0.1526* 0.0806 0.0673 -0.079 0.5752* 1
Mobility at 24 weeks -0.2647* 0.0265 0.3426* 0.1402 0.0662 0.0565 0.1745* -0.0188 0.6112* 0.5693* 1
Self care at Baseline -0.1313 -0.1779* 0.0625 0.0931 0.0155 -0.033 -0.0163 0.0554 0.5514* 0.3826* 0.3773* 1
Self care at 12 weeks -0.1625* -0.0958 0.0703 0.1954* 0.1662* 0.0746 0.0395 0.0463 0.4009* 0.7164* 0.4260* 0.5548* 1
Self care at 24 weeks -0.2104* -0.1874* 0.1562* 0.0732 0.1097 0.0817 -0.0594 -0.0621 0.3096* 0.3019* 0.4926* 0.4451* 0.3856* 1
Usual Activity at Baseline -0.1395 -0.0741 0.2081* 0.1298 -0.0149 0.0078 0.0121 0.0333 0.6141* 0.3955* 0.4977* 0.5836* 0.4232* 0.3183* 1
Usual Activity at 12 weeks -0.0916 0.0189 0.1661* 0.0864 0.0627 0.0357 0.0767 -0.0736 0.3724* 0.6472* 0.4114* 0.3377* 0.6493* 0.3143* 0.3877* 1
Usual Activity at 24 weeks -0.1404 -0.0129 0.3130* 0.1342 0.1377 0.0478 0.1157 -0.0159 0.4655* 0.4240* 0.6909* 0.4087* 0.4458* 0.5163* 0.5021* 0.4528* 1
Pain/discomfort at Baseline -0.2333* -0.2523* 0.1009 0.1132 0.0407 -0.059 -0.0498 -0.1091 0.4863* 0.3527* 0.3768* 0.3550* 0.2501* 0.2357* 0.3113* 0.1465 0.2890* 1
Pain/discomfort at 12 weeks -0.2178* -0.0507 0.1128 0.2036* 0.2057* -0.0535 -0.0036 0.0668 0.3272* 0.6507* 0.3720* 0.2266* 0.5898* 0.1664* 0.1712* 0.3952* 0.2661* 0.4297* 1
Pain/discomfort at 24 weeks -0.2618* -0.1544* 0.1481 0.0249 0.093 0.0619 0.0925 -0.0449 0.3263* 0.2689* 0.5868* 0.1796* 0.2586* 0.3707* 0.2083* 0.2202* 0.5344* 0.5432* 0.4307* 1
Anxiety/depression at Baseline -0.2036* -0.2523* -0.0495 0.0452 0.1112 -0.1079 0.0136 -0.2007* 0.2450* 0.1452 0.1487 0.2695* 0.1569* 0.1577* 0.2154* 0.0843 0.1141 0.3259* 0.1417 0.2658* 1
Anxiety/depression at 12 weeks -0.2184* -0.1672* -0.0056 0.1712* 0.1445 -0.0311 -0.0909 0.0404 0.1533* 0.5903* 0.2449* 0.2203* 0.7195* 0.0878 0.1268 0.4593* 0.2210* 0.1832* 0.6364* 0.1874* 0.2354* 1




















































Appendix 11. Correlations of sociodemographic characteristics and EQ-5D-5L dimensions, Cohort 2 
 
Notes: 
a N=308 Test Bed participants (Cohort 1=167, Cohort 2=126,  Cohort 4=15). 
b Gender (1=Male, 0=Female); Marital Status (1=Single, 2=Married, 3=Civil part, 4=Separated, 5=Divorced, 6=Widowed); Lone Dwelling (1=Living Alone, 0=Otherwise); Education 
(1=None, 2=Primary, 3=Secondary, 4=College, 5=University); Employment (1=Full time emp, 2=Part time, 4=Unable work ill health, 6=Retired, 7=Voluntary) Access to internet (0=No, 
1=Yes, 2=Intermittent). 
c *Correlation coefficients significant at the 5% level or better. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
  
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks
Gender 1
Age 0.1117 1
Risk 0.0992 0.064 1
Marital Status 0.0572 0.1053 0.0523 1
Lone dwelling 0.0143 0.059 0.0666 0.4044* 1
Education 0.0071 -0.0638 0.0459 0.4010* 0.4893* 1
Employment 0.1042 0.0811 0.0469 0.5867* 0.7060* 0.6911* 1
Access to internet 0.0956 0.0062 0.0405 0.5723* 0.7019* 0.7092* 0.9869* 1
Mobility at Baseline 0.1038 -0.0453 0.1204 -0.1937* -0.3721* -0.2467* -0.4070* -0.4240* 1
Mobility at 12 weeks 0.1631 -0.0456 0.1664 0.0968 -0.0112 0.0264 0.1087 0.0987 0.5829* 1
Mobility at 24 weeks 0.0806 -0.0306 0.1588 0.113 -0.017 0.0214 0.0968 0.0813 0.4536* 0.5542* 1
Self care at Baseline -0.0101 -0.1636 0.1331 -0.3199* -0.5955* -0.4163* -0.6282* -0.6281* 0.6997* 0.3190* 0.2696* 1
Self care at 12 weeks 0.1214 -0.1289 0.1074 0.0942 -0.0696 -0.0032 0.0532 0.0551 0.5474* 0.6168* 0.4895* 0.5794* 1
Self care at 24 weeks 0.0458 -0.1271 0.1425 0.0887 -0.037 -0.0388 0.0529 0.0567 0.3732* 0.4320* 0.6832* 0.4061* 0.5927* 1
Usual Activity at Baseline 0.0479 -0.0668 0.0744 -0.2234* -0.3829* -0.2535* -0.4242* -0.4387* 0.8904* 0.5577* 0.3782* 0.7192* 0.5877* 0.3590* 1
Usual Activity at 12 weeks 0.2209* 0.0105 0.1177 0.0474 -0.019 0.027 0.1194 0.1023 0.5110* 0.7561* 0.5049* 0.3011* 0.6493* 0.3334* 0.5314* 1
Usual Activity at 24 weeks 0.1019 -0.0353 0.2006* 0.1176 -0.0224 0.0236 0.1041 0.0938 0.4358* 0.5629* 0.7965* 0.3382* 0.5552* 0.7682* 0.4342* 0.5789* 1
Pain/discomfort at Baseline 0.0092 -0.1249 0.0203 -0.1963* -0.5416* -0.2188* -0.3840* -0.3864* 0.6439* 0.2949* 0.2050* 0.6423* 0.4074* 0.2702* 0.6562* 0.2595* 0.2638* 1
Pain/discomfort at 12 weeks 0.0548 0.0566 -0.0226 0.1663 0.0308 0.0264 0.1097 0.089 0.3452* 0.5521* 0.3241* 0.2201* 0.4628* 0.2521* 0.3454* 0.5167* 0.3760* 0.2670* 1
Pain/discomfort at 24 weeks -0.0551 -0.0437 0.074 0.1273 -0.0486 -0.0037 0.0383 0.0294 0.2727* 0.3844* 0.7325* 0.1798* 0.2690* 0.5244* 0.2010* 0.3286* 0.6546* 0.1599 0.3248* 1
Anxiety/depression at Baseline -0.0581 -0.2317* 0.0555 -0.2492* -0.4354* -0.3861* -0.5264* -0.5178* 0.3638* 0.1185 0.1002 0.5468* 0.2462* 0.1742 0.4073* 0.1306 0.1358 0.6012* 0.0288 0.0713 1
Anxiety/depression at 12 weeks -0.108 -0.3289* 0.0215 0.1057 -0.0585 0.0184 0.0369 0.0688 0.1568 0.2964* 0.2300* 0.2163* 0.4201* 0.3177* 0.2288* 0.3282* 0.3014* 0.1439 0.2034* 0.1750* 0.4410* 1
Anxiety/depression at 24 weeks 0.0073 -0.1646 0.0864 0.0837 -0.0323 -0.032 0.0345 0.0538 0.0324 0.1206 0.3884* 0.0886 0.1676 0.5299* 0.0554 0.0616 0.4646* 0.0189 0.0163 0.3449* 0.2125* 0.3792* 1






















































a N=308 Test Bed participants (Cohort 1=167, Cohort 2=126,  Cohort 4=15). 
b Gender (1=Male, 0=Female); Marital Status (1=Single, 2=Married, 3=Civil part, 4=Separated, 5=Divorced, 6=Widowed); Lone Dwelling (1=Living Alone, 0=Otherwise); Education 
(1=None, 2=Primary, 3=Secondary, 4=College, 5=University); Employment (1=Full time emp, 2=Part time, 4=Unable work ill health, 6=Retired, 7=Voluntary) Access to internet (0=No, 
1=Yes, 2=Intermittent). 
c *Correlation coefficients significant at the 5% level or better. 
Source: Test Bed, Information from 14 October 2016 to 27 April 2018. 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks
Gender 1
Age 0.1745* 1
Risk 0.0771 0.2093* 1
Marital Status 0.0267 0.0994 0.0751 1
Lone dwelling 0.0175 0.057 0.0634 0.4104* 1
Education 0.026 0.0396 0.0407 0.2872* 0.3476* 1
Employment 0.0764 0.1122* 0.0592 0.5796* 0.6995* 0.4817* 1
Access to internet 0.1004 0.0337 0.0539 0.3868* 0.4905* 0.3512* 0.6834* 1
EQ-5D-5L score Baseline 0.1521* 0.1575* -0.2168* -0.0715 -0.0491 -0.0114 -0.0196 0.0949 1
   EQ-5D-5L score 12 weeks 0.1135* 0.1471* -0.1803* -0.1088 0.0067 -0.0354 -0.0689 -0.0295 0.7389* 1
   EQ-5D-5L score 24 weeks 0.1895* 0.1404* -0.2612* -0.1101 0.0441 -0.0355 -0.0647 -0.0325 0.7079* 0.7665* 1
PAM13 Score Baseline -0.107 0.0285 -0.0227 0.0168 0.0079 0.0507 0.0229 0.0181 0.2543* 0.2423* 0.2462* 1
   PAM13 Score 12 weeks 0.0298 0.0678 0.0329 -0.0599 -0.0682 -0.0361 -0.1195* -0.1037 0.2413* 0.3247* 0.3591* 0.5393* 1
   PAM13 Score 24 weeks 0.0234 -0.0052 -0.013 -0.0372 0.0395 0.0378 0.0164 -0.049 0.2403* 0.3039* 0.4072* 0.4953* 0.5876* 1
WEMWBS Score Baseline 0.0663 0.2387* -0.0817 0.0058 0.043 0.0539 -0.0028 0.0349 0.4550* 0.3848* 0.4388* 0.4705* 0.3720* 0.3524* 1
   WEMWBS Score 12 weeks 0.0348 0.2491* -0.0275 -0.0686 -0.0329 -0.0385 -0.0625 -0.0713 0.3774* 0.4453* 0.3575* 0.2379* 0.4063* 0.2943* 0.5196* 1
   WEMWBS Score 24 weeks 0.0256 0.1904* -0.0685 -0.089 -0.0356 0.1083 -0.0652 0.0746 0.3340* 0.2989* 0.4213* 0.2095* 0.3053* 0.3582* 0.4872* 0.5654* 1
De Jong G Score Baseline 0.0548 -0.1777* -0.004 0.028 -0.0867 -0.1247* 0.0567 0.0123 -0.2243* -0.2537* -0.2032* -0.2798* -0.2222* -0.2107* -0.5478* -0.3223* -0.2799* 1
   De Jong G Score 12 weeks -0.014 -0.1638* 0.0152 0.0654 0.0025 0.0092 0.0231 0.032 -0.2211* -0.2861* -0.2233* -0.2103* -0.2739* -0.2385* -0.4512* -0.4509* -0.3280* 0.7625* 1
   De Jong G Score 24 weeks -0.003 -0.2240* -0.0368 0.0858 0.0176 0.0245 0.0692 0.0701 -0.2131* -0.3116* -0.3020* -0.2208* -0.2641* -0.2849* -0.4467* -0.3804* -0.3922* 0.7439* 0.8111* 1



















































Appendix 13. Use of Health and Social Care Services - Fylde Coast 
Hospital services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Accident & Emergency 0.01 0.09 0.03 0.00 0.19 0.03 0.03 0.00 0.03 
General hospital inpatient admission 0.00 0.09 0.03 0.00 0.19 0.03 0.00 0.00 0.03 
Community hospital inpatient admission 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.03 
Day hospital 0.07 0.11 0.21 0.10 0.13 0.26 0.05 0.10 0.18 
Outpatient visits to clinic based at hospital site 0.77 0.61 0.50 0.97 0.65 0.68 0.62 0.59 0.36 
Other 0.04 0.07 0.00 0.00 0.10 0.00 0.08 0.05 0.00 
Mean use of hospital services 0.90 0.97 0.79 1.06 1.26 1.00 0.77 0.74 0.62 
Patients who have used at least one of hospital 
services 
22 37 33 14 20 19 12 17 14 
% 31% 53% 47% 45% 65% 61% 31% 44% 36% 
N 70 70 70 31 31 31 39 39 39 
 
Primary Care, Community Health or Emergency 
Services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
GP 0.26 0.60 0.59 0.16 0.65 0.42 0.33 0.56 0.72 
Paramedic (Ambulance service) 0.00 0.07 0.14 0.00 0.16 0.06 0.00 0.00 0.21 
Community matron 0.13 0.09 0.07 0.03 0.00 0.10 0.21 0.15 0.05 
Community/District nurse 0.51 0.74 0.66 1.16 1.68 1.48 0.00 0.00 0.00 
Practice nurse 0.24 0.50 0.51 0.29 0.87 0.97 0.21 0.21 0.15 
Specialist nurse  0.14 0.13 0.31 0.19 0.13 0.35 0.10 0.13 0.28 
Mean use of primary care services 1.29 2.13 2.29 1.84 3.48 3.39 0.85 1.05 1.41 
Patients who have used at least one of primary 
care services 
28 41 43 16 26 23 12 15 20 
% 40% 59% 61% 52% 84% 74% 31% 38% 51% 
N 70 70 70 31 31 31 39 39 39 
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Social Care Services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Social worker or Care manager 0.14 0.04 0.01 0.26 0.10 0.03 0.05 0.00 0.00 
Home care/home help worker 1.34 1.50 1.24 2.06 2.42 1.84 0.77 0.77 0.77 
Private home help/cleaner 0.60 0.96 1.14 1.26 1.61 1.87 0.08 0.44 0.31 
Mean use of social care services 2.09 2.50 2.40 3.58 4.13 3.74 0.90 1.21 1.33 
Patients who have used at least one of social care 
services 
14 19 17 10 12 11 4 7 6 
% 20% 27% 24% 32% 39% 35% 10% 18% 15% 
N 70 70 70 31 31 31 39 39 39 
 
Community Mental Health Services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Psychiatrist / psycho-geriatrician 0.01 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 
Community psychiatric nurse / Community 
mental health nurse 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Other mental health professional 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Mean use of community mental health services 0.01 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 
Patients who have used at least one of the 
community mental health services 
1 0 0 0 0 0 1 0 0 
% 1% 0% 0% 0% 0% 0% 3% 0% 0% 





Other community-based services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Telecare 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Dentist, oral hygienist 0.13 0.21 0.09 0.03 0.10 0.00 0.21 0.31 0.15 
Optician 0.06 0.04 0.03 0.10 0.03 0.06 0.03 0.05 0.00 
Mean use of other community-based services 0.19 0.26 0.11 0.13 0.13 0.06 0.23 0.36 0.15 
Patients who have used at least one of the other 
community-based services 
8 12 6 3 4 2 5 8 4 
% 11% 17% 9% 10% 13% 6% 13% 21% 10% 
N 70 70 70 31 31 31 39 39 39 
 
Day activity services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Day care – local authority social services 
department 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Day care – voluntary organisation 0.00 0.00 0.03 0.00 0.00 0.06 0.00 0.00 0.00 
Day care – NHS  (community-based) 0.01 0.01 0.00 0.00 0.00 0.00 0.03 0.03 0.00 
Lunch club 0.01 0.01 0.00 0.00 0.03 0.00 0.03 0.00 0.00 
Social club 0.03 0.06 0.04 0.03 0.00 0.03 0.03 0.10 0.05 
Exercise class 0.76 0.76 0.60 0.26 0.06 0.00 1.15 1.31 1.08 
Other services 0.31 0.11 0.04 0.10 0.10 0.10 0.49 0.13 0.00 
Mean use of day activity services 1.13 0.96 0.71 0.39 0.19 0.19 1.72 1.56 1.13 
Patients who have used at least one of the day 
activity services 
31 34 23 3 4 3 28 30 20 
% 44% 49% 33% 10% 13% 10% 72% 77% 51% 
N 70 70 70 31 31 31 39 39 39 
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Appendix 14. Use of Health and Social Care Services - Better Care Together 
Hospital services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Accident & Emergency 0.08 0.05 0.09 0.11 0.07 0.12 0.02 0.06 0.21 
General hospital inpatient admission 0.06 0.04 0.04 0.07 0.06 0.06 0.03 0.12 0.07 
Community hospital inpatient admission 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 
Day hospital 0.15 0.16 0.22 0.18 0.23 0.18 0.83 0.24 2.08 
Outpatient visits to clinic based at hospital site 0.39 0.49 0.43 0.49 0.65 0.54 1.67 1.24 1.83 
Other 0.11 0.09 0.04 0.08 0.11 0.06 0.25 0.12 0.00 
Mean use of hospital services 0.79 0.83 0.83 0.93 1.12 0.96 0.45 0.34 0.59 
Patients who have used at least one of hospital 
services 
88 82 78 66 60 53 12 17 14 
% 39% 37% 35% 49% 44% 39% 14% 20% 16% 
N 223 223 223 136 136 136 87 87 87 
 
Primary Care, Community Health or Emergency 
Services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
GP 0.51 0.53 0.45 0.69 0.60 0.45 1.58 3.00 3.33 
Paramedic (Ambulance service) 0.05 0.02 0.04 0.07 0.04 0.06 0.02 0.00 0.00 
Community matron 0.02 0.01 0.00 0.04 0.02 0.01 0.00 0.00 0.00 
Community/District nurse 0.11 0.12 0.17 0.18 0.18 0.24 0.00 0.01 0.08 
Practice nurse 0.20 0.20 0.14 0.26 0.26 0.16 0.67 0.75 0.83 
Specialist nurse  0.12 0.13 0.18 0.12 0.20 0.18 0.92 0.17 1.25 
Mean use of primary care services 1.01 1.01 0.99 1.36 1.30 1.10 0.46 0.55 0.83 
Patients who have used at least one of primary 
care services 
101 94 84 78 66 54 12 15 20 
% 45% 42% 38% 57% 49% 40% 14% 17% 23% 




Social Care Services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Social worker or Care manager 0.07 0.03 0.02 0.12 0.04 0.03 0.00 0.00 0.00 
Home care/home help worker 0.50 0.35 0.48 0.70 0.57 0.78 4.25 0.01 0.01 
Private home help/cleaner 0.45 0.41 0.72 0.41 0.39 0.76 0.75 4.25 0.67 
Mean use of social care services 1.02 0.78 1.22 1.23 1.00 1.57 0.23 0.21 0.26 
Patients who have used at least one of social care 
services 
33 25 32 23 15 21 4 7 6 
% 15% 11% 14% 17% 11% 15% 5% 8% 7% 
N 223 223 223 136 136 136 87 87 87 
 
 
Community Mental Health Services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Psychiatrist / psycho-geriatrician 0.02 0.00 0.01 0.00 0.01 0.01 0.05 0.00 0.00 
Community psychiatric nurse / Community 
mental health nurse 
0.03 0.01 0.03 0.04 0.02 0.04 0.00 0.00 0.01 
Other mental health professional 0.04 0.08 0.05 0.01 0.07 0.03 0.08 0.09 0.09 
Mean use of community mental health services 0.08 0.09 0.09 0.05 0.10 0.09 0.13 0.09 0.10 
Patients who have used at least one of the 
community mental health services 
5 7 8 2 5 5 1 0 0 
% 2% 3% 4% 1% 4% 4% 1% 0% 0% 





Other community-based services  
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Telecare 0.01 0.11 0.01 0.01 0.09 0.01 0.00 0.15 0.00 
Dentist, oral hygienist 0.12 0.11 0.09 0.10 0.13 0.11 2.40 1.40 1.20 
Optician 0.08 0.07 0.05 0.09 0.07 0.05 1.20 1.40 1.00 
Mean use of other community-based services 0.21 0.30 0.16 0.21 0.29 0.18 0.21 0.31 0.13 
Patients who have used at least one of the other 
community-based services 
29 37 21 18 26 15 5 8 4 
% 13% 17% 9% 13% 19% 11% 6% 9% 5% 
N 223 223 223 136 136 136 87 87 87 
 
Day activity services 
Mean use of service- Test Bed 
population 
Mean use - Cohort 1 Mean use - Cohort 2 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
Day care – local authority social services 
department 
0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 
Day care – voluntary organisation 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
Day care – NHS  (community-based) 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 
Lunch club 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.00 
Social club 0.02 0.07 0.03 0.01 0.08 0.04 0.01 0.05 0.02 
Exercise class 0.04 0.02 0.06 0.07 0.01 0.05 0.52 0.59 0.48 
Other services 0.13 0.13 0.11 0.10 0.03 0.11 0.22 0.06 0.00 
Mean use of day activity services 0.22 0.22 0.21 0.20 0.14 0.21 0.77 0.70 0.51 
Patients who have used at least one of the day 
activity services 
48 51 41 14 14 16 28 30 20 
% 22% 23% 18% 10% 10% 12% 32% 34% 23% 




Appendix 15. Summary of mean use of services per Cohort and per Vanguard 
  Cohort 1 & 2 Cohort 1 Cohort 2 




















Hospital services          
Test Bed Population (both Vanguards) 0.82 0.87 0.82 0.96 1.14 0.97 0.63 0.5 0.61 
Fylde Coast 0.9 0.97 0.79 1.06 1.26 1 0.77 0.74 0.62 
Better Care Together 0.79 0.83 0.83 0.93 1.12 0.96 0.45 0.34 0.59 
Primary care services                   
Test Bed Population (both Vanguards) 1.08 1.28 1.3 1.45 1.71 1.52 0.58 0.71 1.01 
Fylde Coast 1.29 2.13 2.29 1.84 3.48 3.39 0.85 1.05 1.41 
Better Care Together 1.01 1.01 0.99 1.36 1.3 1.1 0.46 0.55 0.83 
Social care services                   
Test Bed Population (both Vanguards) 1.28 1.19 1.5 1.66 1.58 1.97 0.76 0.68 0.88 
Fylde Coast 2.09 2.5 2.4 3.58 4.13 3.74 0.9 1.21 1.33 
Better Care Together 1.02 0.78 1.22 1.23 1 1.57 0.23 0.21 0.26 
Community mental health services                   
Test Bed Population (both Vanguards) 0.06 0.07 0.07 0.04 0.08 0.07 0.1 0.06 0.07 
Fylde Coast 0.01 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 
Better Care Together 0.08 0.09 0.09 0.05 0.1 0.09 0.13 0.09 0.1 
Other community-based services                   
Test Bed Population (both Vanguards) 0.2 0.29 0.15 0.19 0.26 0.16 0.21 0.33 0.13 
Fylde Coast 0.19 0.26 0.11 0.13 0.13 0.06 0.23 0.36 0.15 
Better Care Together 0.21 0.3 0.16 0.21 0.29 0.18 0.21 0.31 0.13 
Day activity services                   
Test Bed Population (both Vanguards) 0.43 0.4 0.33 0.23 0.15 0.2 0.7 0.73 0.49 
Fylde Coast 1.13 0.96 0.71 0.39 0.19 0.19 1.72 1.56 1.13 
Better Care Together 0.22 0.22 0.21 0.2 0.14 0.21 0.77 0.7 0.51 
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Appendix 23. Additional patient information 
Participant payment 
Participants taking part in the qualitative elements of the study will receive a voucher of £20 
as a thank you in recognition of the time they have given to taking part in the evaluation. In 
the quantitative elements of the evaluation we are unable to offer any incentive because of 
the large numbers of participants. 
Data storage 
Personal data is being stored on a password safe university computer accessible only to the 
researchers. The research data is stored in an encrypted file using the software TrueCrypt.  
All data is being stored securely in line with the Data Protection Act [11] and will be kept no 
longer than necessary.[12] Written data will be kept for a maximum of 10 years in a secure 
cabinet. Any electronic copies of data will be kept on the University server, which is a 
password protected system and will be encrypted. If electronic data requires transfer, this is 
done on an encrypted USB device. Any emails sent from participants (e.g. electronic diaries) 
are sent to a password secured email address that has been set up for the purpose of the 
study. Emails are saved electronically with any other electronic copies of data, with the email 
then being deleted. Where emails and interview/focus group data are printed for the 
purposes of analysis, they are stored with other written data in a secure cabinet. At the end 
of the study, the email account will be deleted. The paper copies of any participant contact 
details will be scanned and stored electronically, and paper copies destroyed. 
Participant benefit 
Participants have the direct benefit of using the technology during the two years of the Test 
Bed; however the Test Bed team recognise the need to make clear for those in Cohorts 1 and 
4 that this is time-limited. Patients (particularly those in cohorts 2 and 3) for whom the 
intervention is a text messaging system or an app, will have access to these beyond the six 
month timeframe of the Test Bed programme. Given a key objective of the service is to 
enhance patient activation and ability to self-care, it is also anticipated that potential ongoing 
benefits will support older people with chronic health problems to remain in their own homes 
longer. 
Patients and health professionals also have an opportunity to share directly with researchers 
their experiences of using and implementing this model of care. In this way, all participants 
can take an active part in shaping current and future healthcare services in place for older 
people with chronic conditions or dementia who are living at home. 
Potential risk to participants 
For patients participating in Phase 1 of the evaluation, there are no anticipated risks from 
participation in the project. All validated tools are validated for completion by proxy, and 
patients and family members are therefore made aware that the patient can be supported to 
complete the surveys if required. 
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For patients taking part in Phase 2 of the evaluation research, no specific risks are anticipated. 
However, the following considerations have been made: 
1. It is possible that a patient may become distressed by the presence of the researcher in 
their home during the observational interviews. To avoid this risk, the researcher will take 
care to check with the patient at the beginning of the interview to ensure they are happy to 
continue taking part in the study. The researcher will also do this at the end of the session 
and for the second interview. 
2. If a patient should become distressed for any reason during an observational interview, the 
researcher will provide the patient with the contact details of different support networks for 
older people, as outlined in the participant information sheet. A member of the Test Bed hub 
will also be alerted should this be necessary, in order to assess whether a visit from a member 
of the hub is required. 
Participants involved in the action learning meetings and the focus groups will be reminded 
that discussion in these settings is confidential and information shared (other than the shared 
and agreed action learning) should not be discussed with others outside of the meeting.  
Withdrawal 
Participants may choose to leave the study at any time and are assured that their data can be 
withdrawn up to four weeks after collection. The rationale for this four week time period is 
that, beyond four weeks, analysis will have begun. Those participating in focus groups are 
advised that, although every effort will be undertaken to remove their data should they 
request it during the timeframe, this may not always be possible. This is due to difficulties in 
identifying/attributing specific comments to individuals and because focus group data is often 
the outcome of group discussion, making it hard to distil to whom individual 
thoughts/comments should be attributed. 
Researcher risk  
There is limited risk to the quantitative researchers as they have very limited direct 
engagement with the participants (survey completion is largely through technology or 
telephone).  
The qualitative researcher is interviewing participants in their own homes and is experienced 
in undertaking this type of fieldwork. The researcher is adhering to the University’s lone 
worker policy. In order to minimise any potential risks, for each home visit conducted, the 
researcher identifies a ‘buddy’ (a member of staff within the University) with whom to remain 
in contact with: before the interview commences; when the interview has been terminated; 
and when the researcher has left the patient’s home. The buddy is informed of the time and 
place of the interview, along with a contact telephone number.  
Researchers within the team have the opportunity to debrief with other members of the team 
if required and have full access to counselling services if necessary. 
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Appendix 24. Logic model diaries 
 195 
 







Appendix 25. Lancaster Deliberative Panel 
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Appendix 27. Lessons learned slides 
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